doc_rank	rank	affiliation	firstname	initials	lastname
0	0	"Department of Medical Oncology, Dana-Farber Cancer Institute.
Harvard Medical School."	Girish S	GS	Naik
0	1	"Department of Medical Oncology, Dana-Farber Cancer Institute.
Harvard Medical School.
Brigham and Women's Hospital."	Elizabeth I	EI	Buchbinder
0	2	"Harvard Medical School.
Center for Melanoma, Massachusetts General Hospital, Boston."	Justine V	JV	Cohen
0	3	Department of Medical Oncology, Dana-Farber Cancer Institute.	Michael P	MP	Manos
0	4	Institute of Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA.	Alistair E W	AEW	Johnson
0	5	Department of Medical Oncology, Dana-Farber Cancer Institute.	Peter	P	Bowling
0	6	"Harvard Medical School.
Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center."	Ayal A	AA	Aizer
0	7	"Harvard Medical School.
Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center."	Jonathan D	JD	Schoenfeld
0	8	"Harvard Medical School.
Center for Melanoma, Massachusetts General Hospital, Boston."	Donald P	DP	Lawrence
0	9	"Department of Medical Oncology, Dana-Farber Cancer Institute.
Harvard Medical School.
Brigham and Women's Hospital."	Rizwan	R	Haq
0	10	"Department of Medical Oncology, Dana-Farber Cancer Institute.
Harvard Medical School.
Brigham and Women's Hospital."	Frank Stephen	FS	Hodi
0	11	"Harvard Medical School.
Center for Melanoma, Massachusetts General Hospital, Boston."	Ryan J	RJ	Sullivan
0	12	"Department of Medical Oncology, Dana-Farber Cancer Institute.
Harvard Medical School.
Brigham and Women's Hospital."	Patrick A	PA	Ott
1	0	Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA. Electronic address: sklaeger@broadinstitute.org.	Susan	S	Klaeger
1	1	Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.	Annie	A	Apffel
1	2	Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.	Karl R	KR	Clauser
1	3	Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.	Siranush	S	Sarkizova
1	4	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.	Giacomo	G	Oliveira
1	5	Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.	Suzanna	S	Rachimi
1	6	Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.	Phuong M	PM	Le
1	7	Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.	Anna	A	Tarren
1	8	Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.	Vipheaviny	V	Chea
1	9	Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.	Jennifer G	JG	Abelin
1	10	Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.	David A	DA	Braun
1	11	Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.	Patrick A	PA	Ott
1	12	Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.	Hasmik	H	Keshishian
1	13	Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.	Nir	N	Hacohen
1	14	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Health Informatics Lab, Metropolitan College, Boston University, Boston, Massachusetts, USA.	Derin B	DB	Keskin
1	15	Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.	Catherine J	CJ	Wu
1	16	Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA. Electronic address: scarr@broad.mit.edu.	Steven A	SA	Carr
2	0	Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA anaing@mdanderson.org.	Aung	A	Naing
2	1	Department of Medical Oncology, The Christie Hospital NHS Foundation Trust and University of Manchester, Manchester, UK.	Fiona	F	Thistlethwaite
2	2	Department of Medical Oncology, Universitair Medisch Centrum Groningen, Groningen, The Netherlands.	Elisabeth G E	EGE	De Vries
2	3	Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.	Ferry A L M	FALM	Eskens
2	4	Department of Medicine, Section of Hematology and Oncology, University of Wisconsin, Carbone Cancer Center, Madison, Wisconsin, USA.	Nataliya	N	Uboha
2	5	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.	Patrick A	PA	Ott
2	6	Department of Medical Oncology, Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut, USA.	Patricia	P	LoRusso
2	7	Department of Medical Oncology, Hospital Clinic Barcelona/IDIBAPS, Barcelona, Spain.	Javier	J	Garcia-Corbacho
2	8	Department of Medical Oncology, START Madrid-CIOCC, Hospital Universitario HM Sanchinarro, Madrid, Spain.	Valentina	V	Boni
2	9	Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee, USA.	Johanna	J	Bendell
2	10	Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.	Karen A	KA	Autio
2	11	Department of Medical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK.	Manreet	M	Randhawa
2	12	Department of Medical Oncology, Indiana University, Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, USA.	Greg	G	Durm
2	13	Medical Oncology Department, Institut Català d'Oncologia - IDIBELL, L'Hospitalet-Barcelona, Barcelona, Spain.	Marta	M	Gil-Martin
2	14	CytomX Therapeutics Inc, South San Francisco, California, USA.	Mark	M	Stroh
2	15	CytomX Therapeutics Inc, South San Francisco, California, USA.	Alison L	AL	Hannah
2	16	Drug Development Unit, Sarah Cannon Research Institute and University College London Cancer Institute, London, UK.	Hendrik-Tobias	HT	Arkenau
2	17	Department of Medical Oncology, Virginia Cancer Specialists, Fairfax, Virginia, USA.	Alexander	A	Spira
3	0	Department of Medical Oncology, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA Rachel.Sanborn@providence.org.	Rachel E	RE	Sanborn
3	1	Department of Medical Oncology, The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, California, USA.	Omid	O	Hamid
3	2	Department of Medical Oncology, Universitair Medisch Centrum Groningen, University of Groningen, Groningen, Netherlands.	Elisabeth Ge	EG	de Vries
3	3	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.	Patrick A	PA	Ott
3	4	Department of Medical Oncology, Hospital Clinic Barcelona/IDIBAPS, Barcelona, Spain.	Javier	J	Garcia-Corbacho
3	5	Department of Medical Oncology, START Madrid-CIOCC, Hospital Universitario HM Sanchinarro, Madrid, Spain.	Valentina	V	Boni
3	6	Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee, USA.	Johanna	J	Bendell
3	7	Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.	Karen A	KA	Autio
3	8	Department of Medicine, Perlmutter Cancer Center at NYU Langone Medical Center, New York, New York, USA.	Daniel C	DC	Cho
3	9	Department of Medical Oncology, Northern Centre for Cancer Care, Newcastle Hospitals NHS Trust and Newcastle University, Newcastle upon Tyne, UK.	Ruth	R	Plummer
3	10	CytomX Therapeutics Inc, South San Francisco, California, USA.	Mark	M	Stroh
3	11	CytomX Therapeutics Inc, South San Francisco, California, USA.	Lawrence	L	Lu
3	12	Department of Medical Oncology, The Christie Hospital NHS Foundation Trust and University of Manchester, Manchester, UK.	Fiona	F	Thistlethwaite
4	0	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA."	Giacomo	G	Oliveira
4	1	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Kari	K	Stromhaug
4	2	Broad Institute of MIT and Harvard, Cambridge, MA, USA.	Susan	S	Klaeger
4	3	"TScan Therapeutics, Waltham, MA, USA.
Society of Fellows, Harvard University, Cambridge, MA, USA."	Tomasz	T	Kula
4	4	Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.	Dennie T	DT	Frederick
4	5	Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA.	Phuong M	PM	Le
4	6	Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA.	Juliet	J	Forman
4	7	Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA.	Teddy	T	Huang
4	8	"Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA."	Shuqiang	S	Li
4	9	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Wandi	W	Zhang
4	10	TScan Therapeutics, Waltham, MA, USA.	Qikai	Q	Xu
4	11	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Nicoletta	N	Cieri
4	12	Broad Institute of MIT and Harvard, Cambridge, MA, USA.	Karl R	KR	Clauser
4	13	"Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA."	Sachet A	SA	Shukla
4	14	Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.	Donna	D	Neuberg
4	15	Immunitrack, Copenhagen, Denmark.	Sune	S	Justesen
4	16	TScan Therapeutics, Waltham, MA, USA.	Gavin	G	MacBeath
4	17	Broad Institute of MIT and Harvard, Cambridge, MA, USA.	Steven A	SA	Carr
4	18	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA."	Edward F	EF	Fritsch
4	19	"Harvard Medical School, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA."	Nir	N	Hacohen
4	20	"Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA."	Moshe	M	Sade-Feldman
4	21	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA."	Kenneth J	KJ	Livak
4	22	"Harvard Medical School, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA."	Genevieve M	GM	Boland
4	23	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA."	Patrick A	PA	Ott
4	24	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA."	Derin B	DB	Keskin
4	25	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. cwu@partners.org.
Harvard Medical School, Boston, MA, USA. cwu@partners.org.
Broad Institute of MIT and Harvard, Cambridge, MA, USA. cwu@partners.org.
Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. cwu@partners.org."	Catherine J	CJ	Wu
5	0	1Stanford Cancer Institute.	Susan M	SM	Swetter
5	1	2Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance.	John A	JA	Thompson
5	2	3University of Wisconsin Carbone Cancer Center.	Mark R	MR	Albertini
5	3	4Memorial Sloan Kettering Cancer Center.	Christopher A	CA	Barker
5	4	5UC San Diego Moores Cancer Center.	Joel	J	Baumgartner
5	5	6Massachusetts General Hospital Cancer Center.	Genevieve	G	Boland
5	6	7UCLA Jonsson Comprehensive Cancer Center.	Bartosz	B	Chmielowski
5	7	8Fred & Pamela Buffett Cancer Center.	Dominick	D	DiMaio
5	8	9University of Michigan Rogel Cancer Center.	Alison	A	Durham
5	9	10Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.	Ryan C	RC	Fields
5	10	11St. Jude Children's Research Hospital/The University of Tennessee Health Science Center.	Martin D	MD	Fleming
5	11	12Yale Cancer Center/Smilow Cancer Hospital.	Anjela	A	Galan
5	12	13Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.	Brian	B	Gastman
5	13	14Huntsman Cancer Institute at the University of Utah.	Kenneth	K	Grossmann
5	14	15AIM at Melanoma.	Samantha	S	Guild
5	15	16O'Neal Comprehensive Cancer Center at UAB.	Ashley	A	Holder
5	16	17Vanderbilt-Ingram Cancer Center.	Douglas	D	Johnson
5	17	18Mayo Clinic Cancer Center.	Richard W	RW	Joseph
5	18	19Abramson Cancer Center at the University of Pennsylvania.	Giorgos	G	Karakousis
5	19	20The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.	Kari	K	Kendra
5	20	21The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.	Julie R	JR	Lange
5	21	22University of Colorado Cancer Center.	Ryan	R	Lanning
5	22	23City of Hope National Medical Center.	Kim	K	Margolin
5	23	24Fox Chase Cancer Center.	Anthony J	AJ	Olszanski
5	24	25Dana-Farber/Brigham and Women's Cancer Center.	Patrick A	PA	Ott
5	25	26The University of Texas MD Anderson Cancer Center.	Merrick I	MI	Ross
5	26	27Duke Cancer Institute.	April K	AK	Salama
5	27	28UT Southwestern Simmons Comprehensive Cancer Center.	Rohit	R	Sharma
5	28	29Roswell Park Comprehensive Cancer Center.	Joseph	J	Skitzki
5	29	30Robert H. Lurie Comprehensive Cancer Center of Northwestern University.	Jeffrey	J	Sosman
5	30	31Moffitt Cancer Center; and.	Evan	E	Wuthrick
5	31	32National Comprehensive Cancer Network.	Nicole R	NR	McMillian
5	32	32National Comprehensive Cancer Network.	Anita M	AM	Engh
6	0	Bristol Myers Squibb, Princeton, New Jersey. Ming.Lei1@bms.com.	Ming	M	Lei
6	1	Bristol Myers Squibb, Princeton, New Jersey.	Nathan O	NO	Siemers
6	2	Bristol Myers Squibb, Princeton, New Jersey.	Dimple	D	Pandya
6	3	Bristol Myers Squibb, Princeton, New Jersey.	Han	H	Chang
6	4	Bristol Myers Squibb, Princeton, New Jersey.	Teresa	T	Sanchez
6	5	Bristol Myers Squibb, Princeton, New Jersey.	Christopher	C	Harbison
6	6	Bristol Myers Squibb, Princeton, New Jersey.	Peter M	PM	Szabo
6	7	Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.	Yelena	Y	Janjigian
6	8	Dana-Farber Cancer Institute, Boston, Massachusetts.	Patrick A	PA	Ott
6	9	Genitourinary Medical Oncology and Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas.	Padmanee	P	Sharma
6	10	Drug Development Unit, Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee.	Johanna	J	Bendell
6	11	Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, United Kingdom.	Thomas R Jeffry	TRJ	Evans
6	12	"Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
University of Milan, Milan, Italy."	Filippo	F	de Braud
6	13	Department of Medicine, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom.	Ian	I	Chau
6	14	Bristol Myers Squibb, Princeton, New Jersey.	Zachary	Z	Boyd
7	0	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA."	Elizabeth I	EI	Buchbinder
7	1	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Jason L	JL	Weirather
7	2	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Michael	M	Manos
7	3	Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.	Brian J	BJ	Quattrochi
7	4	Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.	Lynette M	LM	Sholl
7	5	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Ryan C	RC	Brennick
7	6	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Peter	P	Bowling
7	7	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Nancy	N	Bailey
7	8	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Lisa	L	Magarace
7	9	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA."	Patrick A	PA	Ott
7	10	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA."	Rizwan	R	Haq
7	11	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA."	Benjamin	B	Izar
7	12	Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.	Anita	A	Giobbie-Hurder
7	13	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA."	F Stephen	FS	Hodi
8	0	"Harvard Medical School, 25 Shattuck Street, Boston, MA, 02115, USA.
Center for Immuno-Oncology, Department of Medical Oncology, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA."	Kevin	K	Tyan
8	1	Center for Immuno-Oncology, Department of Medical Oncology, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA.	Joanna	J	Baginska
8	2	Center for Immuno-Oncology, Department of Medical Oncology, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA.	Martha	M	Brainard
8	3	Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.	Anita	A	Giobbie-Hurder
8	4	Center for Immuno-Oncology, Department of Medical Oncology, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA.	Mariano	M	Severgnini
8	5	Center for Immuno-Oncology, Department of Medical Oncology, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA.	Michael	M	Manos
8	6	"Harvard Medical School, 25 Shattuck Street, Boston, MA, 02115, USA.
Center for Immuno-Oncology, Department of Medical Oncology, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA."	Rizwan	R	Haq
8	7	"Harvard Medical School, 25 Shattuck Street, Boston, MA, 02115, USA.
Center for Immuno-Oncology, Department of Medical Oncology, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA."	Elizabeth I	EI	Buchbinder
8	8	"Harvard Medical School, 25 Shattuck Street, Boston, MA, 02115, USA.
Center for Immuno-Oncology, Department of Medical Oncology, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA."	Patrick A	PA	Ott
8	9	"Harvard Medical School, 25 Shattuck Street, Boston, MA, 02115, USA.
Center for Immuno-Oncology, Department of Medical Oncology, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA."	F Stephen	FS	Hodi
8	10	"Harvard Medical School, 25 Shattuck Street, Boston, MA, 02115, USA. Osamae_rahma@DFCI.harvard.edu.
Center for Immuno-Oncology, Department of Medical Oncology, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA. Osamae_rahma@DFCI.harvard.edu."	Osama E	OE	Rahma
9	0	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Zhuting	Z	Hu
9	1	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA."	Donna E	DE	Leet
9	2	Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.	Rosa L	RL	Allesøe
9	3	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Giacomo	G	Oliveira
9	4	"Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA."	Shuqiang	S	Li
9	5	Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.	Adrienne M	AM	Luoma
9	6	Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.	Jinyan	J	Liu
9	7	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA."	Juliet	J	Forman
9	8	Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA.	Teddy	T	Huang
9	9	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA."	J Bryan	JB	Iorgulescu
9	10	Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA.	Rebecca	R	Holden
9	11	Broad Institute of MIT and Harvard, Cambridge, MA, USA.	Siranush	S	Sarkizova
9	12	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Department of Academic Haematology, University College London, London, UK."	Satyen H	SH	Gohil
9	13	Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.	Robert A	RA	Redd
9	14	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Jing	J	Sun
9	15	Broad Institute of MIT and Harvard, Cambridge, MA, USA.	Liudmila	L	Elagina
9	16	Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.	Anita	A	Giobbie-Hurder
9	17	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Wandi	W	Zhang
9	18	Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.	Lauren	L	Peter
9	19	Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Zoe	Z	Ciantra
9	20	"Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA."	Scott	S	Rodig
9	21	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Oriol	O	Olive
9	22	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Keerthi	K	Shetty
9	23	Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.	Jason	J	Pyrdol
9	24	"Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA."	Mohamed	M	Uduman
9	25	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA."	Patrick C	PC	Lee
9	26	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA."	Pavan	P	Bachireddy
9	27	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA."	Elizabeth I	EI	Buchbinder
9	28	"Harvard Medical School, Boston, MA, USA.
Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA."	Charles H	CH	Yoon
9	29	Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.	Donna	D	Neuberg
9	30	"Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA.
The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA."	Bradley L	BL	Pentelute
9	31	"Harvard Medical School, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA."	Nir	N	Hacohen
9	32	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA."	Kenneth J	KJ	Livak
9	33	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA."	Sachet A	SA	Shukla
9	34	"Section for Bioinformatics, Department of Health Technology, Technical University of Denmark, Lyngby, Denmark.
Center for Genomic Medicine, Copenhagen University Hospital, Copenhagan, Denmark."	Lars Rønn	LR	Olsen
9	35	"Harvard Medical School, Boston, MA, USA.
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA."	Dan H	DH	Barouch
9	36	"Harvard Medical School, Boston, MA, USA.
Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA."	Kai W	KW	Wucherpfennig
9	37	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA."	Edward F	EF	Fritsch
9	38	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA."	Derin B	DB	Keskin
9	39	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA."	Catherine J	CJ	Wu
9	40	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. patrick_ott@dfci.harvard.edu.
Harvard Medical School, Boston, MA, USA. patrick_ott@dfci.harvard.edu.
Broad Institute of MIT and Harvard, Cambridge, MA, USA. patrick_ott@dfci.harvard.edu.
Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. patrick_ott@dfci.harvard.edu."	Patrick A	PA	Ott
10	0	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Eryn	E	Blass
10	1	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. patrick_ott@dfci.harvard.edu.
Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. patrick_ott@dfci.harvard.edu.
Harvard Medical School, Boston, MA, USA. patrick_ott@dfci.harvard.edu.
Broad Institute of MIT and Harvard, Cambridge, MA, USA. patrick_ott@dfci.harvard.edu."	Patrick A	PA	Ott
11	0	Division of Renal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: nmurakami1@bwh.harvard.edu.	Naoka	N	Murakami
11	1	Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts, USA.	Patrick	P	Mulvaney
11	2	Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts, USA.	Melissa	M	Danesh
11	3	Section of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.	Ala	A	Abudayyeh
11	4	Department of Melanoma Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.	Adi	A	Diab
11	5	Department of Melanoma Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of General Internal Medicine, Section of Rheumatology and Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Rheumatology and Rehabilitation, Faculty of Medicine, Assiut University Hospitals, Assiut, Egypt.	Noha	N	Abdel-Wahab
11	6	Institute for Academic Medicine and Weill Cornell Medical College, Houston Methodist Cancer Center, Houston, Texas, USA.	Maen	M	Abdelrahim
11	7	Division of Nephrology, Columbia University Medical Center, New York, New York, USA.	Pascale	P	Khairallah
11	8	Division of Nephrology, Columbia University Medical Center, New York, New York, USA.	Shayan	S	Shirazian
11	9	Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.	Aleksandra	A	Kukla
11	10	Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.	Itunu O	IO	Owoyemi
11	11	Division of Nephrology, Washington University in St. Louis, St. Louis, Missouri, USA.	Tarek	T	Alhamad
11	12	Division of Nephrology, Washington University in St. Louis, St. Louis, Missouri, USA.	Samir	S	Husami
11	13	Division of Nephrology, Recanati Millar Transplant Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.	Madhav	M	Menon
11	14	Division of Nephrology, Recanati Millar Transplant Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.	Andrew	A	Santeusanio
11	15	Divison of Nephrology, University of Washington, Seattle, Washington, USA.	Christopher D	CD	Blosser
11	16	Divison of Nephrology, University of Washington, Seattle, Washington, USA.	Sandra Carias	SC	Zuniga
11	17	Nephrology Department, Vall d'Hebron Hospital Universitari, Barcelona, Spain.	Maria Jose	MJ	Soler
11	18	Nephrology Department, Vall d'Hebron Hospital Universitari, Barcelona, Spain.	Francesc	F	Moreso
11	19	Division of Nephrology and Hypertension, University of Miami Miller School of Medicine, Miami, Florida, USA.	Zain	Z	Mithani
11	20	Division of Nephrology, Duke University Medical Center, Durham, North Carolina, USA.	David	D	Ortiz-Melo
11	21	Renal Service, Memorial Sloan Kettering Cancer Center and Weil Cornell Medical College, New York, New York, USA.	Edgar A	EA	Jaimes
11	22	Renal Service, Memorial Sloan Kettering Cancer Center and Weil Cornell Medical College, New York, New York, USA.	Victoria	V	Gutgarts
11	23	Division of Nephrology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA.	Erik	E	Lum
11	24	Division of Nephrology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA.	Gabriel M	GM	Danovitch
11	25	Division of Nephrology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.	Francesca	F	Cardarelli
11	26	Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.	Reed E	RE	Drews
11	27	Division of Nephrology and Hypertension, University of South Florida, Tampa, Florida; Renal Service, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.	Claude	C	Bassil
11	28	Division of Nephrology and Hypertension, University of South Florida, Tampa, Florida; Renal Service, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.	Jennifer L	JL	Swank
11	29	Division of Nephrology, University of Nebraska Medical Center, Omaha, Nebraska, USA.	Scott	S	Westphal
11	30	Division of Nephrology, University of Nebraska Medical Center, Omaha, Nebraska, USA.	Roslyn B	RB	Mannon
11	31	Department of Hematology-Oncology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.	Keisuke	K	Shirai
11	32	Division of Nephrology, University Health Network, University of Toronto, Ontario, Canada.	Abhijat	A	Kitchlu
11	33	Division of Nephrology, The University of Alabama at Birmingham, Birmingham, Alabama, USA.	Song	S	Ong
11	34	Division of Nephrology, The University of Alabama at Birmingham, Birmingham, Alabama, USA.	Shana M	SM	Machado
11	35	Division of Renal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.	Suraj S	SS	Mothi
11	36	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.	Patrick A	PA	Ott
11	37	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.	Osama	O	Rahma
11	38	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.	F Stephen	FS	Hodi
11	39	Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA.	Meghan E	ME	Sise
11	40	Division of Renal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.	Shruti	S	Gupta
11	41	Division of Renal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.	David E	DE	Leaf
11	42	Division of Medical Oncology and Hematology, Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Lake Success, New York, USA.	Craig E	CE	Devoe
11	43	Division of Kidney Disease and Hypertension, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA.	Rimda	R	Wanchoo
11	44	Division of Kidney Disease and Hypertension, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA.	Vinay V	VV	Nair
11	45	Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts, USA.	Chrysalyne D	CD	Schmults
11	46	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.	Glenn J	GJ	Hanna
11	47	Laboratory of Molecular Immunology, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, Belgium; Department of Nephrology, University Hospitals Leuven, Leuven, Belgium.	Ben	B	Sprangers
11	48	Division of Renal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA; Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA.	Leonardo V	LV	Riella
11	49	Division of Kidney Disease and Hypertension, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA. Electronic address: Kjhaveri@northwell.edu.	Kenar D	KD	Jhaveri
11	50				
12	0	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Asaf	A	Poran
12	1	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Julian	J	Scherer
12	2	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Meghan E	ME	Bushway
12	3	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Rana	R	Besada
12	4	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Kristen N	KN	Balogh
12	5	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Amy	A	Wanamaker
12	6	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Reid G	RG	Williams
12	7	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Jasmina	J	Prabhakara
12	8	Dana Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.	Patrick A	PA	Ott
12	9	Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.	Siwen	S	Hu-Lieskovan
12	10	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Zakaria S	ZS	Khondker
12	11	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Richard B	RB	Gaynor
12	12	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Michael S	MS	Rooney
12	13	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Lakshmi	L	Srinivasan
13	0	Dana Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA. Electronic address: patrick_ott@dfci.harvard.edu.	Patrick A	PA	Ott
13	1	Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.	Siwen	S	Hu-Lieskovan
13	2	Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.	Bartosz	B	Chmielowski
13	3	Washington University School of Medicine, St. Louis, MO, USA.	Ramaswamy	R	Govindan
13	4	Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.	Aung	A	Naing
13	5	Tisch Cancer Institute, Icahn School of Medicine, New York, NY, USA.	Nina	N	Bhardwaj
13	6	Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA.	Kim	K	Margolin
13	7	Dana Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.	Mark M	MM	Awad
13	8	Memorial Sloan Kettering Cancer Center, New York, NY, USA.	Matthew D	MD	Hellmann
13	9	Cancer Center, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA.	Jessica J	JJ	Lin
13	10	Department of Medicine, Division of Hematology and Oncology, University of California, San Francisco, San Francisco, CA, USA.	Terence	T	Friedlander
13	11	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Meghan E	ME	Bushway
13	12	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Kristen N	KN	Balogh
13	13	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Tracey E	TE	Sciuto
13	14	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Victoria	V	Kohler
13	15	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Samantha J	SJ	Turnbull
13	16	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Rana	R	Besada
13	17	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Riley R	RR	Curran
13	18	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Benjamin	B	Trapp
13	19	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Julian	J	Scherer
13	20	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Asaf	A	Poran
13	21	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Dewi	D	Harjanto
13	22	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Dominik	D	Barthelme
13	23	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Ying Sonia	YS	Ting
13	24	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Jesse Z	JZ	Dong
13	25	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Yvonne	Y	Ware
13	26	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Yuting	Y	Huang
13	27	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Zhengping	Z	Huang
13	28	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Amy	A	Wanamaker
13	29	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Lisa D	LD	Cleary
13	30	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Melissa A	MA	Moles
13	31	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Kelledy	K	Manson
13	32	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Joel	J	Greshock
13	33	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Zakaria S	ZS	Khondker
13	34	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Ed	E	Fritsch
13	35	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Michael S	MS	Rooney
13	36	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Mark	M	DeMario
13	37	Neon Therapeutics/BioNTech US, Cambridge, MA, USA.	Richard B	RB	Gaynor
13	38	Neon Therapeutics/BioNTech US, Cambridge, MA, USA. Electronic address: lakshmi.srinivasan@biontech.us.	Lakshmi	L	Srinivasan
14	0	University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.	Jason J	JJ	Luke
14	1	University of Chicago Medicine, Chicago, Illinois.	Benjamin E	BE	Onderdonk
14	2	Cancer Care Group PC, Indianapolis, Indiana.	Sandeep R	SR	Bhave
14	3	University of Chicago Medicine, Chicago, Illinois.	Theodore	T	Karrison
14	4	Radiation Oncology Associates, Dover, New Hampshire.	Jeffrey M	JM	Lemons
14	5	University of Chicago Medicine, Chicago, Illinois.	Paul	P	Chang
14	6	University of Chicago Medicine, Chicago, Illinois.	Yuanyuan	Y	Zha
14	7	University of Chicago Medicine, Chicago, Illinois.	Tim	T	Carll
14	8	University of Chicago Medicine, Chicago, Illinois.	Thomas	T	Krausz
14	9	University of Chicago Medicine, Chicago, Illinois.	Lei	L	Huang
14	10	University of Chicago Medicine, Chicago, Illinois.	Carlos	C	Martinez
14	11	University of Chicago Medicine, Chicago, Illinois.	Linda A	LA	Janisch
14	12	University of Chicago Medicine, Chicago, Illinois.	Robyn D	RD	Hseu
14	13	University of Chicago Medicine, Chicago, Illinois.	John W	JW	Moroney
14	14	Northwestern Medicine, Chicago, Illinois.	Jyoti D	JD	Patel
14	15	University of Chicago Medicine, Chicago, Illinois.	Nikolai N	NN	Khodarev
14	16	Duke Health, Durham, North Carolina.	Joseph K	JK	Salama
14	17	Dana-Farber Cancer Institute, Boston, Massachusetts.	Patrick A	PA	Ott
14	18	University of Chicago Medicine, Chicago, Illinois.	Gini F	GF	Fleming
14	19	University of Chicago Medicine, Chicago, Illinois.	Thomas F	TF	Gajewski
14	20	University of Chicago Medicine, Chicago, Illinois.	Ralph R	RR	Weichselbaum
14	21	University of Chicago Medicine, Chicago, Illinois.	Sean P	SP	Pitroda
14	22	University of Chicago Medicine, Chicago, Illinois. schmura@radonc.uchicago.edu.	Steven J	SJ	Chmura
15	0	"Harvard Medical School, Boston, Massachusetts.
Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts."	Shilpa	S	Grover
15	1	"Harvard Medical School, Boston, Massachusetts.
Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts."	Michael	M	Dougan
15	2	"Harvard Medical School, Boston, Massachusetts.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."	Kevin	K	Tyan
15	3	Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.	Anita	A	Giobbie-Hurder
15	4	"Harvard Medical School, Boston, Massachusetts.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Broad Institute at MIT and Harvard, Cambridge, Massachusetts.
Massachusetts General Hospital Cancer Center, Boston, Massachusetts."	Steven M	SM	Blum
15	5	Departments of Medicine and Pathology, Yale University School of Medicine, New Haven, Connecticut.	Jeffrey	J	Ishizuka
15	6	"Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Digestive Disease & Surgery Institute, Cleveland Clinic, Cleveland, Ohio."	Taha	T	Qazi
15	7	Hartford HealthCare Cancer Institute, Hartford, Connecticut.	Rawad	R	Elias
15	8	Harvard Medical School, Boston, Massachusetts.	Kruti B	KB	Vora
15	9	Harvard Medical School, Boston, Massachusetts.	Alex B	AB	Ruan
15	10	"Harvard Medical School, Boston, Massachusetts.
Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts."	William	W	Martin-Doyle
15	11	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Michael	M	Manos
15	12	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Lauren	L	Eastman
15	13	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Meredith	M	Davis
15	14	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Maria	M	Gargano
15	15	"Harvard Medical School, Boston, Massachusetts.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."	Rizwan	R	Haq
15	16	"Harvard Medical School, Boston, Massachusetts.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts."	Elizabeth I	EI	Buchbinder
15	17	Massachusetts General Hospital Cancer Center, Boston, Massachusetts.	Ryan J	RJ	Sullivan
15	18	"Harvard Medical School, Boston, Massachusetts.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Broad Institute at MIT and Harvard, Cambridge, Massachusetts.
Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts."	Patrick A	PA	Ott
15	19	"Harvard Medical School, Boston, Massachusetts.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."	F Stephen	FS	Hodi
15	20	"Harvard Medical School, Boston, Massachusetts.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."	Osama E	OE	Rahma
16	0	"Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Boston, MA.
Harvard Medical School, Boston, MA."	Shilpa	S	Grover
16	1	"Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Boston, MA.
Harvard Medical School, Boston, MA."	Alex B	AB	Ruan
16	2	Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Boston, MA.	Padmavathi	P	Srivoleti
16	3	Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA.	Anita	A	Giobbie-Hurder
16	4	"Harvard Medical School, Boston, MA.
Department of Radiology, Brigham and Women's Hospital, Boston, MA."	Marta	M	Braschi-Amirfarzan
16	5	"Harvard Medical School, Boston, MA.
Department of Pathology, Brigham and Women's Hospital, Boston, MA."	Amitabh	A	Srivastava
16	6	"Harvard Medical School, Boston, MA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Brookline, MA."	Elizabeth I	EI	Buchbinder
16	7	"Harvard Medical School, Boston, MA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Brookline, MA."	Patrick A	PA	Ott
16	8	"Harvard Medical School, Boston, MA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Brookline, MA."	Kenneth L	KL	Kehl
16	9	"Harvard Medical School, Boston, MA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Brookline, MA."	Mark M	MM	Awad
16	10	"Harvard Medical School, Boston, MA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Brookline, MA."	F Stephen	FS	Hodi
16	11	"Harvard Medical School, Boston, MA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Brookline, MA."	Osama E	OE	Rahma
17	0	Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.	Janice M	JM	Mehnert
17	1	University of California at San Francisco, San Francisco, California.	Emily	E	Bergsland
17	2	Simon Cancer Center, Indiana University, Indianapolis, Indiana.	Bert H	BH	O'Neil
17	3	"Humanitas Clinical and Research Center IRCCS, Rozzano (Mi), Italy.
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy."	Armando	A	Santoro
17	4	"Netherlands Cancer Institute, Amsterdam, The Netherlands.
Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands."	Jan H M	JHM	Schellens
17	5	University of Pennsylvania, Philadelphia, Pennsylvania.	Roger B	RB	Cohen
17	6	National Cancer Center Hospital East, Chiba, Japan.	Toshihiko	T	Doi
17	7	Dana-Farber Cancer Institute, Boston, Massachusetts.	Patrick A	PA	Ott
17	8	Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.	Michael J	MJ	Pishvaian
17	9	Roswell Park Comprehensive Cancer Center, Buffalo, New York.	Igor	I	Puzanov
17	10	Princess Margaret Cancer Centre, Toronto, Ontario, Canada.	Kyaw L	KL	Aung
17	11	National Taiwan University Hospital, Taipei, Taiwan.	Chiun	C	Hsu
17	12	"Department of Drug Development and Innovation, Curie Institute, Paris & Saint-Cloud, France.
INSERM U900 Research Unit, Curie Institute, Saint-Cloud, France.
Versailles-Saint-Quentin-en-Yvelines University, Montigny-le-Bretonneux, France."	Christophe	C	Le Tourneau
17	13	Gustave Roussy Institute of Oncology Cancer Center, Villejuif, France.	Antoine	A	Hollebecque
17	14	Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.	Elena	E	Élez
17	15	National Cancer Center Hospital, Tokyo, Japan.	Kenji	K	Tamura
17	16	Merck & Co., Inc., Kenilworth, New Jersey.	Marlena	M	Gould
17	17	Merck & Co., Inc., Kenilworth, New Jersey.	Ping	P	Yang
17	18	Merck & Co., Inc., Kenilworth, New Jersey.	Karen	K	Stein
17	19	The University of Texas MD Anderson Cancer Center, Houston, Texas.	Sarina A	SA	Piha-Paul
18	0	Department of Medical Oncology, Dana Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts, USA.	Vivek	V	Kumar
18	1	Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts, USA.	Atul B	AB	Shinagare
18	2	Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.	Helmut G	HG	Rennke
18	3	Transplant Nephrology, Boston Medical Center, Boston, Massachusetts, USA.	Sandeep	S	Ghai
18	4	Department of Medical Oncology, Dana Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts, USA.	Jochen H	JH	Lorch
18	5	Department of Medical Oncology, Dana Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts, USA.	Patrick A	PA	Ott
18	6	Department of Medical Oncology, Dana Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts, USA.	Osama E	OE	Rahma
19	0	Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.	P Kumar	PK	Rao
19	1	Memorial Sloan Kettering Cancer Center.	Christopher	C	Barker
19	2	Memorial Sloan Kettering Cancer Center.	Daniel G	DG	Coit
19	3	Mayo Clinic Cancer Center.	Richard W	RW	Joseph
19	4	Duke Cancer Institute.	Miguel	M	Materin
19	5	Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance.	Ramesh	R	Rengan
19	6	Robert H. Lurie Comprehensive Cancer Center of Northwestern University.	Jeffrey	J	Sosman
19	7	Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance.	John A	JA	Thompson
19	8	University of Wisconsin Carbone Cancer Center.	Mark R	MR	Albertini
19	9	Massachusetts General Hospital Cancer Center.	Genevieve	G	Boland
19	10	The Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute.	William E	WE	Carson Iii
19	11	O'Neal Comprehensive Cancer Center at UAB.	Carlo	C	Contreras
19	12	UC San Diego Moores Cancer Center.	Gregory A	GA	Daniels
19	13	Fred & Pamela Buffett Cancer Center.	Dominick	D	DiMaio
19	14	University of Michigan Rogel Cancer Center.	Alison	A	Durham
19	15	Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.	Ryan C	RC	Fields
19	16	The University of Tennessee Health Science Center.	Martin D	MD	Fleming
19	17	Yale Cancer Center/Smilow Cancer Hospital.	Anjela	A	Galan
19	18	Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.	Brian	B	Gastman
19	19	Huntsman Cancer Institute at the University of Utah.	Kenneth	K	Grossman
19	20	AIM at Melanoma.	Valerie	V	Guild
19	21	Vanderbilt-Ingram Cancer Center.	Douglas	D	Johnson
19	22	Abramson Cancer Center at the University of Pennsylvania.	Giorgos	G	Karakousis
19	23		Julie R	JR	Lange
19	24	The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.			
19	25	City of Hope National Medical Center.	Kim	K	Margolin
19	26	University of Colorado Cancer Center.	Sameer	S	Nath
19	27	Fox Chase Cancer Center.	Anthony J	AJ	Olszanski
19	28	Dana-Farber/Brigham and Women's Cancer Center.	Patrick A	PA	Ott
19	29	The University of Texas MD Anderson Cancer Center.	Merrick I	MI	Ross
19	30	Duke Cancer Institute.	April K	AK	Salama
19	31	Roswell Park Comprehensive Cancer Institute.	Joseph	J	Skitzki
19	32	Stanford Cancer Institute.	Susan M	SM	Swetter
19	33	Moffitt Cancer Center; and.	Evan	E	Wuthrick
19	34	National Comprehensive Cancer Network.	Nicole R	NR	McMillian
19	35	National Comprehensive Cancer Network.	Anita	A	Engh
20	0	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Harvard Medical School, Boston, Massachusetts.
Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts."	Annabelle J	AJ	Anandappa
20	1	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Harvard Medical School, Boston, Massachusetts.
Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Broad Institute of MIT and Harvard, Cambridge, Massachusetts."	Catherine J	CJ	Wu
20	2	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. patrick_ott@dfci.harvard.edu.
Harvard Medical School, Boston, Massachusetts.
Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Broad Institute of MIT and Harvard, Cambridge, Massachusetts."	Patrick A	PA	Ott
21	0	Department of Chemistry, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA.	Nicholas L	NL	Truex
21	1	Department of Chemistry, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA.	Rebecca L	RL	Holden
21	2	Department of Chemistry, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA.	Bin-You	BY	Wang
21	3	Department of Chemistry, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA.	Pu-Guang	PG	Chen
21	4	Department of Chemistry, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA.	Stephanie	S	Hanna
21	5	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.	Zhuting	Z	Hu
21	6	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, 02215, USA."	Keerthi	K	Shetty
21	7	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.	Oriol	O	Olive
21	8	Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.	Donna	D	Neuberg
21	9	"Harvard Medical School, Boston, MA, 02215, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.
Center for Cancer Research, Massachusetts General Hospital, Boston, MA, 02114, USA."	Nir	N	Hacohen
21	10	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Harvard Medical School, Boston, MA, 02215, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02215, USA."	Derin B	DB	Keskin
21	11	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Harvard Medical School, Boston, MA, 02215, USA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02215, USA."	Patrick A	PA	Ott
21	12	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. cwu@partners.org.
Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. cwu@partners.org.
Harvard Medical School, Boston, MA, 02215, USA. cwu@partners.org.
Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA. cwu@partners.org.
Center for Cancer Research, Massachusetts General Hospital, Boston, MA, 02114, USA. cwu@partners.org.
Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02215, USA. cwu@partners.org."	Catherine J	CJ	Wu
21	13	"Department of Chemistry, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA. blp@mit.edu.
Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA. blp@mit.edu.
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA. blp@mit.edu."	Bradley L	BL	Pentelute
22	0	Department of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: unchung8@yuhs.ac.	Hyun Cheol	HC	Chung
22	1	Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.	Sarina A	SA	Piha-Paul
22	2	Department of Medical Oncology, 12 de Octubre University Hospital and Research Institute (i+12), Madrid, Spain.	Jose	J	Lopez-Martin
22	3	Division of Pharmacology, Netherlands Cancer Institute, Amsterdam, Netherlands.	Jan H M	JHM	Schellens
22	4	Medical Oncology, Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia.	Steven	S	Kao
22	5	Segal Cancer Centre, Jewish General Hospital, Montreal, Quebec, Canada; Rossy Cancer Network, Montreal, Quebec, Canada; Department of Medicine, McGill University, Montreal, Quebec, Canada.	Wilson H	WH	Miller
22	6	Department of Oncology, Institut Claudius Regaud Institut Universitaire du Cancer-Oncopole, Toulouse, France.	Jean-Pierre	JP	Delord
22	7	Blacktown Hospital, Western Sydney Local Health District, Blacktown, New South Wales, Australia.	Bo	B	Gao
22	8	Department of Medical Oncology, Thoracic Group, Gustave Roussy, Villejuif, France.	David	D	Planchard
22	9	Oncology, Meir Medical Center, Kfar Saba, Israel.	Maya	M	Gottfried
22	10	Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel.	Alona	A	Zer
22	11	Indiana University, Simon Cancer Center, Indianapolis, Indiana.	Shadia I	SI	Jalal
22	12	Department of Medical Oncology, Centre Oscar Lambret, Lille, France.	Nicolas	N	Penel
22	13	Developmental Therapeutics, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.	Janice M	JM	Mehnert
22	14	Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Barcelona, Spain.	Ignacio	I	Matos
22	15	Institut de Cancérologie de l'Ouest, Nantes, France.	Jaafar	J	Bennouna
22	16	Seoul National University Hospital College of Medicine, Seoul, South Korea.	Dong-Wan	DW	Kim
22	17	Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey.	Lei	L	Xu
22	18	Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey.	Suba	S	Krishnan
22	19	Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey.	Kevin	K	Norwood
22	20	Dana-Farber Cancer Institute, Boston, Massachusetts.	Patrick A	PA	Ott
23	0	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD. Electronic address: dle@jhmi.edu.	Dung T	DT	Le
23	1	Dana-Farber Cancer Institute, Boston, MA.	Patrick A	PA	Ott
23	2	Bristol-Myers Squibb Company, Lawrenceville, NJ.	Beata	B	Korytowsky
23	3	Bristol-Myers Squibb Company, Lawrenceville, NJ.	Hannah	H	Le
23	4	Bristol-Myers Squibb Company, Lawrenceville, NJ.	T Kim	TK	Le
23	5	Bristol-Myers Squibb Company, Lawrenceville, NJ.	Ying	Y	Zhang
23	6	Bristol-Myers Squibb Company, Lawrenceville, NJ.	Gregory A	GA	Maglinte
23	7	Bristol-Myers Squibb Company, Lawrenceville, NJ.	Pranav	P	Abraham
23	8	Bristol-Myers Squibb Company, Lawrenceville, NJ.	Dhiren	D	Patel
23	9	Bristol-Myers Squibb Company, Lawrenceville, NJ.	Tong	T	Shangguan
23	10	Gastrointestinal and Lymphoma Unit, The Royal Marsden Hospital, Surrey, United Kingdom.	Ian	I	Chau
24	0	Cancer Institute, New York University School of Medicine, New York, New York.	Anna	A	Pavlick
24	1	Tisch Cancer Institute, Departments of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.	Ana B	AB	Blazquez
24	2	Tisch Cancer Institute, Departments of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.	Marcia	M	Meseck
24	3	Cancer Institute, New York University School of Medicine, New York, New York.	Michael	M	Lattanzi
24	4	Dana-Farber Cancer Institute, Boston, Massachusetts.	Patrick A	PA	Ott
24	5	Tisch Cancer Institute, Departments of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.	Thomas U	TU	Marron
24	6	New York University School of Medicine, New York, New York.	Rose Marie	RM	Holman
24	7	Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, New York.	John	J	Mandeli
24	8	Oncovir, Inc., Washington, D.C.	Andres M	AM	Salazar
24	9	Tisch Cancer Institute, Departments of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.	Christopher B	CB	McClain
24	10	Tisch Cancer Institute, Departments of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.	Gustavo	G	Gimenez
24	11	Tisch Cancer Institute, Departments of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.	Sreekumar	S	Balan
24	12	"Tisch Cancer Institute, Departments of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.
Precision Immunology Institute at the Icahn School of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York."	Sacha	S	Gnjatic
24	13	Genentech, San Francisco, California.	Rachel Lubong	RL	Sabado
24	14	"Tisch Cancer Institute, Departments of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York. nina.bhardwaj@mssm.edu.
Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, New York."	Nina	N	Bhardwaj
25	0	"Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany."	Marieke J	MJ	Krimphove
25	1	Department of Urology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany.	Karl H	KH	Tully
25	2	Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.	David F	DF	Friedlander
25	3	Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.	Maya	M	Marchese
25	4	Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.	Praful	P	Ravi
25	5	Department of General Internal Medicine and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.	Stuart R	SR	Lipsitz
25	6	Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.	Kerry L	KL	Kilbridge
25	7	Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.	Adam S	AS	Kibel
25	8	Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany.	Luis A	LA	Kluth
25	9	Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.	Patrick A	PA	Ott
25	10	Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.	Toni K	TK	Choueiri
25	11	Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. qtrinh@bwh.harvard.edu.	Quoc-Dien	QD	Trinh
26	0	Gastrointestinal and Lymphoma Unit, The Royal Marsden Hospital, Surrey, SM2 5PT, UK. Ian.Chau@rmh.nhs.uk.	Ian	I	Chau
26	1	Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, MD, USA.	Dung T	DT	Le
26	2	Dana-Farber Cancer Institute, Boston, MA, USA.	Patrick A	PA	Ott
26	3	Bristol-Myers Squibb Company, Lawrenceville, NJ, USA.	Beata	B	Korytowsky
26	4	Bristol-Myers Squibb Company, Lawrenceville, NJ, USA.	Hannah	H	Le
26	5	Bristol-Myers Squibb Company, Lawrenceville, NJ, USA.	T Kim	TK	Le
26	6	Bristol-Myers Squibb Company, Lawrenceville, NJ, USA.	Ying	Y	Zhang
26	7	Bristol-Myers Squibb Company, Lawrenceville, NJ, USA.	Teresa	T	Sanchez
26	8	Bristol-Myers Squibb Company, Lawrenceville, NJ, USA.	Gregory A	GA	Maglinte
26	9	Bristol-Myers Squibb Company, Lawrenceville, NJ, USA.	Melissa	M	Laurie
26	10	Bristol-Myers Squibb Company, Lawrenceville, NJ, USA.	Pranav	P	Abraham
26	11	Bristol-Myers Squibb Company, Lawrenceville, NJ, USA.	Dhiren	D	Patel
26	12	Bristol-Myers Squibb Company, Lawrenceville, NJ, USA.	Tong	T	Shangguan
27	0	Duke University Medical Center, Durham, North Carolina. Electronic address: neal.ready@duke.edu.	Neal E	NE	Ready
27	1	Dana Farber Cancer Institute, Boston, Massachusetts.	Patrick A	PA	Ott
27	2	Memorial Sloan-Kettering Cancer Center, New York, New York; Weill Cornell Medical College, New York, New York.	Matthew D	MD	Hellmann
27	3	University Hospital 12 de Octubre, Madrid, Spain.	Jon	J	Zugazagoitia
27	4	Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.	Christine L	CL	Hann
27	5	Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; University of Milan, Milan, Italy.	Filippo	F	de Braud
27	6	H. Lee Moffitt Cancer Center, Tampa, Florida.	Scott J	SJ	Antonia
27	7	"Istituto Nazionale Tumori IRCCS ""Fondazione G. Pascale"", Naples, Italy."	Paolo A	PA	Ascierto
27	8	START Madrid - FJD, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.	Victor	V	Moreno
27	9	Department of Oncology and Hematology, Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt, Germany.	Akin	A	Atmaca
27	10	Policlinico S.Orsola-Malpighi, Azienda Ospedaliero Universitaria, Bologna, Italy.	Stefania	S	Salvagni
27	11	Oregon Health & Science University, Portland, Oregon.	Matthew	M	Taylor
27	12	Levine Cancer Institute, Atrium Healthcare System, Charlotte, North Carolina.	Asim	A	Amin
27	13	University of Colorado Denver, Aurora, Colorado.	D Ross	DR	Camidge
27	14	Vanderbilt Ingram Cancer Center, Nashville, Tennessee.	Leora	L	Horn
27	15	START Madrid - CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain.	Emiliano	E	Calvo
27	16	Bristol-Myers Squibb, Lawrenceville, New Jersey.	Ang	A	Li
27	17	Bristol-Myers Squibb, Lawrenceville, New Jersey.	Wen Hong	WH	Lin
27	18	Memorial Sloan-Kettering Cancer Center, New York, New York.	Margaret K	MK	Callahan
27	19	Sarah Cannon Research Institute/Tennessee Oncology Nashville, Nashville, Tennessee.	David R	DR	Spigel
28	0	Gastrointestinal and Lymphoma Unit, The Royal Marsden Hospital, Surrey, SM2 5PT, UK. Ian.Chau@rmh.nhs.uk.	Ian	I	Chau
28	1	Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, MD, USA.	Dung T	DT	Le
28	2	Dana-Farber Cancer Institute, Boston, MA, USA.	Patrick A	PA	Ott
28	3	Bristol-Myers Squibb Company, Lawrenceville, NJ, USA.	Beata	B	Korytowsky
28	4	Bristol-Myers Squibb Company, Lawrenceville, NJ, USA.	Hannah	H	Le
28	5	Bristol-Myers Squibb Company, Lawrenceville, NJ, USA.	T Kim	TK	Le
28	6	Bristol-Myers Squibb Company, Lawrenceville, NJ, USA.	Ying	Y	Zhang
28	7	Bristol-Myers Squibb Company, Lawrenceville, NJ, USA.	Teresa	T	Sanchez
28	8	Bristol-Myers Squibb Company, Lawrenceville, NJ, USA.	Gregory A	GA	Maglinte
28	9	Bristol-Myers Squibb Company, Lawrenceville, NJ, USA.	Melissa	M	Laurie
28	10	Bristol-Myers Squibb Company, Lawrenceville, NJ, USA.	Pranav	P	Abraham
28	11	Bristol-Myers Squibb Company, Lawrenceville, NJ, USA.	Dhiren	D	Patel
28	12	Bristol-Myers Squibb Company, Lawrenceville, NJ, USA.	Tong	T	Shangguan
29	0	1 Department of Medical Oncology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA.	Patrick A	PA	Ott
29	1	2 Department of Microbiology and Immunology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC.	Gianpietro	G	Dotti
29	2	3 Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX.	Cassian	C	Yee
29	3	4 Center for Cancer Research, National Cancer Institute, Bethesda, MD.	Stephanie L	SL	Goff
30	0	Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.	Muhammad Mohsin	MM	Fareed
30	1	Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.	Luke R G	LRG	Pike
30	2	Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, ON, United States.	Andrew	A	Bang
30	3	Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.	Mai Anh	MA	Huynh
30	4	Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.	Allison	A	Taylor
30	5	Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.	Alexander	A	Spektor
30	6	Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.	Mark M	MM	Awad
30	7	Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.	Patrick A	PA	Ott
30	8	Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.	Monica	M	Krishnan
30	9	Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.	Tracy A	TA	Balboni
30	10	Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.	Jonathan D	JD	Schoenfeld
31	0	"Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.
Harvard Medical School, Boston, MA, USA."	Girish S	GS	Naik
31	1	"Harvard Medical School, Boston, MA, USA.
Division of Renal Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA."	Sushrut S	SS	Waikar
31	2	Institute of Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA, USA.	Alistair E W	AEW	Johnson
31	3	"Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.
Harvard Medical School, Boston, MA, USA."	Elizabeth I	EI	Buchbinder
31	4	"Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.
Harvard Medical School, Boston, MA, USA."	Rizwan	R	Haq
31	5	"Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.
Harvard Medical School, Boston, MA, USA."	F Stephen	FS	Hodi
31	6	"Harvard Medical School, Boston, MA, USA.
Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA."	Jonathan D	JD	Schoenfeld
31	7	"Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA. Patrick_Ott@dfci.harvard.edu.
Harvard Medical School, Boston, MA, USA. Patrick_Ott@dfci.harvard.edu.
Melanoma Center & Center for Immuno-Oncology, Boston, MA, USA. Patrick_Ott@dfci.harvard.edu."	Patrick A	PA	Ott
32	0	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
Harvard Medical School, Boston, Massachusetts."	Patrick A	PA	Ott
32	1	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. cwu@partners.org.
Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. cwu@partners.org.
Broad Institute of MIT and Harvard, Cambridge, Massachusetts. cwu@partners.org.
Harvard Medical School, Boston, Massachusetts. cwu@partners.org."	Catherine J	CJ	Wu
33	0	Melanoma Center & Center for Immuno-Oncology, Dana Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215-5450, USA. Electronic address: Patrick_Ott@DFCI.harvard.edu.	Patrick A	PA	Ott
34	0	Department of Medical Oncology, Melanoma Center, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215-5450, USA; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: Patrick_Ott@DFCI.harvard.edu.	Patrick A	PA	Ott
35	0	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Patrick A	PA	Ott
35	1	Department of Medical Oncology, New York University School of Medicine, New York, New York.	Anna C	AC	Pavlick
35	2	Department of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.	Douglas B	DB	Johnson
35	3	Florida Cancer Specialists and Research Institute, Fort Myers, Florida.	Lowell L	LL	Hart
35	4	Tennessee Oncology, PLLC, Nashville, Tennessee.	Jeffrey R	JR	Infante
35	5	Department of Hematology/Oncology, University of Chicago Medical Center, Chicago, Illinois.	Jason J	JJ	Luke
35	6	Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida.	Jose	J	Lutzky
35	7	Florida Cancer Specialists, West Palm Beach, Florida.	Neal E	NE	Rothschild
35	8	St. Mary's Medical Center, San Francisco, California.	Lynn E	LE	Spitler
35	9	Northern California Melanoma Center, Baylor University Medical Center, Dallas, Texas.	C Lance	CL	Cowey
35	10	Northside Hospital Cancer Institute, Decatur, Georgia.	Aaron R	AR	Alizadeh
35	11	Department of Medical Oncology, Duke University, Durham, North Carolina.	April K	AK	Salama
35	12	Celldex Therapeutics, Inc, Hampton, New Jersey.	Yi	Y	He
35	13	Celldex Therapeutics, Inc, Hampton, New Jersey.	Thomas R	TR	Hawthorne
35	14	Celldex Therapeutics, Inc, Hampton, New Jersey.	Rebecca G	RG	Bagley
35	15	Celldex Therapeutics, Inc, Hampton, New Jersey.	Joshua	J	Zhang
35	16	Celldex Therapeutics, Inc, Hampton, New Jersey.	Christopher D	CD	Turner
35	17	The Angeles Clinic and Research Institute, Los Angeles, California.	Omid	O	Hamid
36	0	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Harvard Medical School, Boston, MA, USA.
Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA."	Derin B	DB	Keskin
36	1	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA."	Annabelle J	AJ	Anandappa
36	2	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Jing	J	Sun
36	3	"Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel."	Itay	I	Tirosh
36	4	"Harvard Medical School, Boston, MA, USA.
Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA."	Nathan D	ND	Mathewson
36	5	"Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA."	Shuqiang	S	Li
36	6	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Giacomo	G	Oliveira
36	7	Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.	Anita	A	Giobbie-Hurder
36	8	Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Kristen	K	Felt
36	9	Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Evisa	E	Gjini
36	10	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA."	Sachet A	SA	Shukla
36	11	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Zhuting	Z	Hu
36	12	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Letitia	L	Li
36	13	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Phuong M	PM	Le
36	14	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Bio- and Health Informatics, Technical University of Denmark, Kongens Lyngby, Denmark."	Rosa L	RL	Allesøe
36	15	"Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Harvard Medical School, Boston, MA, USA.
Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA."	Alyssa R	AR	Richman
36	16	Broad Institute of MIT and Harvard, Cambridge, MA, USA.	Monika S	MS	Kowalczyk
36	17	Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Sara	S	Abdelrahman
36	18	Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.	Jack E	JE	Geduldig
36	19	Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.	Sarah	S	Charbonneau
36	20	Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.	Kristine	K	Pelton
36	21	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA."	J Bryan	JB	Iorgulescu
36	22	Broad Institute of MIT and Harvard, Cambridge, MA, USA.	Liudmila	L	Elagina
36	23	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Wandi	W	Zhang
36	24	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Oriol	O	Olive
36	25	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Christine	C	McCluskey
36	26	Department of Bio- and Health Informatics, Technical University of Denmark, Kongens Lyngby, Denmark.	Lars R	LR	Olsen
36	27	Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.	Jonathan	J	Stevens
36	28	"Harvard Medical School, Boston, MA, USA.
Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA."	William J	WJ	Lane
36	29	Oncovir Inc, Washington, DC, USA.	Andres M	AM	Salazar
36	30	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Heather	H	Daley
36	31	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA."	Patrick Y	PY	Wen
36	32	"Harvard Medical School, Boston, MA, USA.
Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA."	E Antonio	EA	Chiocca
36	33	Broad Institute of MIT and Harvard, Cambridge, MA, USA.	Maegan	M	Harden
36	34	Broad Institute of MIT and Harvard, Cambridge, MA, USA.	Niall J	NJ	Lennon
36	35	Broad Institute of MIT and Harvard, Cambridge, MA, USA.	Stacey	S	Gabriel
36	36	"Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Harvard Medical School, Boston, MA, USA.
Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA."	Gad	G	Getz
36	37	Broad Institute of MIT and Harvard, Cambridge, MA, USA.	Eric S	ES	Lander
36	38	Broad Institute of MIT and Harvard, Cambridge, MA, USA.	Aviv	A	Regev
36	39	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA."	Jerome	J	Ritz
36	40	Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.	Donna	D	Neuberg
36	41	"Harvard Medical School, Boston, MA, USA.
Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA."	Scott J	SJ	Rodig
36	42	"Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Harvard Medical School, Boston, MA, USA.
Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA."	Keith L	KL	Ligon
36	43	"Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Harvard Medical School, Boston, MA, USA.
Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA."	Mario L	ML	Suvà
36	44	"Harvard Medical School, Boston, MA, USA.
Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA."	Kai W	KW	Wucherpfennig
36	45	"Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Harvard Medical School, Boston, MA, USA.
Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA."	Nir	N	Hacohen
36	46	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Neon Therapeutics Inc, Cambridge, MA, USA."	Edward F	EF	Fritsch
36	47	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA."	Kenneth J	KJ	Livak
36	48	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA."	Patrick A	PA	Ott
36	49	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Harvard Medical School, Boston, MA, USA."	Catherine J	CJ	Wu
36	50	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. david_reardon@dfci.harvard.edu.
Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. david_reardon@dfci.harvard.edu.
Harvard Medical School, Boston, MA, USA. david_reardon@dfci.harvard.edu."	David A	DA	Reardon
37	0	Dana-Farber Cancer Institute, Boston, MA.	Patrick A	PA	Ott
37	1	Seoul National University College of Medicine, Seoul, The Republic of Korea.	Yung-Jue	YJ	Bang
37	2	University of Texas MD Anderson Cancer Center, Houston, TX.	Sarina A	SA	Piha-Paul
37	3	Princess Margaret Cancer Centre, Toronto, Ontario, Canada.	Albiruni R Abdul	ARA	Razak
37	4	Centre Hospitalier Universitaire Nantes, Nantes.	Jaafar	J	Bennouna
37	5	University Paris-Sud and Gustave Roussy, Villejuif, France.	Jean-Charles	JC	Soria
37	6	University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.	Hope S	HS	Rugo
37	7	University of Pennsylvania, Philadelphia, PA.	Roger B	RB	Cohen
37	8	Indiana University, Bloomington, IN.	Bert H	BH	O'Neil
37	9	Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.	Janice M	JM	Mehnert
37	10	Institute of Cancer Research, London, United Kingdom.	Juanita	J	Lopez
37	11	National Cancer Center Hospital East, Chiba, Japan.	Toshihiko	T	Doi
37	12	Netherlands Cancer Institute, Amsterdam, the Netherlands.	Emilie M J	EMJ	van Brummelen
37	13	Merck & Co., Inc., Kenilworth, NJ.	Razvan	R	Cristescu
37	14	Merck & Co., Inc., Kenilworth, NJ.	Ping	P	Yang
37	15	Merck & Co., Inc., Kenilworth, NJ.	Kenneth	K	Emancipator
37	16	Merck & Co., Inc., Kenilworth, NJ.	Karen	K	Stein
37	17	Merck & Co., Inc., Kenilworth, NJ.	Mark	M	Ayers
37	18	Merck & Co., Inc., Kenilworth, NJ.	Andrew K	AK	Joe
37	19	Merck & Co., Inc., Kenilworth, NJ.	Jared K	JK	Lunceford
38	0	Department of Drug Development, Gustave Roussy Cancer Campus, Villejuif, France. Electronic address: Andrea.VARGA@gustaveroussy.fr.	Andrea	A	Varga
38	1	Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.	Sarina	S	Piha-Paul
38	2	Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Patrick A	PA	Ott
38	3	Developmental Therapeutics/Phase I Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.	Janice M	JM	Mehnert
38	4	Service de Cancérologie médicale, ICO Centre René Gauducheau, Saint-Herblain, France.	Dominique	D	Berton-Rigaud
38	5	Department of Oncology, Merck & Co., Inc., Kenilworth, NJ, USA.	Anne	A	Morosky
38	6	Biostatistics and Research Decision Sciences, MSD China, Beijing, China.	Ping	P	Yang
38	7	Department of Oncology, Merck & Co., Inc., Kenilworth, NJ, USA.	Jane	J	Ruman
38	8	Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.	Daniela	D	Matei
39	0	Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana 2127, Boston, MA, 02215, USA.	Romualdo	R	Barroso-Sousa
39	1	Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana 2127, Boston, MA, 02215, USA. patrick_ott@dfci.harvard.edu.	Patrick A	PA	Ott
40	0	MD Anderson Cancer Center, Houston, TX, USA.	Aung	A	Naing
40	1	Sarah Cannon Research Institute / Tennessee Oncology, PLLC, Nashville, TN, USA.	Jeffrey R	JR	Infante
40	2	START Center for Cancer Care, San Antonio, TX, USA.	Kyriakos P	KP	Papadopoulos
40	3	ARMO BioSciences, Eli Lilly and Company, Redwood City, CA, USA.	Ivan H	IH	Chan
40	4	Memorial Sloan Kettering Cancer Center, New York, NY, USA.	Cong	C	Shen
40	5	ARMO BioSciences, Eli Lilly and Company, Redwood City, CA, USA.	Navneet P	NP	Ratti
40	6	ARMO BioSciences, Eli Lilly and Company, Redwood City, CA, USA.	Bianca	B	Rojo
40	7	Memorial Sloan Kettering Cancer Center, New York, NY, USA.	Karen A	KA	Autio
40	8	University of California Los Angeles (UCLA), Los Angeles, CA, USA.	Deborah J	DJ	Wong
40	9	Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL, USA.	Manish R	MR	Patel
40	10	Dana-Farber Cancer Institute, Boston, MA, USA.	Patrick A	PA	Ott
40	11	Sarah Cannon Research Institute at HealthONE, Denver, CO, USA.	Gerald S	GS	Falchook
40	12	Oklahoma University, Oklahoma City, OK, USA.	Shubham	S	Pant
40	13	ARMO BioSciences, Eli Lilly and Company, Redwood City, CA, USA.	Annie	A	Hung
40	14	ARMO BioSciences, Eli Lilly and Company, Redwood City, CA, USA.	Kara L	KL	Pekarek
40	15	ARMO BioSciences, Eli Lilly and Company, Redwood City, CA, USA.	Victoria	V	Wu
40	16	Memorial Sloan Kettering Cancer Center, New York, NY, USA.	Matthew	M	Adamow
40	17	ARMO BioSciences, Eli Lilly and Company, Redwood City, CA, USA.	Scott	S	McCauley
40	18	ARMO BioSciences, Eli Lilly and Company, Redwood City, CA, USA.	John B	JB	Mumm
40	19	Memorial Sloan Kettering Cancer Center, New York, NY, USA.	Phillip	P	Wong
40	20	ARMO BioSciences, Eli Lilly and Company, Redwood City, CA, USA.	Peter	P	Van Vlasselaer
40	21	ARMO BioSciences, Eli Lilly and Company, Redwood City, CA, USA.	Joseph	J	Leveque
40	22	MD Anderson Cancer Center, Houston, TX, USA.	Nizar M	NM	Tannir
40	23	ARMO BioSciences, Eli Lilly and Company, Redwood City, CA, USA. Electronic address: martinoft@gmail.com.	Martin	M	Oft
41	0	Broad Institute of MIT and Harvard, Cambridge, MA, USA.	Livnat	L	Jerby-Arnon
41	1	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Parin	P	Shah
41	2	Broad Institute of MIT and Harvard, Cambridge, MA, USA.	Michael S	MS	Cuoco
41	3	Broad Institute of MIT and Harvard, Cambridge, MA, USA.	Christopher	C	Rodman
41	4	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Center for Cancer Precision Medicine of Dana-Farber Cancer Institute, Boston, MA, USA.	Mei-Ju	MJ	Su
41	5	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Johannes C	JC	Melms
41	6	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Center for Cancer Precision Medicine of Dana-Farber Cancer Institute, Boston, MA, USA.	Rachel	R	Leeson
41	7	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Center for Cancer Precision Medicine of Dana-Farber Cancer Institute, Boston, MA, USA.	Abhay	A	Kanodia
41	8	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Laboratory for Systems Pharmacology, Harvard Medical School, Boston, MA, USA.	Shaolin	S	Mei
41	9	Laboratory for Systems Pharmacology, Harvard Medical School, Boston, MA, USA.	Jia-Ren	JR	Lin
41	10	Laboratory for Systems Pharmacology, Harvard Medical School, Boston, MA, USA.	Shu	S	Wang
41	11	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Bokang	B	Rabasha
41	12	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	David	D	Liu
41	13	Molecular & Cellular Oncogenesis Program and Melanoma Research Center, The Wistar Institute, Philadelphia, PA, USA.	Gao	G	Zhang
41	14	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Claire	C	Margolais
41	15	Broad Institute of MIT and Harvard, Cambridge, MA, USA.	Orr	O	Ashenberg
41	16	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Patrick A	PA	Ott
41	17	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Elizabeth I	EI	Buchbinder
41	18	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Rizwan	R	Haq
41	19	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	F Stephen	FS	Hodi
41	20	Massachusetts General Hospital Cancer Center, Boston, MA, USA.	Genevieve M	GM	Boland
41	21	Massachusetts General Hospital Cancer Center, Boston, MA, USA.	Ryan J	RJ	Sullivan
41	22	Massachusetts General Hospital Cancer Center, Boston, MA, USA.	Dennie T	DT	Frederick
41	23	Massachusetts General Hospital Cancer Center, Boston, MA, USA.	Benchun	B	Miao
41	24	Massachusetts General Hospital Cancer Center, Boston, MA, USA.	Tabea	T	Moll
41	25	Massachusetts General Hospital Cancer Center, Boston, MA, USA.	Keith T	KT	Flaherty
41	26	Molecular & Cellular Oncogenesis Program and Melanoma Research Center, The Wistar Institute, Philadelphia, PA, USA.	Meenhard	M	Herlyn
41	27	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Massachusetts General Hospital Cancer Center, Boston, MA, USA.	Russell W	RW	Jenkins
41	28	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Rohit	R	Thummalapalli
41	29	Broad Institute of MIT and Harvard, Cambridge, MA, USA; Celsius Therapeutics, Cambridge, MA, USA.	Monika S	MS	Kowalczyk
41	30	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Israel	I	Cañadas
41	31	Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium, Essen, Germany; Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany.	Bastian	B	Schilling
41	32	Center for Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.	Adam N R	ANR	Cartwright
41	33	Center for Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.	Adrienne M	AM	Luoma
41	34	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Shruti	S	Malu
41	35	Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.	Patrick	P	Hwu
41	36	Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.	Chantale	C	Bernatchez
41	37	Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.	Marie-Andrée	MA	Forget
41	38	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	David A	DA	Barbie
41	39	Broad Institute of MIT and Harvard, Cambridge, MA, USA.	Alex K	AK	Shalek
41	40	Broad Institute of MIT and Harvard, Cambridge, MA, USA.	Itay	I	Tirosh
41	41	Laboratory for Systems Pharmacology, Harvard Medical School, Boston, MA, USA.	Peter K	PK	Sorger
41	42	Center for Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.	Kai	K	Wucherpfennig
41	43	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Eliezer M	EM	Van Allen
41	44	Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium, Essen, Germany.	Dirk	D	Schadendorf
41	45	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Center for Cancer Precision Medicine of Dana-Farber Cancer Institute, Boston, MA, USA.	Bruce E	BE	Johnson
41	46	Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Center for Cancer Precision Medicine of Dana-Farber Cancer Institute, Boston, MA, USA.	Asaf	A	Rotem
41	47	Broad Institute of MIT and Harvard, Cambridge, MA, USA.	Orit	O	Rozenblatt-Rosen
41	48	Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Center for Cancer Precision Medicine of Dana-Farber Cancer Institute, Boston, MA, USA; Ludwig Center for Cancer Research at Harvard, Boston, MA, USA; Howard Hughes Medical Institute, Chevy Chase, MD, USA.	Levi A	LA	Garraway
41	49	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Brigham and Women's Hospital, Department of Surgical Oncology, Boston, MA, USA.	Charles H	CH	Yoon
41	50	Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Center for Cancer Precision Medicine of Dana-Farber Cancer Institute, Boston, MA, USA; Laboratory for Systems Pharmacology, Harvard Medical School, Boston, MA, USA; Center for Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA; Ludwig Center for Cancer Research at Harvard, Boston, MA, USA. Electronic address: benjamin_izar@dfci.harvard.edu.	Benjamin	B	Izar
41	51	Broad Institute of MIT and Harvard, Cambridge, MA, USA; Howard Hughes Medical Institute, Chevy Chase, MD, USA; Ludwig Center for Cancer Research at MIT, Boston, MA, USA; Massachusetts Institute of Technology, Department of Biology, Cambridge, MA, USA.	Aviv	A	Regev
42	0	Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.	Frederick C	FC	Morgan
42	1	Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.	Juanita	J	Duran
42	2	Value and Population Health Management, Dana-Farber Cancer Institute, Boston, Massachusetts.	Belen	B	Fraile
42	3	Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.	Pritesh S	PS	Karia
42	4	Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Melanoma Disease Center, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.	Jennifer Y	JY	Lin
42	5	Melanoma Disease Center, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.	Patrick A	PA	Ott
42	6	Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.	Emily Stamell	ES	Ruiz
42	7	Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.	David M	DM	Wang
42	8	Value and Population Health Management, Dana-Farber Cancer Institute, Boston, Massachusetts.	Yichen	Y	Zhang
42	9	Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: cschmults@bwh.harvard.edu.	Chrysalyne D	CD	Schmults
43	0	Merck & Co., Kenilworth, NJ 07033, USA. razvan_cristescu@merck.com.	Razvan	R	Cristescu
43	1	Merck & Co., Kenilworth, NJ 07033, USA.	Robin	R	Mogg
43	2	Merck & Co., Kenilworth, NJ 07033, USA.	Mark	M	Ayers
43	3	Merck & Co., Kenilworth, NJ 07033, USA.	Andrew	A	Albright
43	4	Merck & Co., Kenilworth, NJ 07033, USA.	Erin	E	Murphy
43	5	Merck & Co., Kenilworth, NJ 07033, USA.	Jennifer	J	Yearley
43	6	Merck & Co., Kenilworth, NJ 07033, USA.	Xinwei	X	Sher
43	7	Merck & Co., Kenilworth, NJ 07033, USA.	Xiao Qiao	XQ	Liu
43	8	Merck & Co., Kenilworth, NJ 07033, USA.	Hongchao	H	Lu
43	9	Merck & Co., Kenilworth, NJ 07033, USA.	Michael	M	Nebozhyn
43	10	Merck & Co., Kenilworth, NJ 07033, USA.	Chunsheng	C	Zhang
43	11	Merck & Co., Kenilworth, NJ 07033, USA.	Jared K	JK	Lunceford
43	12	Merck & Co., Kenilworth, NJ 07033, USA.	Andrew	A	Joe
43	13	Merck & Co., Kenilworth, NJ 07033, USA.	Jonathan	J	Cheng
43	14	Merck & Co., Kenilworth, NJ 07033, USA.	Andrea L	AL	Webber
43	15	Merck & Co., Kenilworth, NJ 07033, USA.	Nageatte	N	Ibrahim
43	16	Fox Chase Cancer Center, Philadelphia, PA 19111, USA.	Elizabeth R	ER	Plimack
43	17	Dana-Farber Cancer Institute, Boston, MA 02215, USA.	Patrick A	PA	Ott
43	18	University of Chicago, Chicago, IL 60637, USA.	Tanguy Y	TY	Seiwert
43	19	University of California, Los Angeles, Los Angeles, CA 90095, USA.	Antoni	A	Ribas
43	20	Merck & Co., Kenilworth, NJ 07033, USA.	Terrill K	TK	McClanahan
43	21	Merck & Co., Kenilworth, NJ 07033, USA.	Joanne E	JE	Tomassini
43	22	Merck & Co., Kenilworth, NJ 07033, USA.	Andrey	A	Loboda
43	23	Merck & Co., Kenilworth, NJ 07033, USA.	David	D	Kaufman
44	0	Brigham and Women's Hospital and Dana-Farber/Harvard Cancer Center, Boston, Massachusetts; Harvard Radiation Oncology Program, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: lrpike@partners.org.	Luke R G	LRG	Pike
44	1	Brigham and Women's Hospital and Dana-Farber/Harvard Cancer Center, Boston, Massachusetts; Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.	Andrew	A	Bang
44	2	Brigham and Women's Hospital and Dana-Farber/Harvard Cancer Center, Boston, Massachusetts; Harvard Radiation Oncology Program, Massachusetts General Hospital, Boston, Massachusetts.	Brandon A	BA	Mahal
44	3	Brigham and Women's Hospital and Dana-Farber/Harvard Cancer Center, Boston, Massachusetts.	Allison	A	Taylor
44	4	Brigham and Women's Hospital and Dana-Farber/Harvard Cancer Center, Boston, Massachusetts.	Monica	M	Krishnan
44	5	Brigham and Women's Hospital and Dana-Farber/Harvard Cancer Center, Boston, Massachusetts.	Alexander	A	Spektor
44	6	Brigham and Women's Hospital and Dana-Farber/Harvard Cancer Center, Boston, Massachusetts.	Daniel N	DN	Cagney
44	7	Brigham and Women's Hospital and Dana-Farber/Harvard Cancer Center, Boston, Massachusetts.	Ayal A	AA	Aizer
44	8	Brigham and Women's Hospital and Dana-Farber/Harvard Cancer Center, Boston, Massachusetts.	Brian M	BM	Alexander
44	9	Brigham and Women's Hospital and Dana-Farber/Harvard Cancer Center, Boston, Massachusetts.	Osama	O	Rahma
44	10	Brigham and Women's Hospital and Dana-Farber/Harvard Cancer Center, Boston, Massachusetts.	Tracy	T	Balboni
44	11	Brigham and Women's Hospital and Dana-Farber/Harvard Cancer Center, Boston, Massachusetts.	Patrick A	PA	Ott
44	12	Brigham and Women's Hospital and Dana-Farber/Harvard Cancer Center, Boston, Massachusetts.	F Stephen	FS	Hodi
44	13	Brigham and Women's Hospital and Dana-Farber/Harvard Cancer Center, Boston, Massachusetts.	Jonathan D	JD	Schoenfeld
45	0	Department of Medicine, Medical University of South Carolina, Charleston, South Carolina.	Shalin	S	Shah
45	1	Department of Medicine, University of Chicago, Chicago, Illinois.	Jason J	JJ	Luke
45	2	"Department of Radiology, Brigham and Women's Hospital.
Department of Biostatics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA."	Heather A	HA	Jacene
45	3	"Department of Radiology, Brigham and Women's Hospital.
Department of Biostatics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA."	Tianqi	T	Chen
45	4	"Department of Radiology, Brigham and Women's Hospital.
Department of Biostatics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA."	Anita	A	Giobbie-Hurder
45	5	Department of Medicine, Dana-Farber Cancer Institute.	Nageatte	N	Ibrahim
45	6	Department of Medicine, Beth Israel Deaconess Medical Center.	Elizabeth L	EL	Buchbinder
45	7	Department of Medicine, Beth Israel Deaconess Medical Center.	David F	DF	McDermott
45	8	Department of Medicine, Massachusetts General Hospital Cancer Center.	Keith T	KT	Flaherty
45	9	Department of Medicine, Massachusetts General Hospital Cancer Center.	Ryan J	RJ	Sullivan
45	10	Department of Medicine, Massachusetts General Hospital Cancer Center.	Donald P	DP	Lawrence
45	11	Department of Medicine, Dana-Farber Cancer Institute.	Patrick A	PA	Ott
45	12	Department of Medicine, Dana-Farber Cancer Institute.	F Stephen	FS	Hodi
46	0	"Harvard Medical School, Boston, MA, USA.
Department of Dermatology, University of California Irvine, School of Medicine, Irvine, CA, USA."	Allison S	AS	Dobry
46	1	"Center for Surgery and Public Health, Brigham and Women's Hospital, Boston, MA, USA.
Yale School of Medicine, New Haven, CT, USA."	Cheryl K	CK	Zogg
46	2	"Harvard Medical School, Boston, MA, USA.
Melanoma Center and Center for Immuno-Oncology, Dana-Farber Cancer Center, Boston, MA, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA."	F Stephen	FS	Hodi
46	3	"Harvard Medical School, Boston, MA, USA.
Department of Neurosurgery, Brigham and Women's Hospital, Computational Neuroscience Outcomes Center, Boston, MA, USA."	Timothy R	TR	Smith
46	4	"Harvard Medical School, Boston, MA, USA.
Melanoma Center and Center for Immuno-Oncology, Dana-Farber Cancer Center, Boston, MA, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA."	Patrick A	PA	Ott
46	5	"Harvard Medical School, Boston, MA, USA. jiorgulescu@bwh.harvard.edu.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. jiorgulescu@bwh.harvard.edu.
Department of Neurosurgery, Brigham and Women's Hospital, Computational Neuroscience Outcomes Center, Boston, MA, USA. jiorgulescu@bwh.harvard.edu.
Department of Pathology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, 75 Francis St., Boston, MA, 02115, USA. jiorgulescu@bwh.harvard.edu."	J Bryan	JB	Iorgulescu
47	0	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.	Zhuting	Z	Hu
47	1	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Harvard Medical School, Boston, MA."	Annabelle J	AJ	Anandappa
47	2	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.	Jing	J	Sun
47	3	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.	Jintaek	J	Kim
47	4	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Harvard Medical School, Boston, MA."	Donna E	DE	Leet
47	5	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Harvard Medical School, Boston, MA."	David J	DJ	Bozym
47	6	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.	Christina	C	Chen
47	7	Broad Institute of MIT and Harvard, Cambridge, MA.	Louise	L	Williams
47	8	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Broad Institute of MIT and Harvard, Cambridge, MA.
Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA."	Sachet A	SA	Shukla
47	9	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.	Wandi	W	Zhang
47	10	Broad Institute of MIT and Harvard, Cambridge, MA.	Diana	D	Tabbaa
47	11	Broad Institute of MIT and Harvard, Cambridge, MA.	Scott	S	Steelman
47	12	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.	Oriol	O	Olive
47	13	Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA.	Kenneth J	KJ	Livak
47	14	Department of Immunology, University of Toyama, Toyama, Japan.	Hiroyuki	H	Kishi
47	15	Department of Immunology, University of Toyama, Toyama, Japan.	Atsushi	A	Muraguchi
47	16	Department of Pathology, Brigham and Women's Hospital, Boston, MA.	Indira	I	Guleria
47	17	Department of Pathology, Brigham and Women's Hospital, Boston, MA.	Jonathan	J	Stevens
47	18	"Harvard Medical School, Boston, MA.
Department of Pathology, Brigham and Women's Hospital, Boston, MA."	William J	WJ	Lane
47	19	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.	Ute E	UE	Burkhardt
47	20	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Broad Institute of MIT and Harvard, Cambridge, MA."	Edward F	EF	Fritsch
47	21	Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA.	Donna	D	Neuberg
47	22	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Harvard Medical School, Boston, MA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA; and."	Patrick A	PA	Ott
47	23	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Harvard Medical School, Boston, MA.
Broad Institute of MIT and Harvard, Cambridge, MA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA; and."	Derin B	DB	Keskin
47	24	"Harvard Medical School, Boston, MA.
Broad Institute of MIT and Harvard, Cambridge, MA.
Massachusetts General Hospital, Boston, MA."	Nir	N	Hacohen
47	25	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Harvard Medical School, Boston, MA.
Broad Institute of MIT and Harvard, Cambridge, MA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA; and."	Catherine J	CJ	Wu
48	0	Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Johanna Bendell, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; Joseph W. Kim, Yale Cancer Center, New Haven, CT; Paolo A. Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Katriina Peltola, Docrates Cancer Center, Helsinki, Finland; Dirk Jaeger, University Hospital Heidelberg, Heidelberg, Germany; Jeffry Evans, University of Glasgow, Glasgow; Ian Chau, Royal Marsden Hospital, London and Surrey, United Kingdom; Christopher T. Harbison, Cecile Dorange, Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ; and Dung T. Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.	Yelena Y	YY	Janjigian
48	1	Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Johanna Bendell, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; Joseph W. Kim, Yale Cancer Center, New Haven, CT; Paolo A. Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Katriina Peltola, Docrates Cancer Center, Helsinki, Finland; Dirk Jaeger, University Hospital Heidelberg, Heidelberg, Germany; Jeffry Evans, University of Glasgow, Glasgow; Ian Chau, Royal Marsden Hospital, London and Surrey, United Kingdom; Christopher T. Harbison, Cecile Dorange, Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ; and Dung T. Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.	Johanna	J	Bendell
48	2	Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Johanna Bendell, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; Joseph W. Kim, Yale Cancer Center, New Haven, CT; Paolo A. Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Katriina Peltola, Docrates Cancer Center, Helsinki, Finland; Dirk Jaeger, University Hospital Heidelberg, Heidelberg, Germany; Jeffry Evans, University of Glasgow, Glasgow; Ian Chau, Royal Marsden Hospital, London and Surrey, United Kingdom; Christopher T. Harbison, Cecile Dorange, Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ; and Dung T. Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.	Emiliano	E	Calvo
48	3	Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Johanna Bendell, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; Joseph W. Kim, Yale Cancer Center, New Haven, CT; Paolo A. Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Katriina Peltola, Docrates Cancer Center, Helsinki, Finland; Dirk Jaeger, University Hospital Heidelberg, Heidelberg, Germany; Jeffry Evans, University of Glasgow, Glasgow; Ian Chau, Royal Marsden Hospital, London and Surrey, United Kingdom; Christopher T. Harbison, Cecile Dorange, Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ; and Dung T. Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.	Joseph W	JW	Kim
48	4	Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Johanna Bendell, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; Joseph W. Kim, Yale Cancer Center, New Haven, CT; Paolo A. Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Katriina Peltola, Docrates Cancer Center, Helsinki, Finland; Dirk Jaeger, University Hospital Heidelberg, Heidelberg, Germany; Jeffry Evans, University of Glasgow, Glasgow; Ian Chau, Royal Marsden Hospital, London and Surrey, United Kingdom; Christopher T. Harbison, Cecile Dorange, Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ; and Dung T. Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.	Paolo A	PA	Ascierto
48	5	Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Johanna Bendell, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; Joseph W. Kim, Yale Cancer Center, New Haven, CT; Paolo A. Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Katriina Peltola, Docrates Cancer Center, Helsinki, Finland; Dirk Jaeger, University Hospital Heidelberg, Heidelberg, Germany; Jeffry Evans, University of Glasgow, Glasgow; Ian Chau, Royal Marsden Hospital, London and Surrey, United Kingdom; Christopher T. Harbison, Cecile Dorange, Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ; and Dung T. Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.	Padmanee	P	Sharma
48	6	Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Johanna Bendell, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; Joseph W. Kim, Yale Cancer Center, New Haven, CT; Paolo A. Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Katriina Peltola, Docrates Cancer Center, Helsinki, Finland; Dirk Jaeger, University Hospital Heidelberg, Heidelberg, Germany; Jeffry Evans, University of Glasgow, Glasgow; Ian Chau, Royal Marsden Hospital, London and Surrey, United Kingdom; Christopher T. Harbison, Cecile Dorange, Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ; and Dung T. Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.	Patrick A	PA	Ott
48	7	Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Johanna Bendell, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; Joseph W. Kim, Yale Cancer Center, New Haven, CT; Paolo A. Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Katriina Peltola, Docrates Cancer Center, Helsinki, Finland; Dirk Jaeger, University Hospital Heidelberg, Heidelberg, Germany; Jeffry Evans, University of Glasgow, Glasgow; Ian Chau, Royal Marsden Hospital, London and Surrey, United Kingdom; Christopher T. Harbison, Cecile Dorange, Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ; and Dung T. Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.	Katriina	K	Peltola
48	8	Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Johanna Bendell, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; Joseph W. Kim, Yale Cancer Center, New Haven, CT; Paolo A. Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Katriina Peltola, Docrates Cancer Center, Helsinki, Finland; Dirk Jaeger, University Hospital Heidelberg, Heidelberg, Germany; Jeffry Evans, University of Glasgow, Glasgow; Ian Chau, Royal Marsden Hospital, London and Surrey, United Kingdom; Christopher T. Harbison, Cecile Dorange, Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ; and Dung T. Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.	Dirk	D	Jaeger
48	9	Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Johanna Bendell, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; Joseph W. Kim, Yale Cancer Center, New Haven, CT; Paolo A. Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Katriina Peltola, Docrates Cancer Center, Helsinki, Finland; Dirk Jaeger, University Hospital Heidelberg, Heidelberg, Germany; Jeffry Evans, University of Glasgow, Glasgow; Ian Chau, Royal Marsden Hospital, London and Surrey, United Kingdom; Christopher T. Harbison, Cecile Dorange, Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ; and Dung T. Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.	Jeffry	J	Evans
48	10	Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Johanna Bendell, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; Joseph W. Kim, Yale Cancer Center, New Haven, CT; Paolo A. Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Katriina Peltola, Docrates Cancer Center, Helsinki, Finland; Dirk Jaeger, University Hospital Heidelberg, Heidelberg, Germany; Jeffry Evans, University of Glasgow, Glasgow; Ian Chau, Royal Marsden Hospital, London and Surrey, United Kingdom; Christopher T. Harbison, Cecile Dorange, Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ; and Dung T. Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.	Filippo	F	de Braud
48	11	Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Johanna Bendell, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; Joseph W. Kim, Yale Cancer Center, New Haven, CT; Paolo A. Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Katriina Peltola, Docrates Cancer Center, Helsinki, Finland; Dirk Jaeger, University Hospital Heidelberg, Heidelberg, Germany; Jeffry Evans, University of Glasgow, Glasgow; Ian Chau, Royal Marsden Hospital, London and Surrey, United Kingdom; Christopher T. Harbison, Cecile Dorange, Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ; and Dung T. Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.	Ian	I	Chau
48	12	Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Johanna Bendell, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; Joseph W. Kim, Yale Cancer Center, New Haven, CT; Paolo A. Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Katriina Peltola, Docrates Cancer Center, Helsinki, Finland; Dirk Jaeger, University Hospital Heidelberg, Heidelberg, Germany; Jeffry Evans, University of Glasgow, Glasgow; Ian Chau, Royal Marsden Hospital, London and Surrey, United Kingdom; Christopher T. Harbison, Cecile Dorange, Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ; and Dung T. Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.	Christopher T	CT	Harbison
48	13	Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Johanna Bendell, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; Joseph W. Kim, Yale Cancer Center, New Haven, CT; Paolo A. Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Katriina Peltola, Docrates Cancer Center, Helsinki, Finland; Dirk Jaeger, University Hospital Heidelberg, Heidelberg, Germany; Jeffry Evans, University of Glasgow, Glasgow; Ian Chau, Royal Marsden Hospital, London and Surrey, United Kingdom; Christopher T. Harbison, Cecile Dorange, Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ; and Dung T. Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.	Cecile	C	Dorange
48	14	Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Johanna Bendell, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; Joseph W. Kim, Yale Cancer Center, New Haven, CT; Paolo A. Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Katriina Peltola, Docrates Cancer Center, Helsinki, Finland; Dirk Jaeger, University Hospital Heidelberg, Heidelberg, Germany; Jeffry Evans, University of Glasgow, Glasgow; Ian Chau, Royal Marsden Hospital, London and Surrey, United Kingdom; Christopher T. Harbison, Cecile Dorange, Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ; and Dung T. Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.	Marina	M	Tschaika
48	15	Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Johanna Bendell, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; Joseph W. Kim, Yale Cancer Center, New Haven, CT; Paolo A. Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Katriina Peltola, Docrates Cancer Center, Helsinki, Finland; Dirk Jaeger, University Hospital Heidelberg, Heidelberg, Germany; Jeffry Evans, University of Glasgow, Glasgow; Ian Chau, Royal Marsden Hospital, London and Surrey, United Kingdom; Christopher T. Harbison, Cecile Dorange, Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ; and Dung T. Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.	Dung T	DT	Le
49	0	Division of Medical Oncology, UHN Princess Margaret Cancer Centre, Toronto, Ontario, Canada. Electronic address: aaron.hansen@uhn.ca.	A R	AR	Hansen
49	1	Department of Medical Oncology, Gustave Roussy, Villejuif, France.	C	C	Massard
49	2	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.	P A	PA	Ott
49	3	Division of Hematology Oncology, Hospital of the University of Pennsylvania, Philadelphia, USA.	N B	NB	Haas
49	4	The Royal Marsden and the Institute of Cancer Research, London, UK.	J S	JS	Lopez
49	5	Department of Medical Oncology, Virginia G. Piper Cancer Center at HonorHealth, Scottsdale, USA.	S	S	Ejadi
49	6	Department of Medical Oncology, Associates in Oncology & Hematology, Rockville, USA.	J M	JM	Wallmark
49	7	Department of HematoOncology, Seoul National University Hospital, Seoul, Republic of Korea.	B	B	Keam
49	8	Department of Medical Oncology, Institut Claudius Regaud, Toulouse, France.	J-P	JP	Delord
49	9	Department of Medicine, Division of Hematology/Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA.	R	R	Aggarwal
49	10	Department of Oncology, Merck & Co., Inc, Kenilworth, USA.	M	M	Gould
49	11	Department of Oncology, Merck & Co., Inc, Kenilworth, USA.	P	P	Yang
49	12	Department of Oncology, Merck & Co., Inc, Kenilworth, USA.	S M	SM	Keefe
49	13	Department of Investigational Clinical Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.	S A	SA	Piha-Paul
50	0	Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California. Hope.Rugo@ucsf.edu.	Hope S	HS	Rugo
50	1	Department of Medical Oncology, Institut Claudius Regaud, Oncolpole-Toulouse, France.	Jean-Pierre	JP	Delord
50	2	Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.	Seock-Ah	SA	Im
50	3	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Patrick A	PA	Ott
50	4	Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.	Sarina A	SA	Piha-Paul
50	5	Division of Medical Oncology, UHN Princess Margaret Cancer Centre, Toronto, ON, Canada.	Philippe L	PL	Bedard
50	6	Breast and GYN Early Trials Program, Scottsdale Healthcare Shea Medical Center, Scottsdale, Arizona.	Jasgit	J	Sachdev
50	7	Department of Drug Development and Innovation, Institut Curie, Paris & Saint-Cloud, France, INSERM U900 Research Unit, Saint-Cloud France, and Versailles-Saint-Quentin-en-Yvelines University, Montigny-le-Bretonneux, France.	Christophe	C	Le Tourneau
50	8	Department of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam, the Netherlands.	Emilie M J	EMJ	van Brummelen
50	9	Drug Development Department, Gustave Roussy, Villejuif, France.	Andrea	A	Varga
50	10	Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.	Roberto	R	Salgado
50	11	Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.	Sherene	S	Loi
50	12	Department of Clinical Oncology, Merck & Co., Inc., Kenilworth, New Jersey.	Sanatan	S	Saraf
50	13	Department of Clinical Oncology, Merck & Co., Inc., Kenilworth, New Jersey.	Dina	D	Pietrangelo
50	14	Department of Clinical Oncology, Merck & Co., Inc., Kenilworth, New Jersey.	Vassiliki	V	Karantza
50	15	Division of Medical Oncology, Department of Medicine, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.	Antoinette R	AR	Tan
51	0		Patrick A	PA	Ott
51	1		Zhuting	Z	Hu
51	2		Derin B	DB	Keskin
51	3		Sachet A	SA	Shukla
51	4		Jing	J	Sun
51	5		David J	DJ	Bozym
51	6		Wandi	W	Zhang
51	7		Adrienne	A	Luoma
51	8		Anita	A	Giobbie-Hurder
51	9		Lauren	L	Peter
51	10		Christina	C	Chen
51	11		Oriol	O	Olive
51	12		Todd A	TA	Carter
51	13		Shuqiang	S	Li
51	14		David J	DJ	Lieb
51	15		Thomas	T	Eisenhaure
51	16		Evisa	E	Gjini
51	17		Jonathan	J	Stevens
51	18		William J	WJ	Lane
51	19		Indu	I	Javeri
51	20		Kaliappanadar	K	Nellaiappan
51	21		Andres M	AM	Salazar
51	22		Heather	H	Daley
51	23		Michael	M	Seaman
51	24		Elizabeth I	EI	Buchbinder
51	25		Charles H	CH	Yoon
51	26		Maegan	M	Harden
51	27		Niall	N	Lennon
51	28		Stacey	S	Gabriel
51	29		Scott J	SJ	Rodig
51	30		Dan H	DH	Barouch
51	31		Jon C	JC	Aster
51	32		Gad	G	Getz
51	33		Kai	K	Wucherpfennig
51	34		Donna	D	Neuberg
51	35		Jerome	J	Ritz
51	36		Eric S	ES	Lander
51	37		Edward F	EF	Fritsch
51	38		Nir	N	Hacohen
51	39		Catherine J	CJ	Wu
52	0	Department of Medical Oncology, Dana Farber Cancer Institute, the Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.	Patrick A	PA	Ott
53	0	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Romualdo	R	Barroso-Sousa
53	1	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Patrick A	PA	Ott
53	2	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	F Stephen	FS	Hodi
53	3	Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Boston, Massachusetts.	Ursula B	UB	Kaiser
53	4	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Sara M	SM	Tolaney
53	5	Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Boston, Massachusetts.	Le	L	Min
54	0	Patrick A. Ott: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.	Romualdo	R	Barroso-Sousa
54	1	Patrick A. Ott: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.	Patrick A	PA	Ott
55	0	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.	Zhuting	Z	Hu
55	1	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.
Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
Harvard Medical School, Boston, Massachusetts 02115, USA."	Patrick A	PA	Ott
55	2	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.
Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
Harvard Medical School, Boston, Massachusetts 02115, USA.
Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA."	Catherine J	CJ	Wu
56	0	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Division of Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts."	Russell W	RW	Jenkins
56	1	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts."	Amir R	AR	Aref
56	2	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts."	Patrick H	PH	Lizotte
56	3	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts."	Elena	E	Ivanova
56	4	Gilead Sciences, Foster City, California.	Susanna	S	Stinson
56	5	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts."	Chensheng W	CW	Zhou
56	6	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts."	Michaela	M	Bowden
56	7	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Jiehui	J	Deng
56	8	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Laboratory of Systems Pharmacology, Harvard Medical School, Boston, Massachusetts."	Hongye	H	Liu
56	9	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Broad Institute of Harvard and MIT, Cambridge, Massachusetts."	Diana	D	Miao
56	10	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Harvard Graduate Program in Biophysics, Boston, Massachusetts."	Meng Xiao	MX	He
56	11	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts."	William	W	Walker
56	12	Melanoma Research Center and Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, Pennsylvania.	Gao	G	Zhang
56	13	Department of Computer Science, New Jersey Institute of Technology, Newark, New Jersey.	Tian	T	Tian
56	14	Department of Computer Science, New Jersey Institute of Technology, Newark, New Jersey.	Chaoran	C	Cheng
56	15	Department of Computer Science, New Jersey Institute of Technology, Newark, New Jersey.	Zhi	Z	Wei
56	16	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts."	Sangeetha	S	Palakurthi
56	17	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts."	Mark	M	Bittinger
56	18	Division of Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.	Hans	H	Vitzthum
56	19	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Broad Institute of Harvard and MIT, Cambridge, Massachusetts."	Jong Wook	JW	Kim
56	20	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Ashley	A	Merlino
56	21	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Max	M	Quinn
56	22	Gilead Sciences, Foster City, California.	Chandrasekar	C	Venkataramani
56	23	Gilead Sciences, Foster City, California.	Joshua A	JA	Kaplan
56	24	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts."	Andrew	A	Portell
56	25	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts."	Prafulla C	PC	Gokhale
56	26	Gilead Sciences, Foster City, California.	Bart	B	Phillips
56	27	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Broad Institute of Harvard and MIT, Cambridge, Massachusetts."	Alicia	A	Smart
56	28	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Asaf	A	Rotem
56	29	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts."	Robert E	RE	Jones
56	30	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts."	Lauren	L	Keogh
56	31	Center for Applied Medical Research, University of Navarra, Pamplona, Spain.	Maria	M	Anguiano
56	32	Gilead Sciences, Foster City, California.	Lance	L	Stapleton
56	33	Gilead Sciences, Foster City, California.	Zhiheng	Z	Jia
56	34	Division of Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.	Michal	M	Barzily-Rokni
56	35	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Israel	I	Cañadas
56	36	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Tran C	TC	Thai
56	37	Division of Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.	Marc R	MR	Hammond
56	38	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts."	Raven	R	Vlahos
56	39	Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Eric S	ES	Wang
56	40	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Hua	H	Zhang
56	41	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Shuai	S	Li
56	42	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Glenn J	GJ	Hanna
56	43	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts."	Wei	W	Huang
56	44	Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.	Mai P	MP	Hoang
56	45	Department of Pathology, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts.	Adriano	A	Piris
56	46	Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.	Jean-Pierre	JP	Eliane
56	47	Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.	Anat O	AO	Stemmer-Rachamimov
56	48	Confocal and Light Microscopy Core Facility, Dana-Farber Cancer Institute, Boston, Massachusetts.	Lisa	L	Cameron
56	49	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Mei-Ju	MJ	Su
56	50	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Parin	P	Shah
56	51	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Broad Institute of Harvard and MIT, Cambridge, Massachusetts."	Benjamin	B	Izar
56	52	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts."	Manisha	M	Thakuria
56	53	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts."	Nicole R	NR	LeBoeuf
56	54	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Guilherme	G	Rabinowits
56	55	Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.	Viswanath	V	Gunda
56	56	Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.	Sareh	S	Parangi
56	57	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	James M	JM	Cleary
56	58	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Brian C	BC	Miller
56	59	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Shunsuke	S	Kitajima
56	60	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Rohit	R	Thummalapalli
56	61	Division of Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.	Benchun	B	Miao
56	62	Department of Surgical Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.	Thanh U	TU	Barbie
56	63	Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts.	Vivek	V	Sivathanu
56	64	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Joshua	J	Wong
56	65	Division of Thoracic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.	William G	WG	Richards
56	66	Division of Thoracic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.	Raphael	R	Bueno
56	67	Department of Surgical Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.	Charles H	CH	Yoon
56	68	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts."	Juan	J	Miret
56	69	Melanoma Research Center and Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, Pennsylvania.	Meenhard	M	Herlyn
56	70	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Levi A	LA	Garraway
56	71	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Broad Institute of Harvard and MIT, Cambridge, Massachusetts."	Eliezer M	EM	Van Allen
56	72	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Gordon J	GJ	Freeman
56	73	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts."	Paul T	PT	Kirschmeier
56	74	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Jochen H	JH	Lorch
56	75	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Patrick A	PA	Ott
56	76	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	F Stephen	FS	Hodi
56	77	Division of Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.	Keith T	KT	Flaherty
56	78	"Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts."	Roger D	RD	Kamm
56	79	Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.	Genevieve M	GM	Boland
56	80	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts."	Kwok-Kin	KK	Wong
56	81	Gilead Sciences, Foster City, California. dbarbie@partners.org CloudP_Paweletz@dfci.harvard.edu David.Dornan@gilead.com.	David	D	Dornan
56	82	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. dbarbie@partners.org CloudP_Paweletz@dfci.harvard.edu David.Dornan@gilead.com.
Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts."	Cloud Peter	CP	Paweletz
56	83	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. dbarbie@partners.org CloudP_Paweletz@dfci.harvard.edu David.Dornan@gilead.com.	David A	DA	Barbie
57	0	Jean-Sebastien Frenel, Institut de Cancerologie de l'Ouest, Centre René Gauducheau, Saint-Herblain; Christophe Le Tourneau, Institut Curie, Paris and Saint-Cloud, and Institut National de la Santé et de la Recherche Médicale U900 Research Unit, Saint-Cloud; Carlos Gomez-Roca, Institut Claudius Regaud, Toulouse; Andrea Varga, Gustave Roussy, Villejuif, France; Bert O'Neil, Indiana University Health University Hospital, Indianapolis, IN; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Sarina A. Piha-Paul, The University of Texas MD Anderson Cancer Center, Houston, TX; Emilie M.J. van Brummelen, The Netherlands Cancer Institute, Amsterdam, Netherlands; Hope S. Rugo, University of California, San Francisco, San Francisco, CA; and Shari Thomas, Sanatan Saraf, and Reshma Rangwala, Merck & Co., Inc., Kenilworth, NJ.	Jean-Sebastien	JS	Frenel
57	1	Jean-Sebastien Frenel, Institut de Cancerologie de l'Ouest, Centre René Gauducheau, Saint-Herblain; Christophe Le Tourneau, Institut Curie, Paris and Saint-Cloud, and Institut National de la Santé et de la Recherche Médicale U900 Research Unit, Saint-Cloud; Carlos Gomez-Roca, Institut Claudius Regaud, Toulouse; Andrea Varga, Gustave Roussy, Villejuif, France; Bert O'Neil, Indiana University Health University Hospital, Indianapolis, IN; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Sarina A. Piha-Paul, The University of Texas MD Anderson Cancer Center, Houston, TX; Emilie M.J. van Brummelen, The Netherlands Cancer Institute, Amsterdam, Netherlands; Hope S. Rugo, University of California, San Francisco, San Francisco, CA; and Shari Thomas, Sanatan Saraf, and Reshma Rangwala, Merck & Co., Inc., Kenilworth, NJ.	Christophe	C	Le Tourneau
57	2	Jean-Sebastien Frenel, Institut de Cancerologie de l'Ouest, Centre René Gauducheau, Saint-Herblain; Christophe Le Tourneau, Institut Curie, Paris and Saint-Cloud, and Institut National de la Santé et de la Recherche Médicale U900 Research Unit, Saint-Cloud; Carlos Gomez-Roca, Institut Claudius Regaud, Toulouse; Andrea Varga, Gustave Roussy, Villejuif, France; Bert O'Neil, Indiana University Health University Hospital, Indianapolis, IN; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Sarina A. Piha-Paul, The University of Texas MD Anderson Cancer Center, Houston, TX; Emilie M.J. van Brummelen, The Netherlands Cancer Institute, Amsterdam, Netherlands; Hope S. Rugo, University of California, San Francisco, San Francisco, CA; and Shari Thomas, Sanatan Saraf, and Reshma Rangwala, Merck & Co., Inc., Kenilworth, NJ.	Bert	B	O'Neil
57	3	Jean-Sebastien Frenel, Institut de Cancerologie de l'Ouest, Centre René Gauducheau, Saint-Herblain; Christophe Le Tourneau, Institut Curie, Paris and Saint-Cloud, and Institut National de la Santé et de la Recherche Médicale U900 Research Unit, Saint-Cloud; Carlos Gomez-Roca, Institut Claudius Regaud, Toulouse; Andrea Varga, Gustave Roussy, Villejuif, France; Bert O'Neil, Indiana University Health University Hospital, Indianapolis, IN; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Sarina A. Piha-Paul, The University of Texas MD Anderson Cancer Center, Houston, TX; Emilie M.J. van Brummelen, The Netherlands Cancer Institute, Amsterdam, Netherlands; Hope S. Rugo, University of California, San Francisco, San Francisco, CA; and Shari Thomas, Sanatan Saraf, and Reshma Rangwala, Merck & Co., Inc., Kenilworth, NJ.	Patrick A	PA	Ott
57	4	Jean-Sebastien Frenel, Institut de Cancerologie de l'Ouest, Centre René Gauducheau, Saint-Herblain; Christophe Le Tourneau, Institut Curie, Paris and Saint-Cloud, and Institut National de la Santé et de la Recherche Médicale U900 Research Unit, Saint-Cloud; Carlos Gomez-Roca, Institut Claudius Regaud, Toulouse; Andrea Varga, Gustave Roussy, Villejuif, France; Bert O'Neil, Indiana University Health University Hospital, Indianapolis, IN; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Sarina A. Piha-Paul, The University of Texas MD Anderson Cancer Center, Houston, TX; Emilie M.J. van Brummelen, The Netherlands Cancer Institute, Amsterdam, Netherlands; Hope S. Rugo, University of California, San Francisco, San Francisco, CA; and Shari Thomas, Sanatan Saraf, and Reshma Rangwala, Merck & Co., Inc., Kenilworth, NJ.	Sarina A	SA	Piha-Paul
57	5	Jean-Sebastien Frenel, Institut de Cancerologie de l'Ouest, Centre René Gauducheau, Saint-Herblain; Christophe Le Tourneau, Institut Curie, Paris and Saint-Cloud, and Institut National de la Santé et de la Recherche Médicale U900 Research Unit, Saint-Cloud; Carlos Gomez-Roca, Institut Claudius Regaud, Toulouse; Andrea Varga, Gustave Roussy, Villejuif, France; Bert O'Neil, Indiana University Health University Hospital, Indianapolis, IN; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Sarina A. Piha-Paul, The University of Texas MD Anderson Cancer Center, Houston, TX; Emilie M.J. van Brummelen, The Netherlands Cancer Institute, Amsterdam, Netherlands; Hope S. Rugo, University of California, San Francisco, San Francisco, CA; and Shari Thomas, Sanatan Saraf, and Reshma Rangwala, Merck & Co., Inc., Kenilworth, NJ.	Carlos	C	Gomez-Roca
57	6	Jean-Sebastien Frenel, Institut de Cancerologie de l'Ouest, Centre René Gauducheau, Saint-Herblain; Christophe Le Tourneau, Institut Curie, Paris and Saint-Cloud, and Institut National de la Santé et de la Recherche Médicale U900 Research Unit, Saint-Cloud; Carlos Gomez-Roca, Institut Claudius Regaud, Toulouse; Andrea Varga, Gustave Roussy, Villejuif, France; Bert O'Neil, Indiana University Health University Hospital, Indianapolis, IN; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Sarina A. Piha-Paul, The University of Texas MD Anderson Cancer Center, Houston, TX; Emilie M.J. van Brummelen, The Netherlands Cancer Institute, Amsterdam, Netherlands; Hope S. Rugo, University of California, San Francisco, San Francisco, CA; and Shari Thomas, Sanatan Saraf, and Reshma Rangwala, Merck & Co., Inc., Kenilworth, NJ.	Emilie M J	EMJ	van Brummelen
57	7	Jean-Sebastien Frenel, Institut de Cancerologie de l'Ouest, Centre René Gauducheau, Saint-Herblain; Christophe Le Tourneau, Institut Curie, Paris and Saint-Cloud, and Institut National de la Santé et de la Recherche Médicale U900 Research Unit, Saint-Cloud; Carlos Gomez-Roca, Institut Claudius Regaud, Toulouse; Andrea Varga, Gustave Roussy, Villejuif, France; Bert O'Neil, Indiana University Health University Hospital, Indianapolis, IN; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Sarina A. Piha-Paul, The University of Texas MD Anderson Cancer Center, Houston, TX; Emilie M.J. van Brummelen, The Netherlands Cancer Institute, Amsterdam, Netherlands; Hope S. Rugo, University of California, San Francisco, San Francisco, CA; and Shari Thomas, Sanatan Saraf, and Reshma Rangwala, Merck & Co., Inc., Kenilworth, NJ.	Hope S	HS	Rugo
57	8	Jean-Sebastien Frenel, Institut de Cancerologie de l'Ouest, Centre René Gauducheau, Saint-Herblain; Christophe Le Tourneau, Institut Curie, Paris and Saint-Cloud, and Institut National de la Santé et de la Recherche Médicale U900 Research Unit, Saint-Cloud; Carlos Gomez-Roca, Institut Claudius Regaud, Toulouse; Andrea Varga, Gustave Roussy, Villejuif, France; Bert O'Neil, Indiana University Health University Hospital, Indianapolis, IN; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Sarina A. Piha-Paul, The University of Texas MD Anderson Cancer Center, Houston, TX; Emilie M.J. van Brummelen, The Netherlands Cancer Institute, Amsterdam, Netherlands; Hope S. Rugo, University of California, San Francisco, San Francisco, CA; and Shari Thomas, Sanatan Saraf, and Reshma Rangwala, Merck & Co., Inc., Kenilworth, NJ.	Shari	S	Thomas
57	9	Jean-Sebastien Frenel, Institut de Cancerologie de l'Ouest, Centre René Gauducheau, Saint-Herblain; Christophe Le Tourneau, Institut Curie, Paris and Saint-Cloud, and Institut National de la Santé et de la Recherche Médicale U900 Research Unit, Saint-Cloud; Carlos Gomez-Roca, Institut Claudius Regaud, Toulouse; Andrea Varga, Gustave Roussy, Villejuif, France; Bert O'Neil, Indiana University Health University Hospital, Indianapolis, IN; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Sarina A. Piha-Paul, The University of Texas MD Anderson Cancer Center, Houston, TX; Emilie M.J. van Brummelen, The Netherlands Cancer Institute, Amsterdam, Netherlands; Hope S. Rugo, University of California, San Francisco, San Francisco, CA; and Shari Thomas, Sanatan Saraf, and Reshma Rangwala, Merck & Co., Inc., Kenilworth, NJ.	Sanatan	S	Saraf
57	10	Jean-Sebastien Frenel, Institut de Cancerologie de l'Ouest, Centre René Gauducheau, Saint-Herblain; Christophe Le Tourneau, Institut Curie, Paris and Saint-Cloud, and Institut National de la Santé et de la Recherche Médicale U900 Research Unit, Saint-Cloud; Carlos Gomez-Roca, Institut Claudius Regaud, Toulouse; Andrea Varga, Gustave Roussy, Villejuif, France; Bert O'Neil, Indiana University Health University Hospital, Indianapolis, IN; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Sarina A. Piha-Paul, The University of Texas MD Anderson Cancer Center, Houston, TX; Emilie M.J. van Brummelen, The Netherlands Cancer Institute, Amsterdam, Netherlands; Hope S. Rugo, University of California, San Francisco, San Francisco, CA; and Shari Thomas, Sanatan Saraf, and Reshma Rangwala, Merck & Co., Inc., Kenilworth, NJ.	Reshma	R	Rangwala
57	11	Jean-Sebastien Frenel, Institut de Cancerologie de l'Ouest, Centre René Gauducheau, Saint-Herblain; Christophe Le Tourneau, Institut Curie, Paris and Saint-Cloud, and Institut National de la Santé et de la Recherche Médicale U900 Research Unit, Saint-Cloud; Carlos Gomez-Roca, Institut Claudius Regaud, Toulouse; Andrea Varga, Gustave Roussy, Villejuif, France; Bert O'Neil, Indiana University Health University Hospital, Indianapolis, IN; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Sarina A. Piha-Paul, The University of Texas MD Anderson Cancer Center, Houston, TX; Emilie M.J. van Brummelen, The Netherlands Cancer Institute, Amsterdam, Netherlands; Hope S. Rugo, University of California, San Francisco, San Francisco, CA; and Shari Thomas, Sanatan Saraf, and Reshma Rangwala, Merck & Co., Inc., Kenilworth, NJ.	Andrea	A	Varga
58	0	"Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Boston, Massachusetts.
MetroWest Medical Center, Framingham, Massachusetts."	Hyunju	H	Lee
58	1	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	F Stephen	FS	Hodi
58	2	Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Anita	A	Giobbie-Hurder
58	3	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Patrick A	PA	Ott
58	4	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Elizabeth I	EI	Buchbinder
58	5	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Rizwan	R	Haq
58	6	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Sara	S	Tolaney
58	7	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Romualdo	R	Barroso-Sousa
58	8	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Kevin	K	Zhang
58	9	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Hilary	H	Donahue
58	10	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Meredith	M	Davis
58	11	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Maria E	ME	Gargano
58	12	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Kristina M	KM	Kelley
58	13	Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Boston, Massachusetts.	Rona S	RS	Carroll
58	14	Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Boston, Massachusetts.	Ursula B	UB	Kaiser
58	15	Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Boston, Massachusetts. lmin1@partners.org.	Le	L	Min
59	0	Patrick A. Ott, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; and Jean-Charles Soria, Gustave Roussy and University Paris-Sud, Villejuif, France.	Patrick A	PA	Ott
59	1	Patrick A. Ott, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; and Jean-Charles Soria, Gustave Roussy and University Paris-Sud, Villejuif, France.	Jean-Charles	JC	Soria
60	0	Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Elena Elez, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Sandrine Hiret, ICO René Gauducheau, Nantes, France; Dong-Wan Kim, Seoul National University Hospital, Seoul, South Korea; Anne Morosky, Sanatan Saraf, and Bilal Piperdi, Merck & Co, Kenilworth; and Janice M. Mehnert, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.	Patrick A	PA	Ott
60	1	Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Elena Elez, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Sandrine Hiret, ICO René Gauducheau, Nantes, France; Dong-Wan Kim, Seoul National University Hospital, Seoul, South Korea; Anne Morosky, Sanatan Saraf, and Bilal Piperdi, Merck & Co, Kenilworth; and Janice M. Mehnert, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.	Elena	E	Elez
60	2	Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Elena Elez, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Sandrine Hiret, ICO René Gauducheau, Nantes, France; Dong-Wan Kim, Seoul National University Hospital, Seoul, South Korea; Anne Morosky, Sanatan Saraf, and Bilal Piperdi, Merck & Co, Kenilworth; and Janice M. Mehnert, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.	Sandrine	S	Hiret
60	3	Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Elena Elez, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Sandrine Hiret, ICO René Gauducheau, Nantes, France; Dong-Wan Kim, Seoul National University Hospital, Seoul, South Korea; Anne Morosky, Sanatan Saraf, and Bilal Piperdi, Merck & Co, Kenilworth; and Janice M. Mehnert, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.	Dong-Wan	DW	Kim
60	4	Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Elena Elez, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Sandrine Hiret, ICO René Gauducheau, Nantes, France; Dong-Wan Kim, Seoul National University Hospital, Seoul, South Korea; Anne Morosky, Sanatan Saraf, and Bilal Piperdi, Merck & Co, Kenilworth; and Janice M. Mehnert, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.	Anne	A	Morosky
60	5	Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Elena Elez, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Sandrine Hiret, ICO René Gauducheau, Nantes, France; Dong-Wan Kim, Seoul National University Hospital, Seoul, South Korea; Anne Morosky, Sanatan Saraf, and Bilal Piperdi, Merck & Co, Kenilworth; and Janice M. Mehnert, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.	Sanatan	S	Saraf
60	6	Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Elena Elez, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Sandrine Hiret, ICO René Gauducheau, Nantes, France; Dong-Wan Kim, Seoul National University Hospital, Seoul, South Korea; Anne Morosky, Sanatan Saraf, and Bilal Piperdi, Merck & Co, Kenilworth; and Janice M. Mehnert, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.	Bilal	B	Piperdi
60	7	Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Elena Elez, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Sandrine Hiret, ICO René Gauducheau, Nantes, France; Dong-Wan Kim, Seoul National University Hospital, Seoul, South Korea; Anne Morosky, Sanatan Saraf, and Bilal Piperdi, Merck & Co, Kenilworth; and Janice M. Mehnert, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.	Janice M	JM	Mehnert
61	0	Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave D1230, Boston, MA, 02215, USA.	Dylan J	DJ	Martini
61	1	Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave D1230, Boston, MA, 02215, USA.	Aly-Khan A	AA	Lalani
61	2	Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave D1230, Boston, MA, 02215, USA.	Dominick	D	Bossé
61	3	Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave D1230, Boston, MA, 02215, USA.	John A	JA	Steinharter
61	4	Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave D1230, Boston, MA, 02215, USA.	Lauren C	LC	Harshman
61	5	"Melanoma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Center for Immuno-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA."	F Stephen	FS	Hodi
61	6	"Melanoma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Center for Immuno-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA."	Patrick A	PA	Ott
61	7	Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave D1230, Boston, MA, 02215, USA. Toni_Choueiri@dfci.harvard.edu.	Toni K	TK	Choueiri
62	0	Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.	Raphael B	RB	Moreira
62	1	Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.	Lana	L	Hamieh
62	2	Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Evisa	E	Gjini
62	3	Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Ana	A	Lako
62	4	Department of Imaging, Dana Farber Cancer Institute, Brigham and Women's Hospital Harvard Medical School, Boston, MA, USA.	Katherine M	KM	Krajewski
62	5	Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.	Charles H	CH	Yoon
62	6	"Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA. Patrick_Ott@dfci.harvard.edu.
Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Patrick_Ott@dfci.harvard.edu.
Melanoma Disease Center & Center for Immuno-Oncology, Dana Farber Cancer Institute Harvard Medical School, Boston, MA, 02215, USA. Patrick_Ott@dfci.harvard.edu."	Patrick A	PA	Ott
63	0	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.
Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02215, USA.
Harvard Medical School, Boston, Massachusetts 02215, USA."	Patrick A	PA	Ott
63	1	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.	Zhuting	Z	Hu
63	2	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.
Harvard Medical School, Boston, Massachusetts 02215, USA.
Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA."	Derin B	DB	Keskin
63	3	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.
Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA."	Sachet A	SA	Shukla
63	4	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.	Jing	J	Sun
63	5	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.	David J	DJ	Bozym
63	6	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.	Wandi	W	Zhang
63	7	Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.	Adrienne	A	Luoma
63	8	Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.	Anita	A	Giobbie-Hurder
63	9	"Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA.
Ragon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts 02139, USA."	Lauren	L	Peter
63	10	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.	Christina	C	Chen
63	11	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.	Oriol	O	Olive
63	12	Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.	Todd A	TA	Carter
63	13	Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.	Shuqiang	S	Li
63	14	Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.	David J	DJ	Lieb
63	15	Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.	Thomas	T	Eisenhaure
63	16	Center for Immuno-Oncology (CIO), Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.	Evisa	E	Gjini
63	17	Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts 02215, USA.	Jonathan	J	Stevens
63	18	Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts 02215, USA.	William J	WJ	Lane
63	19	CuriRx, Inc., Wilmington, Massachusetts 01887, USA.	Indu	I	Javeri
63	20	CuriRx, Inc., Wilmington, Massachusetts 01887, USA.	Kaliappanadar	K	Nellaiappan
63	21	Oncovir, Inc., 3203 Cleveland Avenue, NW, Washington DC 20008, USA.	Andres M	AM	Salazar
63	22	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.	Heather	H	Daley
63	23	Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA.	Michael	M	Seaman
63	24	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.
Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02215, USA.
Harvard Medical School, Boston, Massachusetts 02215, USA."	Elizabeth I	EI	Buchbinder
63	25	"Harvard Medical School, Boston, Massachusetts 02215, USA.
Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts 02215, USA."	Charles H	CH	Yoon
63	26	Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.	Maegan	M	Harden
63	27	Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.	Niall	N	Lennon
63	28	Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.	Stacey	S	Gabriel
63	29	"Center for Immuno-Oncology (CIO), Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.
Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts 02215, USA."	Scott J	SJ	Rodig
63	30	"Harvard Medical School, Boston, Massachusetts 02215, USA.
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA.
Ragon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts 02139, USA."	Dan H	DH	Barouch
63	31	"Harvard Medical School, Boston, Massachusetts 02215, USA.
Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts 02215, USA."	Jon C	JC	Aster
63	32	"Harvard Medical School, Boston, Massachusetts 02215, USA.
Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA."	Gad	G	Getz
63	33	"Harvard Medical School, Boston, Massachusetts 02215, USA.
Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA."	Kai	K	Wucherpfennig
63	34	Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.	Donna	D	Neuberg
63	35	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.
Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02215, USA.
Harvard Medical School, Boston, Massachusetts 02215, USA."	Jerome	J	Ritz
63	36	"Harvard Medical School, Boston, Massachusetts 02215, USA.
Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA."	Eric S	ES	Lander
63	37	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.
Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA."	Edward F	EF	Fritsch
63	38	"Harvard Medical School, Boston, Massachusetts 02215, USA.
Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA."	Nir	N	Hacohen
63	39	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.
Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02215, USA.
Harvard Medical School, Boston, Massachusetts 02215, USA.
Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA."	Catherine J	CJ	Wu
64	0	The Ronald O. Perelman Department of Dermatology, Perlmutter Cancer Center, New York University School of Medicine, New York, NY, USA.	Chloe	C	Goldman
64	1		Jeremy	J	Tchack
64	2		Eric M	EM	Robinson
64	3		Sung Won	SW	Han
64	4		Una	U	Moran
64	5		David	D	Polsky
64	6		Russell S	RS	Berman
64	7		Richard L	RL	Shapiro
64	8		Patrick A	PA	Ott
64	9		Iman	I	Osman
64	10		Hua	H	Zhong
64	11		Anna C	AC	Pavlick
64	12		Melissa Ann	MA	Wilson
65	0	Department of Radiology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts. Mizuki_Nishino@dfci.harvard.edu.	Mizuki	M	Nishino
65	1	Department of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Anita	A	Giobbie-Hurder
65	2	"Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.
Department of Medicine, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts."	Michael P	MP	Manos
65	3	"Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.
Department of Medicine, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts."	Nancy	N	Bailey
65	4	"Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.
Department of Medicine, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts."	Elizabeth I	EI	Buchbinder
65	5	"Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.
Department of Medicine, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts."	Patrick A	PA	Ott
65	6	Department of Radiology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts.	Nikhil H	NH	Ramaiya
65	7	"Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.
Department of Medicine, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts."	F Stephen	FS	Hodi
66	0	Department of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA. dcagney@lroc.harvard.edu.	Daniel N	DN	Cagney
66	1	Department of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA.	Brian M	BM	Alexander
66	2	Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.	F Stephen	FS	Hodi
66	3	Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.	Elizabeth I	EI	Buchbinder
66	4	Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.	Patrick A	PA	Ott
66	5	Department of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA.	Ayal A	AA	Aizer
67	0	Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Michael J. Pishvaian, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC; Hope S. Rugo, University of California San Francisco, San Francisco, CA; Igor Puzanov, Roswell Park Cancer Institute, Buffalo, NY; Janice M. Mehnert, Rutgers Cancer Institute of New Jersey, New Brunswick; Marion Carrigan, Sanatan Saraf, and Mei Chen, Merck, Kenilworth, NJ; Yung-Jue Bang, Seoul National University College of Medicine, Seoul, Republic of Korea; Dominique Berton-Rigaud, Institut de Cancérologie de l'Ouest Centre René Gauducheau, Saint-Herblain; Jean-Charles Soria, Gustave Roussy and University Paris-Sud, Villejuif, France; Elena Elez, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Kyaw L. Aung, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; and Juanita Lopez, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom.	Patrick A	PA	Ott
67	1	Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Michael J. Pishvaian, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC; Hope S. Rugo, University of California San Francisco, San Francisco, CA; Igor Puzanov, Roswell Park Cancer Institute, Buffalo, NY; Janice M. Mehnert, Rutgers Cancer Institute of New Jersey, New Brunswick; Marion Carrigan, Sanatan Saraf, and Mei Chen, Merck, Kenilworth, NJ; Yung-Jue Bang, Seoul National University College of Medicine, Seoul, Republic of Korea; Dominique Berton-Rigaud, Institut de Cancérologie de l'Ouest Centre René Gauducheau, Saint-Herblain; Jean-Charles Soria, Gustave Roussy and University Paris-Sud, Villejuif, France; Elena Elez, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Kyaw L. Aung, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; and Juanita Lopez, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom.	Yung-Jue	YJ	Bang
67	2	Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Michael J. Pishvaian, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC; Hope S. Rugo, University of California San Francisco, San Francisco, CA; Igor Puzanov, Roswell Park Cancer Institute, Buffalo, NY; Janice M. Mehnert, Rutgers Cancer Institute of New Jersey, New Brunswick; Marion Carrigan, Sanatan Saraf, and Mei Chen, Merck, Kenilworth, NJ; Yung-Jue Bang, Seoul National University College of Medicine, Seoul, Republic of Korea; Dominique Berton-Rigaud, Institut de Cancérologie de l'Ouest Centre René Gauducheau, Saint-Herblain; Jean-Charles Soria, Gustave Roussy and University Paris-Sud, Villejuif, France; Elena Elez, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Kyaw L. Aung, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; and Juanita Lopez, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom.	Dominique	D	Berton-Rigaud
67	3	Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Michael J. Pishvaian, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC; Hope S. Rugo, University of California San Francisco, San Francisco, CA; Igor Puzanov, Roswell Park Cancer Institute, Buffalo, NY; Janice M. Mehnert, Rutgers Cancer Institute of New Jersey, New Brunswick; Marion Carrigan, Sanatan Saraf, and Mei Chen, Merck, Kenilworth, NJ; Yung-Jue Bang, Seoul National University College of Medicine, Seoul, Republic of Korea; Dominique Berton-Rigaud, Institut de Cancérologie de l'Ouest Centre René Gauducheau, Saint-Herblain; Jean-Charles Soria, Gustave Roussy and University Paris-Sud, Villejuif, France; Elena Elez, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Kyaw L. Aung, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; and Juanita Lopez, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom.	Elena	E	Elez
67	4	Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Michael J. Pishvaian, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC; Hope S. Rugo, University of California San Francisco, San Francisco, CA; Igor Puzanov, Roswell Park Cancer Institute, Buffalo, NY; Janice M. Mehnert, Rutgers Cancer Institute of New Jersey, New Brunswick; Marion Carrigan, Sanatan Saraf, and Mei Chen, Merck, Kenilworth, NJ; Yung-Jue Bang, Seoul National University College of Medicine, Seoul, Republic of Korea; Dominique Berton-Rigaud, Institut de Cancérologie de l'Ouest Centre René Gauducheau, Saint-Herblain; Jean-Charles Soria, Gustave Roussy and University Paris-Sud, Villejuif, France; Elena Elez, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Kyaw L. Aung, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; and Juanita Lopez, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom.	Michael J	MJ	Pishvaian
67	5	Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Michael J. Pishvaian, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC; Hope S. Rugo, University of California San Francisco, San Francisco, CA; Igor Puzanov, Roswell Park Cancer Institute, Buffalo, NY; Janice M. Mehnert, Rutgers Cancer Institute of New Jersey, New Brunswick; Marion Carrigan, Sanatan Saraf, and Mei Chen, Merck, Kenilworth, NJ; Yung-Jue Bang, Seoul National University College of Medicine, Seoul, Republic of Korea; Dominique Berton-Rigaud, Institut de Cancérologie de l'Ouest Centre René Gauducheau, Saint-Herblain; Jean-Charles Soria, Gustave Roussy and University Paris-Sud, Villejuif, France; Elena Elez, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Kyaw L. Aung, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; and Juanita Lopez, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom.	Hope S	HS	Rugo
67	6	Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Michael J. Pishvaian, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC; Hope S. Rugo, University of California San Francisco, San Francisco, CA; Igor Puzanov, Roswell Park Cancer Institute, Buffalo, NY; Janice M. Mehnert, Rutgers Cancer Institute of New Jersey, New Brunswick; Marion Carrigan, Sanatan Saraf, and Mei Chen, Merck, Kenilworth, NJ; Yung-Jue Bang, Seoul National University College of Medicine, Seoul, Republic of Korea; Dominique Berton-Rigaud, Institut de Cancérologie de l'Ouest Centre René Gauducheau, Saint-Herblain; Jean-Charles Soria, Gustave Roussy and University Paris-Sud, Villejuif, France; Elena Elez, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Kyaw L. Aung, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; and Juanita Lopez, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom.	Igor	I	Puzanov
67	7	Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Michael J. Pishvaian, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC; Hope S. Rugo, University of California San Francisco, San Francisco, CA; Igor Puzanov, Roswell Park Cancer Institute, Buffalo, NY; Janice M. Mehnert, Rutgers Cancer Institute of New Jersey, New Brunswick; Marion Carrigan, Sanatan Saraf, and Mei Chen, Merck, Kenilworth, NJ; Yung-Jue Bang, Seoul National University College of Medicine, Seoul, Republic of Korea; Dominique Berton-Rigaud, Institut de Cancérologie de l'Ouest Centre René Gauducheau, Saint-Herblain; Jean-Charles Soria, Gustave Roussy and University Paris-Sud, Villejuif, France; Elena Elez, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Kyaw L. Aung, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; and Juanita Lopez, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom.	Janice M	JM	Mehnert
67	8	Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Michael J. Pishvaian, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC; Hope S. Rugo, University of California San Francisco, San Francisco, CA; Igor Puzanov, Roswell Park Cancer Institute, Buffalo, NY; Janice M. Mehnert, Rutgers Cancer Institute of New Jersey, New Brunswick; Marion Carrigan, Sanatan Saraf, and Mei Chen, Merck, Kenilworth, NJ; Yung-Jue Bang, Seoul National University College of Medicine, Seoul, Republic of Korea; Dominique Berton-Rigaud, Institut de Cancérologie de l'Ouest Centre René Gauducheau, Saint-Herblain; Jean-Charles Soria, Gustave Roussy and University Paris-Sud, Villejuif, France; Elena Elez, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Kyaw L. Aung, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; and Juanita Lopez, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom.	Kyaw L	KL	Aung
67	9	Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Michael J. Pishvaian, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC; Hope S. Rugo, University of California San Francisco, San Francisco, CA; Igor Puzanov, Roswell Park Cancer Institute, Buffalo, NY; Janice M. Mehnert, Rutgers Cancer Institute of New Jersey, New Brunswick; Marion Carrigan, Sanatan Saraf, and Mei Chen, Merck, Kenilworth, NJ; Yung-Jue Bang, Seoul National University College of Medicine, Seoul, Republic of Korea; Dominique Berton-Rigaud, Institut de Cancérologie de l'Ouest Centre René Gauducheau, Saint-Herblain; Jean-Charles Soria, Gustave Roussy and University Paris-Sud, Villejuif, France; Elena Elez, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Kyaw L. Aung, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; and Juanita Lopez, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom.	Juanita	J	Lopez
67	10	Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Michael J. Pishvaian, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC; Hope S. Rugo, University of California San Francisco, San Francisco, CA; Igor Puzanov, Roswell Park Cancer Institute, Buffalo, NY; Janice M. Mehnert, Rutgers Cancer Institute of New Jersey, New Brunswick; Marion Carrigan, Sanatan Saraf, and Mei Chen, Merck, Kenilworth, NJ; Yung-Jue Bang, Seoul National University College of Medicine, Seoul, Republic of Korea; Dominique Berton-Rigaud, Institut de Cancérologie de l'Ouest Centre René Gauducheau, Saint-Herblain; Jean-Charles Soria, Gustave Roussy and University Paris-Sud, Villejuif, France; Elena Elez, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Kyaw L. Aung, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; and Juanita Lopez, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom.	Marion	M	Carrigan
67	11	Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Michael J. Pishvaian, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC; Hope S. Rugo, University of California San Francisco, San Francisco, CA; Igor Puzanov, Roswell Park Cancer Institute, Buffalo, NY; Janice M. Mehnert, Rutgers Cancer Institute of New Jersey, New Brunswick; Marion Carrigan, Sanatan Saraf, and Mei Chen, Merck, Kenilworth, NJ; Yung-Jue Bang, Seoul National University College of Medicine, Seoul, Republic of Korea; Dominique Berton-Rigaud, Institut de Cancérologie de l'Ouest Centre René Gauducheau, Saint-Herblain; Jean-Charles Soria, Gustave Roussy and University Paris-Sud, Villejuif, France; Elena Elez, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Kyaw L. Aung, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; and Juanita Lopez, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom.	Sanatan	S	Saraf
67	12	Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Michael J. Pishvaian, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC; Hope S. Rugo, University of California San Francisco, San Francisco, CA; Igor Puzanov, Roswell Park Cancer Institute, Buffalo, NY; Janice M. Mehnert, Rutgers Cancer Institute of New Jersey, New Brunswick; Marion Carrigan, Sanatan Saraf, and Mei Chen, Merck, Kenilworth, NJ; Yung-Jue Bang, Seoul National University College of Medicine, Seoul, Republic of Korea; Dominique Berton-Rigaud, Institut de Cancérologie de l'Ouest Centre René Gauducheau, Saint-Herblain; Jean-Charles Soria, Gustave Roussy and University Paris-Sud, Villejuif, France; Elena Elez, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Kyaw L. Aung, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; and Juanita Lopez, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom.	Mei	M	Chen
67	13	Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Michael J. Pishvaian, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC; Hope S. Rugo, University of California San Francisco, San Francisco, CA; Igor Puzanov, Roswell Park Cancer Institute, Buffalo, NY; Janice M. Mehnert, Rutgers Cancer Institute of New Jersey, New Brunswick; Marion Carrigan, Sanatan Saraf, and Mei Chen, Merck, Kenilworth, NJ; Yung-Jue Bang, Seoul National University College of Medicine, Seoul, Republic of Korea; Dominique Berton-Rigaud, Institut de Cancérologie de l'Ouest Centre René Gauducheau, Saint-Herblain; Jean-Charles Soria, Gustave Roussy and University Paris-Sud, Villejuif, France; Elena Elez, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Kyaw L. Aung, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; and Juanita Lopez, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom.	Jean-Charles	JC	Soria
68	0	Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts; Division of Radiation Oncology, University of Ottawa, Ottawa, Ontario, Canada.	Andrew	A	Bang
68	1	Harvard Medical School, Boston, Massachusetts.	Tyler J	TJ	Wilhite
68	2	Harvard Radiation Oncology Program, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts.	Luke R G	LRG	Pike
68	3	Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts.	Daniel N	DN	Cagney
68	4	Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts.	Ayal A	AA	Aizer
68	5	Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts.	Allison	A	Taylor
68	6	Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts.	Alexander	A	Spektor
68	7	Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts.	Monica	M	Krishnan
68	8	Department of Medical Oncology and Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Patrick A	PA	Ott
68	9	Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts.	Tracy A	TA	Balboni
68	10	Department of Medical Oncology and Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	F Stephen	FS	Hodi
68	11	Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts. Electronic address: jdschoenfeld@partners.org.	Jonathan D	JD	Schoenfeld
69	0	Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, USA.	P A	PA	Ott
69	1	Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA.	S A	SA	Piha-Paul
69	2	Department of Medicine (Hematology/Oncology), Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, USA.	P	P	Munster
69	3	Department of Hematology/Oncology, Georgetown University, Washington DC, USA.	M J	MJ	Pishvaian
69	4	Department of Molecular Pathology & Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands.	E M J	EMJ	van Brummelen
69	5	Department of Medicine, University of Pennsylvania, Philadelphia, USA.	R B	RB	Cohen
69	6	Clinical Research Unit, Institut Claudius Regaud and Institut Universitaire du Cancer-Oncopole, Toulouse, France.	C	C	Gomez-Roca
69	7	Department of Medical Oncology, Virginia G. Piper Cancer Center, Scottsdale, USA.	S	S	Ejadi
69	8	Department of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, USA.	M	M	Stein
69	9	Department of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center, Nashville, USA.	E	E	Chan
69	10	Department of Medical Oncology and Hematology, Humanitas Cancer Center, Rozzano, Italy.	M	M	Simonelli
69	11	Department of Clinical Oncology, Merck & Co, Inc., Kenilworth, USA.	A	A	Morosky
69	12	Department of Clinical Oncology, Merck & Co, Inc., Kenilworth, USA.	S	S	Saraf
69	13	Department of Clinical Oncology, Merck & Co, Inc., Kenilworth, USA.	K	K	Emancipator
69	14	Department of Clinical Oncology, Merck & Co, Inc., Kenilworth, USA.	M	M	Koshiji
69	15	Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Nantes, France.	J	J	Bennouna
70	0	Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.	Daniel Y	DY	Wang
70	1	Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida.	Zeynep	Z	Eroglu
70	2	Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida.	Alpaslan	A	Ozgun
70	3	Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.	Paul D	PD	Leger
70	4	Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.	Shilin	S	Zhao
70	5	Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.	Fei	F	Ye
70	6	Department of Medicine, University of Chicago, Chicago, Illinois.	Jason J	JJ	Luke
70	7	Department of Medicine, Mayo Clinic Florida, Jacksonville, Florida.	Richard W	RW	Joseph
70	8	Melanoma Disease Center, Dana Farber Cancer Institute, Boston, Massachusetts.	Rizwan	R	Haq
70	9	Melanoma Disease Center, Dana Farber Cancer Institute, Boston, Massachusetts.	Patrick A	PA	Ott
70	10	Melanoma Disease Center, Dana Farber Cancer Institute, Boston, Massachusetts.	F Stephen	FS	Hodi
70	11	Department of Medicine, Northwestern Feinberg School of Medicine, Chicago, Illinois.	Jeffrey A	JA	Sosman
70	12	Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. douglas.b.johnson@vanderbilt.edu elizabeth_buchbinder@dfci.harvard.edu.	Douglas B	DB	Johnson
70	13	Melanoma Disease Center, Dana Farber Cancer Institute, Boston, Massachusetts. douglas.b.johnson@vanderbilt.edu elizabeth_buchbinder@dfci.harvard.edu.	Elizabeth I	EI	Buchbinder
71	0	Department of Medical Oncology Dana Farber Cancer Institute, Boston, Massachusetts.	Marlene	M	Garcia-Neuer
71	1	Department of Medical Oncology, University of Pennsylvania, Philadelphia, Pennsylvania.	Melina E	ME	Marmarelis
71	2	Department of Medicine, Division of Gastroenterology, Brigham and Women's Hospital, Boston, Massachusetts.	Sushrut R	SR	Jangi
71	3	Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, Illinois.	Jason J	JJ	Luke
71	4	"Department of Medical Oncology Dana Farber Cancer Institute, Boston, Massachusetts.
Harvard Medical School, Boston, Massachusetts.
Current affiliation: Merck; Merck & Co., Inc., Kenilworth, NJ, USA."	Nageatte	N	Ibrahim
71	5	Department of Medical Oncology Dana Farber Cancer Institute, Boston, Massachusetts.	Meredith	M	Davis
71	6	Department of Biostatistics, Boston University, Boston, Massachusetts.	Janice	J	Weinberg
71	7	Department of Medical Oncology Dana Farber Cancer Institute, Boston, Massachusetts.	Hilary	H	Donahue
71	8	Department of Medical Oncology Dana Farber Cancer Institute, Boston, Massachusetts.	Nancy	N	Bailey
71	9	"Department of Medical Oncology Dana Farber Cancer Institute, Boston, Massachusetts.
Harvard Medical School, Boston, Massachusetts."	F Stephen	FS	Hodi
71	10	"Department of Medical Oncology Dana Farber Cancer Institute, Boston, Massachusetts.
Harvard Medical School, Boston, Massachusetts."	Elizabeth L	EL	Buchbinder
71	11	"Department of Medical Oncology Dana Farber Cancer Institute, Boston, Massachusetts. patrick_ott@dfci.harvard.edu.
Harvard Medical School, Boston, Massachusetts."	Patrick A	PA	Ott
72	0	Resident Physician, University of Southern California, Los Angeles, CA, USA.	David J	DJ	Hermel
72	1	Melanoma Disease Center and Center for Immuno-Oncology, Dana-Farber Cancer Institute/Harvard Medical School, Boston, MA, 02215-5450, USA. Patrick_Ott@DFCI.harvard.edu.	Patrick A	PA	Ott
73	0	"Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Department of Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain."	Guillermo	G	De Velasco
73	1	Department of Food and Nutrition, College of Human Ecology, Kyung Hee University, Seoul, Korea.	Youjin	Y	Je
73	2	Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.	Dominick	D	Bossé
73	3	Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.	Mark M	MM	Awad
73	4	Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.	Patrick A	PA	Ott
73	5	Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.	Raphael B	RB	Moreira
73	6	Department of Medical Oncology, Hospital São José, Beneficência Portuguesa de São Paulo, Brazil.	Fabio	F	Schutz
73	7	Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.	Joaquim	J	Bellmunt
73	8	Division of Oncology and Hematology, University of Alabama, Birmingham, Alabama.	Guru P	GP	Sonpavde
73	9	Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.	F Stephen	FS	Hodi
73	10	Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. toni_choueiri@dfci.harvard.edu.	Toni K	TK	Choueiri
74	0	Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Dana540C, Boston, MA 02215 USA.	Patrick A	PA	Ott
74	1	Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Dana540C, Boston, MA 02215 USA.	F Stephen	FS	Hodi
74	2	Rutgers Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08901 USA.	Howard L	HL	Kaufman
74	3	MacroGenics, Inc., 9640 Medical Center Drive, Rockville, MD 20850 USA.	Jon M	JM	Wigginton
74	4	Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Z-1503, New York, NY 10065 USA.	Jedd D	JD	Wolchok
75	0	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.	Suzanne	S	George
75	1	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.	Diana	D	Miao
75	2	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Ludwig Center at Harvard, Boston, MA 02215, USA.	George D	GD	Demetri
75	3	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.	Dennis	D	Adeegbe
75	4	Department of Pathology, Brigham and Women's Hospital, Boston, MA 02215, USA; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.	Scott J	SJ	Rodig
75	5	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.	Sachet	S	Shukla
75	6	Department of Pathology, Brigham and Women's Hospital, Boston, MA 02215, USA.	Mikel	M	Lipschitz
75	7	Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.	Ali	A	Amin-Mansour
75	8	Department of Surgery, Brigham and Women's Hospital, Boston, MA 02215, USA.	Chandrajit P	CP	Raut
75	9	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, MA 02215, USA.	Scott L	SL	Carter
75	10	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.	Peter	P	Hammerman
75	11	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.	Gordon J	GJ	Freeman
75	12	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.	Catherine J	CJ	Wu
75	13	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.	Patrick A	PA	Ott
75	14	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.	Kwok-Kin	KK	Wong
75	15	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address: eliezerm_vanallen@dfci.harvard.edu.	Eliezer M	EM	Van Allen
76	0	Resident Physician, University of Southern California, Los Angeles, CA, USA.	David J	DJ	Hermel
76	1	Melanoma Disease Center and Center for Immuno-Oncology, Dana-Farber Cancer Institute/Harvard Medical School, Boston, MA, 02215-5450, USA. Patrick_Ott@DFCI.harvard.edu.	Patrick A	PA	Ott
77	0	Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts.	Kent W	KW	Mouw
77	1	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	James M	JM	Cleary
77	2	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Broad Institute of MIT and Harvard, Cambridge, Massachusetts."	Brendan	B	Reardon
77	3	Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts.	Jonathan	J	Pike
77	4	Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts.	Lior Z	LZ	Braunstein
77	5	Broad Institute of MIT and Harvard, Cambridge, Massachusetts.	Jaegil	J	Kim
77	6	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Broad Institute of MIT and Harvard, Cambridge, Massachusetts."	Ali	A	Amin-Mansour
77	7	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Broad Institute of MIT and Harvard, Cambridge, Massachusetts."	Diana	D	Miao
77	8	Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts.	Alexis	A	Damish
77	9	Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts.	Joanna	J	Chin
77	10	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Patrick A	PA	Ott
77	11	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Charles S	CS	Fuchs
77	12	Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts.	Neil E	NE	Martin
77	13	Broad Institute of MIT and Harvard, Cambridge, Massachusetts.	Gad	G	Getz
77	14	"Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts."	Scott	S	Carter
77	15	Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts.	Harvey J	HJ	Mamon
77	16	Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.	Jason L	JL	Hornick
77	17	"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. alan_dandrea@dfci.harvard.edu eliezerm_vanallen@dfci.harvard.edu.
Broad Institute of MIT and Harvard, Cambridge, Massachusetts."	Eliezer M	EM	Van Allen
77	18	"Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts. alan_dandrea@dfci.harvard.edu eliezerm_vanallen@dfci.harvard.edu.
Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, Massachusetts.
Ludwig Center at Harvard, Boston, Massachusetts."	Alan D	AD	D'Andrea
78	0	"Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, New York, New York. shoushta@mskcc.org.
Weill Cornell Medical College, New York, New York. shoushta@mskcc.org."	Alexander N	AN	Shoushtari
78	1	Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, New York, New York.	Rodrigo R	RR	Munhoz
78	2	Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.	Deborah	D	Kuk
78	3	Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.	Patrick A	PA	Ott
78	4	Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee.	Douglas B	DB	Johnson
78	5	Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.	Katy K	KK	Tsai
78	6	Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia.	Suthee	S	Rapisuwon
78	7	Moffitt Cancer Center, Tampa, Florida.	Zeynep	Z	Eroglu
78	8	Massachussetts General Hospital, Harvard Medical School, Boston, Massachusetts.	Ryan J	RJ	Sullivan
78	9	University of Chicago Comprehensive Cancer Center Chicago, Illinois.	Jason J	JJ	Luke
78	10	Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.	Tara C	TC	Gangadhar
78	11	Duke University School of Medicine, Durham, North Carolina.	April K S	AK	Salama
78	12	Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, New York, New York.	Varina	V	Clark
78	13	Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, New York, New York.	Clare	C	Burias
78	14	Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee.	Igor	I	Puzanov
78	15	Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia.	Michael B	MB	Atkins
78	16	Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.	Alain P	AP	Algazi
78	17	Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, California.	Antoni	A	Ribas
78	18	"Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Weill Cornell Medical College, New York, New York."	Jedd D	JD	Wolchok
78	19	"Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Weill Cornell Medical College, New York, New York."	Michael A	MA	Postow
79	0	Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California. alain.algazi@ucsf.edu.	Alain P	AP	Algazi
79	1	Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.	Katy K	KK	Tsai
79	2	Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, New York, New York.	Alexander N	AN	Shoushtari
79	3	Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, New York, New York.	Rodrigo R	RR	Munhoz
79	4	Moffitt Cancer Center, Tampa, Florida.	Zeynep	Z	Eroglu
79	5	Spanish Melanoma Multidisciplinary Group, Barcelona, Spain.	Josep M	JM	Piulats
79	6	Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.	Patrick A	PA	Ott
79	7	Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee.	Douglas B	DB	Johnson
79	8	Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.	Jimmy	J	Hwang
79	9	Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.	Adil I	AI	Daud
79	10	Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee.	Jeffrey A	JA	Sosman
79	11	Columbia University Medical Center, New York, New York.	Richard D	RD	Carvajal
79	12	Johansson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California.	Bartosz	B	Chmielowski
79	13	Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, New York, New York.	Michael A	MA	Postow
79	14	Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York.	Jeffrey S	JS	Weber
79	15	Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.	Ryan J	RJ	Sullivan
80	0	Department of Genitourinary Medical Oncology, Department of Immunology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA. Electronic address: padsharma@mdanderson.org.	Padmanee	P	Sharma
80	1	Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.	Margaret K	MK	Callahan
80	2	Department of Oncology, Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.	Petri	P	Bono
80	3	Prostate and Urologic Cancers Program and Early Drug Development Program, Yale Cancer Center, New Haven, CT, USA.	Joseph	J	Kim
80	4	Department of Medical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK.	Pavlina	P	Spiliopoulou
80	5	Medical Oncology Division, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain.	Emiliano	E	Calvo
80	6	Department of Hematology and Oncology, Emory Winship Cancer Institute, Atlanta, GA, USA.	Rathi N	RN	Pillai
80	7	Melanoma Center, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.	Patrick A	PA	Ott
80	8	Department of Medical Oncology, Istituto Nazionale dei Tumori-Università degli Studi di Milano, Milan, Italy.	Filippo	F	de Braud
80	9	Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA.	Michael	M	Morse
80	10	Division of Oncology-Gastrointestinal Cancer, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.	Dung T	DT	Le
80	11	National Center for Tumor Diseases, Department of Medical Oncology, Heidelberg University Hospital, Heidelberg, Germany.	Dirk	D	Jaeger
80	12	Department of Medicine, Division of Hematology and Medical Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.	Emily	E	Chan
80	13	NIVO/IPI LCM Biomarkers, Bristol-Myers Squibb, Princeton, NJ, USA.	Chris	C	Harbison
80	14	Clinical Biostatistics, Bristol-Myers Squibb, Princeton, NJ, USA.	Chen-Sheng	CS	Lin
80	15	Global Clinical Research/Oncology, Bristol-Myers Squibb, Princeton, NJ, USA.	Marina	M	Tschaika
80	16	Global Clinical Research/Oncology, Bristol-Myers Squibb, Princeton, NJ, USA.	Alex	A	Azrilevich
80	17	Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.	Jonathan E	JE	Rosenberg
81	0	Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: stephen_hodi@dfci.harvard.edu.	F Stephen	FS	Hodi
81	1	University of Louisville, Louisville, KY, USA.	Jason	J	Chesney
81	2	New York University, New York, NY, USA.	Anna C	AC	Pavlick
81	3	Gustave Roussy, INSERM U981, Paris, France.	Caroline	C	Robert
81	4	Huntsman Cancer Institute, Salt Lake City, UT, USA.	Kenneth F	KF	Grossmann
81	5	Beth Israel Deaconess Medical Center, Boston, MA, USA.	David F	DF	McDermott
81	6	Washington University School of Medicine, St Louis, MO, USA.	Gerald P	GP	Linette
81	7	Institut Universitaire du Cancer, Toulouse, France.	Nicolas	N	Meyer
81	8	Greenville Health System Cancer Institute, Greenville, SC, USA.	Jeffrey K	JK	Giguere
81	9	St Luke's Cancer Center and Temple University, Bethlehem, PA, USA.	Sanjiv S	SS	Agarwala
81	10	University of New Mexico, Albuquerque, NM, USA.	Montaser	M	Shaheen
81	11	Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.	Marc S	MS	Ernstoff
81	12	California Pacific Center for Melanoma Research, San Francisco, CA, USA.	David R	DR	Minor
81	13	Duke University Medical Center, Durham, NC, USA.	April K	AK	Salama
81	14	Oregon Health & Science University, Portland, OR, USA.	Matthew H	MH	Taylor
81	15	Dana-Farber Cancer Institute, Boston, MA, USA.	Patrick A	PA	Ott
81	16	Bristol-Myers Squibb, Princeton, NJ, USA.	Christine	C	Horak
81	17	Bristol-Myers Squibb, Princeton, NJ, USA.	Paul	P	Gagnier
81	18	Bristol-Myers Squibb, Princeton, NJ, USA.	Joel	J	Jiang
81	19	Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.	Jedd D	JD	Wolchok
81	20	Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.	Michael A	MA	Postow
82	0	Department of Radiology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts. Mizuki_Nishino@dfci.harvard.edu.	Mizuki	M	Nishino
82	1	Department of Radiology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts.	Nikhil H	NH	Ramaiya
82	2	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Mark M	MM	Awad
82	3	Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.	Lynette M	LM	Sholl
82	4	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Jennifer A	JA	Maattala
82	5	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Myriam	M	Taibi
82	6	Department of Radiology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts.	Hiroto	H	Hatabu
82	7	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Patrick A	PA	Ott
82	8	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Philippe F	PF	Armand
82	9	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	F Stephen	FS	Hodi
83	0	University Hospital Erlangen, Erlangen, Germany ; Department of Dermatology, University Hospital Erlangen, Ulmenweg 18, 91054 Erlangen, Germany.	Lucie	L	Heinzerling
83	1	Dana Farber Cancer Institute, Boston, MA USA.	Patrick A	PA	Ott
83	2	Dana Farber Cancer Institute, Boston, MA USA.	F Stephen	FS	Hodi
83	3	University of Chicago Comprehensive Cancer Center and Pathology, Chicago, IL USA.	Aliya N	AN	Husain
83	4	University Hospital Erlangen, Erlangen, Germany.	Azadeh	A	Tajmir-Riahi
83	5	University of Texas MD Anderson Center, Houston, TX USA.	Hussein	H	Tawbi
83	6	Paracelsus University Hospital Nuremberg, Nürnberg, Germany.	Matthias	M	Pauschinger
83	7	University of Chicago Comprehensive Cancer Center and Pathology, Chicago, IL USA.	Thomas F	TF	Gajewski
83	8	Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD USA.	Evan J	EJ	Lipson
83	9	University of Chicago Comprehensive Cancer Center and Pathology, Chicago, IL USA.	Jason J	JJ	Luke
84	0	Aung Naing, Rivka R. Colen, David S. Hong, and Nizar M. Tannir, MD Anderson Cancer Center, Houston; Kyriakos P. Papadopoulos and Drew R. Rasco, START Center for Cancer Care, San Antonio, TX; Karen A. Autio, Memorial Sloan Kettering Cancer Center, New York, NY; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Manish R. Patel, Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Deborah J. Wong, University of California Los Angeles, Los Angeles; Melinda Whiteside, John B. Mumm, Ivan H. Chan, Peter Van Vlasselaer, and Martin Oft, ARMO BioSciences, Redwood City, CA; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Shubham Pant, Oklahoma University, Oklahoma City, OK; and Johanna C. Bendell, Todd M. Bauer, and Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.	Aung	A	Naing
84	1	Aung Naing, Rivka R. Colen, David S. Hong, and Nizar M. Tannir, MD Anderson Cancer Center, Houston; Kyriakos P. Papadopoulos and Drew R. Rasco, START Center for Cancer Care, San Antonio, TX; Karen A. Autio, Memorial Sloan Kettering Cancer Center, New York, NY; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Manish R. Patel, Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Deborah J. Wong, University of California Los Angeles, Los Angeles; Melinda Whiteside, John B. Mumm, Ivan H. Chan, Peter Van Vlasselaer, and Martin Oft, ARMO BioSciences, Redwood City, CA; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Shubham Pant, Oklahoma University, Oklahoma City, OK; and Johanna C. Bendell, Todd M. Bauer, and Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.	Kyriakos P	KP	Papadopoulos
84	2	Aung Naing, Rivka R. Colen, David S. Hong, and Nizar M. Tannir, MD Anderson Cancer Center, Houston; Kyriakos P. Papadopoulos and Drew R. Rasco, START Center for Cancer Care, San Antonio, TX; Karen A. Autio, Memorial Sloan Kettering Cancer Center, New York, NY; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Manish R. Patel, Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Deborah J. Wong, University of California Los Angeles, Los Angeles; Melinda Whiteside, John B. Mumm, Ivan H. Chan, Peter Van Vlasselaer, and Martin Oft, ARMO BioSciences, Redwood City, CA; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Shubham Pant, Oklahoma University, Oklahoma City, OK; and Johanna C. Bendell, Todd M. Bauer, and Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.	Karen A	KA	Autio
84	3	Aung Naing, Rivka R. Colen, David S. Hong, and Nizar M. Tannir, MD Anderson Cancer Center, Houston; Kyriakos P. Papadopoulos and Drew R. Rasco, START Center for Cancer Care, San Antonio, TX; Karen A. Autio, Memorial Sloan Kettering Cancer Center, New York, NY; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Manish R. Patel, Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Deborah J. Wong, University of California Los Angeles, Los Angeles; Melinda Whiteside, John B. Mumm, Ivan H. Chan, Peter Van Vlasselaer, and Martin Oft, ARMO BioSciences, Redwood City, CA; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Shubham Pant, Oklahoma University, Oklahoma City, OK; and Johanna C. Bendell, Todd M. Bauer, and Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.	Patrick A	PA	Ott
84	4	Aung Naing, Rivka R. Colen, David S. Hong, and Nizar M. Tannir, MD Anderson Cancer Center, Houston; Kyriakos P. Papadopoulos and Drew R. Rasco, START Center for Cancer Care, San Antonio, TX; Karen A. Autio, Memorial Sloan Kettering Cancer Center, New York, NY; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Manish R. Patel, Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Deborah J. Wong, University of California Los Angeles, Los Angeles; Melinda Whiteside, John B. Mumm, Ivan H. Chan, Peter Van Vlasselaer, and Martin Oft, ARMO BioSciences, Redwood City, CA; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Shubham Pant, Oklahoma University, Oklahoma City, OK; and Johanna C. Bendell, Todd M. Bauer, and Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.	Manish R	MR	Patel
84	5	Aung Naing, Rivka R. Colen, David S. Hong, and Nizar M. Tannir, MD Anderson Cancer Center, Houston; Kyriakos P. Papadopoulos and Drew R. Rasco, START Center for Cancer Care, San Antonio, TX; Karen A. Autio, Memorial Sloan Kettering Cancer Center, New York, NY; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Manish R. Patel, Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Deborah J. Wong, University of California Los Angeles, Los Angeles; Melinda Whiteside, John B. Mumm, Ivan H. Chan, Peter Van Vlasselaer, and Martin Oft, ARMO BioSciences, Redwood City, CA; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Shubham Pant, Oklahoma University, Oklahoma City, OK; and Johanna C. Bendell, Todd M. Bauer, and Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.	Deborah J	DJ	Wong
84	6	Aung Naing, Rivka R. Colen, David S. Hong, and Nizar M. Tannir, MD Anderson Cancer Center, Houston; Kyriakos P. Papadopoulos and Drew R. Rasco, START Center for Cancer Care, San Antonio, TX; Karen A. Autio, Memorial Sloan Kettering Cancer Center, New York, NY; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Manish R. Patel, Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Deborah J. Wong, University of California Los Angeles, Los Angeles; Melinda Whiteside, John B. Mumm, Ivan H. Chan, Peter Van Vlasselaer, and Martin Oft, ARMO BioSciences, Redwood City, CA; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Shubham Pant, Oklahoma University, Oklahoma City, OK; and Johanna C. Bendell, Todd M. Bauer, and Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.	Gerald S	GS	Falchook
84	7	Aung Naing, Rivka R. Colen, David S. Hong, and Nizar M. Tannir, MD Anderson Cancer Center, Houston; Kyriakos P. Papadopoulos and Drew R. Rasco, START Center for Cancer Care, San Antonio, TX; Karen A. Autio, Memorial Sloan Kettering Cancer Center, New York, NY; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Manish R. Patel, Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Deborah J. Wong, University of California Los Angeles, Los Angeles; Melinda Whiteside, John B. Mumm, Ivan H. Chan, Peter Van Vlasselaer, and Martin Oft, ARMO BioSciences, Redwood City, CA; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Shubham Pant, Oklahoma University, Oklahoma City, OK; and Johanna C. Bendell, Todd M. Bauer, and Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.	Shubham	S	Pant
84	8	Aung Naing, Rivka R. Colen, David S. Hong, and Nizar M. Tannir, MD Anderson Cancer Center, Houston; Kyriakos P. Papadopoulos and Drew R. Rasco, START Center for Cancer Care, San Antonio, TX; Karen A. Autio, Memorial Sloan Kettering Cancer Center, New York, NY; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Manish R. Patel, Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Deborah J. Wong, University of California Los Angeles, Los Angeles; Melinda Whiteside, John B. Mumm, Ivan H. Chan, Peter Van Vlasselaer, and Martin Oft, ARMO BioSciences, Redwood City, CA; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Shubham Pant, Oklahoma University, Oklahoma City, OK; and Johanna C. Bendell, Todd M. Bauer, and Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.	Melinda	M	Whiteside
84	9	Aung Naing, Rivka R. Colen, David S. Hong, and Nizar M. Tannir, MD Anderson Cancer Center, Houston; Kyriakos P. Papadopoulos and Drew R. Rasco, START Center for Cancer Care, San Antonio, TX; Karen A. Autio, Memorial Sloan Kettering Cancer Center, New York, NY; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Manish R. Patel, Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Deborah J. Wong, University of California Los Angeles, Los Angeles; Melinda Whiteside, John B. Mumm, Ivan H. Chan, Peter Van Vlasselaer, and Martin Oft, ARMO BioSciences, Redwood City, CA; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Shubham Pant, Oklahoma University, Oklahoma City, OK; and Johanna C. Bendell, Todd M. Bauer, and Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.	Drew R	DR	Rasco
84	10	Aung Naing, Rivka R. Colen, David S. Hong, and Nizar M. Tannir, MD Anderson Cancer Center, Houston; Kyriakos P. Papadopoulos and Drew R. Rasco, START Center for Cancer Care, San Antonio, TX; Karen A. Autio, Memorial Sloan Kettering Cancer Center, New York, NY; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Manish R. Patel, Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Deborah J. Wong, University of California Los Angeles, Los Angeles; Melinda Whiteside, John B. Mumm, Ivan H. Chan, Peter Van Vlasselaer, and Martin Oft, ARMO BioSciences, Redwood City, CA; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Shubham Pant, Oklahoma University, Oklahoma City, OK; and Johanna C. Bendell, Todd M. Bauer, and Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.	John B	JB	Mumm
84	11	Aung Naing, Rivka R. Colen, David S. Hong, and Nizar M. Tannir, MD Anderson Cancer Center, Houston; Kyriakos P. Papadopoulos and Drew R. Rasco, START Center for Cancer Care, San Antonio, TX; Karen A. Autio, Memorial Sloan Kettering Cancer Center, New York, NY; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Manish R. Patel, Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Deborah J. Wong, University of California Los Angeles, Los Angeles; Melinda Whiteside, John B. Mumm, Ivan H. Chan, Peter Van Vlasselaer, and Martin Oft, ARMO BioSciences, Redwood City, CA; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Shubham Pant, Oklahoma University, Oklahoma City, OK; and Johanna C. Bendell, Todd M. Bauer, and Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.	Ivan H	IH	Chan
84	12	Aung Naing, Rivka R. Colen, David S. Hong, and Nizar M. Tannir, MD Anderson Cancer Center, Houston; Kyriakos P. Papadopoulos and Drew R. Rasco, START Center for Cancer Care, San Antonio, TX; Karen A. Autio, Memorial Sloan Kettering Cancer Center, New York, NY; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Manish R. Patel, Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Deborah J. Wong, University of California Los Angeles, Los Angeles; Melinda Whiteside, John B. Mumm, Ivan H. Chan, Peter Van Vlasselaer, and Martin Oft, ARMO BioSciences, Redwood City, CA; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Shubham Pant, Oklahoma University, Oklahoma City, OK; and Johanna C. Bendell, Todd M. Bauer, and Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.	Johanna C	JC	Bendell
84	13	Aung Naing, Rivka R. Colen, David S. Hong, and Nizar M. Tannir, MD Anderson Cancer Center, Houston; Kyriakos P. Papadopoulos and Drew R. Rasco, START Center for Cancer Care, San Antonio, TX; Karen A. Autio, Memorial Sloan Kettering Cancer Center, New York, NY; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Manish R. Patel, Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Deborah J. Wong, University of California Los Angeles, Los Angeles; Melinda Whiteside, John B. Mumm, Ivan H. Chan, Peter Van Vlasselaer, and Martin Oft, ARMO BioSciences, Redwood City, CA; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Shubham Pant, Oklahoma University, Oklahoma City, OK; and Johanna C. Bendell, Todd M. Bauer, and Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.	Todd M	TM	Bauer
84	14	Aung Naing, Rivka R. Colen, David S. Hong, and Nizar M. Tannir, MD Anderson Cancer Center, Houston; Kyriakos P. Papadopoulos and Drew R. Rasco, START Center for Cancer Care, San Antonio, TX; Karen A. Autio, Memorial Sloan Kettering Cancer Center, New York, NY; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Manish R. Patel, Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Deborah J. Wong, University of California Los Angeles, Los Angeles; Melinda Whiteside, John B. Mumm, Ivan H. Chan, Peter Van Vlasselaer, and Martin Oft, ARMO BioSciences, Redwood City, CA; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Shubham Pant, Oklahoma University, Oklahoma City, OK; and Johanna C. Bendell, Todd M. Bauer, and Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.	Rivka R	RR	Colen
84	15	Aung Naing, Rivka R. Colen, David S. Hong, and Nizar M. Tannir, MD Anderson Cancer Center, Houston; Kyriakos P. Papadopoulos and Drew R. Rasco, START Center for Cancer Care, San Antonio, TX; Karen A. Autio, Memorial Sloan Kettering Cancer Center, New York, NY; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Manish R. Patel, Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Deborah J. Wong, University of California Los Angeles, Los Angeles; Melinda Whiteside, John B. Mumm, Ivan H. Chan, Peter Van Vlasselaer, and Martin Oft, ARMO BioSciences, Redwood City, CA; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Shubham Pant, Oklahoma University, Oklahoma City, OK; and Johanna C. Bendell, Todd M. Bauer, and Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.	David S	DS	Hong
84	16	Aung Naing, Rivka R. Colen, David S. Hong, and Nizar M. Tannir, MD Anderson Cancer Center, Houston; Kyriakos P. Papadopoulos and Drew R. Rasco, START Center for Cancer Care, San Antonio, TX; Karen A. Autio, Memorial Sloan Kettering Cancer Center, New York, NY; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Manish R. Patel, Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Deborah J. Wong, University of California Los Angeles, Los Angeles; Melinda Whiteside, John B. Mumm, Ivan H. Chan, Peter Van Vlasselaer, and Martin Oft, ARMO BioSciences, Redwood City, CA; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Shubham Pant, Oklahoma University, Oklahoma City, OK; and Johanna C. Bendell, Todd M. Bauer, and Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.	Peter	P	Van Vlasselaer
84	17	Aung Naing, Rivka R. Colen, David S. Hong, and Nizar M. Tannir, MD Anderson Cancer Center, Houston; Kyriakos P. Papadopoulos and Drew R. Rasco, START Center for Cancer Care, San Antonio, TX; Karen A. Autio, Memorial Sloan Kettering Cancer Center, New York, NY; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Manish R. Patel, Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Deborah J. Wong, University of California Los Angeles, Los Angeles; Melinda Whiteside, John B. Mumm, Ivan H. Chan, Peter Van Vlasselaer, and Martin Oft, ARMO BioSciences, Redwood City, CA; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Shubham Pant, Oklahoma University, Oklahoma City, OK; and Johanna C. Bendell, Todd M. Bauer, and Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.	Nizar M	NM	Tannir
84	18	Aung Naing, Rivka R. Colen, David S. Hong, and Nizar M. Tannir, MD Anderson Cancer Center, Houston; Kyriakos P. Papadopoulos and Drew R. Rasco, START Center for Cancer Care, San Antonio, TX; Karen A. Autio, Memorial Sloan Kettering Cancer Center, New York, NY; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Manish R. Patel, Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Deborah J. Wong, University of California Los Angeles, Los Angeles; Melinda Whiteside, John B. Mumm, Ivan H. Chan, Peter Van Vlasselaer, and Martin Oft, ARMO BioSciences, Redwood City, CA; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Shubham Pant, Oklahoma University, Oklahoma City, OK; and Johanna C. Bendell, Todd M. Bauer, and Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.	Martin	M	Oft
84	19	Aung Naing, Rivka R. Colen, David S. Hong, and Nizar M. Tannir, MD Anderson Cancer Center, Houston; Kyriakos P. Papadopoulos and Drew R. Rasco, START Center for Cancer Care, San Antonio, TX; Karen A. Autio, Memorial Sloan Kettering Cancer Center, New York, NY; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Manish R. Patel, Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Deborah J. Wong, University of California Los Angeles, Los Angeles; Melinda Whiteside, John B. Mumm, Ivan H. Chan, Peter Van Vlasselaer, and Martin Oft, ARMO BioSciences, Redwood City, CA; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Shubham Pant, Oklahoma University, Oklahoma City, OK; and Johanna C. Bendell, Todd M. Bauer, and Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.	Jeffrey R	JR	Infante
85	0	Department of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA. dcagney@lroc.harvard.edu.	Daniel N	DN	Cagney
85	1	Department of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA.	Brian M	BM	Alexander
85	2	Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.	F Stephen	FS	Hodi
85	3	Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.	Elizabeth I	EI	Buchbinder
85	4	Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.	Patrick A	PA	Ott
85	5	Department of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA.	Ayal A	AA	Aizer
86	0	Renal Division, Massachusetts General Hospital, Boston, Massachusetts, USA.	Frank B	FB	Cortazar
86	1	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA.	Kristen A	KA	Marrone
86	2	Department of Pathology, Oregon Health and Science University, Portland, Oregon, USA.	Megan L	ML	Troxell
86	3	Division of Nephrology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.	Kenneth M	KM	Ralto
86	4	Division of Nephrology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.	Melanie P	MP	Hoenig
86	5	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA.	Julie R	JR	Brahmer
86	6	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA.	Dung T	DT	Le
86	7	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA.	Evan J	EJ	Lipson
86	8	Memorial Sloan Kettering Cancer Center, New York, New York, USA.	Ilya G	IG	Glezerman
86	9	Memorial Sloan Kettering Cancer Center, New York, New York, USA.	Jedd	J	Wolchok
86	10	Department of Pathology, Mayo Clinic, Rochester, Minnesota, USA.	Lynn D	LD	Cornell
86	11	Advanced Kidney Care of Hudson Valley, Poughkeepsie, New York, USA.	Paul	P	Feldman
86	12	Department of Pathology, Columbia University Medical Center, New York, New York, USA.	Michael B	MB	Stokes
86	13	Division of Nephrology, Kaiser Permanente, Portland, Oregon, USA.	Sarah A	SA	Zapata
86	14	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.	F Stephen	FS	Hodi
86	15	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.	Patrick A	PA	Ott
86	16	Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.	Michifumi	M	Yamashita
86	17	Divison of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA. Electronic address: DELEAF@partners.org.	David E	DE	Leaf
87	0	H Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.	Scott J	SJ	Antonia
87	1	Hospital Universitario 12 de Octubre, Madrid, Spain.	José A	JA	López-Martin
87	2	Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN, USA.	Johanna	J	Bendell
87	3	Dana-Farber Cancer Institute, Boston, MA, USA.	Patrick A	PA	Ott
87	4	Oregon Health & Science University, Portland, OR, USA.	Matthew	M	Taylor
87	5	Yale Comprehensive Cancer Center, New Haven, CT, USA.	Joseph Paul	JP	Eder
87	6	Nationales Centrum für Tumorerkrankungen (NCT), University Medical Center, Heidelberg, Germany.	Dirk	D	Jäger
87	7	Memorial Sloan Kettering Cancer Center, New York, NY, USA.	M Catherine	MC	Pietanza
87	8	The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA.	Dung T	DT	Le
87	9	Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Milan, Italy.	Filippo	F	de Braud
87	10	Duke University Medical Center, Durham, NC, USA.	Michael A	MA	Morse
87	11	Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy.	Paolo A	PA	Ascierto
87	12	Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.	Leora	L	Horn
87	13	Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC, USA.	Asim	A	Amin
87	14	Winship Cancer Institute of Emory University, Atlanta, GA, USA.	Rathi N	RN	Pillai
87	15	University of Glasgow, Glasgow, UK.	Jeffry	J	Evans
87	16	Royal Marsden Hospital, Sutton, UK.	Ian	I	Chau
87	17	Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.	Petri	P	Bono
87	18	Krankenhaus Nordwest UCT-University Cancer Center, Frankfurt, Germany.	Akin	A	Atmaca
87	19	The University of Texas MD Anderson Cancer Center, Houston, TX, USA.	Padmanee	P	Sharma
87	20	Bristol-Myers Squibb, Princeton, NJ, USA.	Christopher T	CT	Harbison
87	21	Bristol-Myers Squibb, Princeton, NJ, USA.	Chen-Sheng	CS	Lin
87	22	Bristol-Myers Squibb, Princeton, NJ, USA.	Olaf	O	Christensen
87	23	START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain. Electronic address: emiliano.calvo@start.stoh.com.	Emiliano	E	Calvo
88	0	Department of Medical Oncology, Melanoma Disease Center, and Center for Immuno-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. Patrick_Ott@DFCI.harvard.edu.	Patrick A	PA	Ott
88	1	Department of Medical Oncology, Melanoma Disease Center, and Center for Immuno-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.	F Stephen	FS	Hodi
89	0	Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA USA.	Melina E	ME	Marmarelis
89	1	Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA USA.	Meredith R	MR	Davis
89	2	Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA USA.	Nilay S	NS	Sethi
89	3	Department of Imaging, Dana Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA USA.	Katherine M	KM	Krajewksi
89	4	Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA USA.	Rana R	RR	McKay
89	5	Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA USA.	Toni K	TK	Choueiri
89	6	Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA USA.	Patrick A	PA	Ott
90	0	Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.	Patrick A	PA	Ott
91	0	Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.	Douglas B	DB	Johnson
91	1	Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.	Ryan J	RJ	Sullivan
91	2	Department of Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.	Patrick A	PA	Ott
91	3	Department of Medicine, Crown Princess Mary Cancer Centre, Westmead and Blacktown Hospitals, Sydney, New South Wales, Australia5Department of Medicine, University of Sydney, Sydney, New South Wales, Australia.	Matteo S	MS	Carlino
91	4	Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York.	Nikhil I	NI	Khushalani
91	5	Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.	Fei	F	Ye
91	6	Department of Medicine, University of Sydney, Sydney, New South Wales, Australia8Department of Medicine, Melanoma Institute Australia, Sydney, New South Wales, Australia.	Alexander	A	Guminski
91	7	Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.	Igor	I	Puzanov
91	8	Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.	Donald P	DP	Lawrence
91	9	Department of Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.	Elizabeth I	EI	Buchbinder
91	10	medical student at School of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.	Tejaswi	T	Mudigonda
91	11	Department of Medicine, Rutgers Cancer Institute of New Jersey, New Brunswick.	Kristen	K	Spencer
91	12	Department of Medicine, Heidelberg University Hospital, Heidelberg, Germany.	Carolin	C	Bender
91	13	Department of Medicine, Crown Princess Mary Cancer Centre, Westmead and Blacktown Hospitals, Sydney, New South Wales, Australia8Department of Medicine, Melanoma Institute Australia, Sydney, New South Wales, Australia.	Jenny	J	Lee
91	14	Department of Surgery, Rutgers Cancer Institute of New Jersey, New Brunswick.	Howard L	HL	Kaufman
91	15	Department of Medicine, University of Sydney, Sydney, New South Wales, Australia8Department of Medicine, Melanoma Institute Australia, Sydney, New South Wales, Australia.	Alexander M	AM	Menzies
91	16	Department of Medicine, Heidelberg University Hospital, Heidelberg, Germany.	Jessica C	JC	Hassel
91	17	Department of Medicine, Rutgers Cancer Institute of New Jersey, New Brunswick.	Janice M	JM	Mehnert
91	18	Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.	Jeffrey A	JA	Sosman
91	19	Department of Medicine, University of Sydney, Sydney, New South Wales, Australia8Department of Medicine, Melanoma Institute Australia, Sydney, New South Wales, Australia.	Georgina V	GV	Long
91	20	Department of Medicine, Loyola University Medical Center, Maywood, Illinois.	Joseph I	JI	Clark
92	0	Harvard Radiation Oncology Program ; Boston, MA USA.	Ravi A	RA	Chandra
92	1	Harvard Medical School ; Boston, MA USA.	Tyler J	TJ	Wilhite
92	2	Department of Radiation Oncology; Brigham and Women's Hospital/Dana-Farber Cancer Institute ; Boston, MA USA.	Tracy A	TA	Balboni
92	3	Department of Radiation Oncology; Brigham and Women's Hospital/Dana-Farber Cancer Institute ; Boston, MA USA.	Brian M	BM	Alexander
92	4	Department of Radiation Oncology; Brigham and Women's Hospital/Dana-Farber Cancer Institute ; Boston, MA USA.	Alexander	A	Spektor
92	5	Medical Oncology and Center for Immuno-Oncology; Dana-Farber Cancer Institute ; Boston, MA USA.	Patrick A	PA	Ott
92	6	Department of Radiation Oncology; Brigham and Women's Hospital/Dana-Farber Cancer Institute ; Boston, MA USA.	Andrea K	AK	Ng
92	7	Medical Oncology and Center for Immuno-Oncology; Dana-Farber Cancer Institute ; Boston, MA USA.	F Stephen	FS	Hodi
92	8	Department of Radiation Oncology; Brigham and Women's Hospital/Dana-Farber Cancer Institute ; Boston, MA USA.	Jonathan D	JD	Schoenfeld
93	0	Department of Medical Oncology, Melanoma Disease Center, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Harvard Medical School , Boston, MA , USA ; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School , Boston, MA , USA.	Patrick A	PA	Ott
93	1	Department of Medical Oncology, Melanoma Disease Center, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Harvard Medical School , Boston, MA , USA ; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School , Boston, MA , USA.	F Stephen	FS	Hodi
93	2	Department of Medical Oncology, Melanoma Disease Center, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Harvard Medical School , Boston, MA , USA ; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School , Boston, MA , USA.	Elizabeth I	EI	Buchbinder
94	0	Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Avenue, EBRC Suite 401, Boston, MA 02115 USA.	Jonathan J	JJ	Lee
94	1	Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Avenue, EBRC Suite 401, Boston, MA 02115 USA.	Lynette M	LM	Sholl
94	2	Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Avenue, EBRC Suite 401, Boston, MA 02115 USA.	Neal I	NI	Lindeman
94	3	Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Avenue, EBRC Suite 401, Boston, MA 02115 USA.	Scott R	SR	Granter
94	4	Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Avenue, EBRC Suite 401, Boston, MA 02115 USA.	Alvaro C	AC	Laga
94	5	Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Avenue, EBRC Suite 401, Boston, MA 02115 USA.	Priyanka	P	Shivdasani
94	6	Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Avenue, EBRC Suite 401, Boston, MA 02115 USA.	Gary	G	Chin
94	7	Melanoma Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave., Boston, MA 02215-5450 USA.	Jason J	JJ	Luke
94	8	Melanoma Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave., Boston, MA 02215-5450 USA.	Patrick A	PA	Ott
94	9	Melanoma Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave., Boston, MA 02215-5450 USA.	F Stephen	FS	Hodi
94	10	Melanoma Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave., Boston, MA 02215-5450 USA.	Martin C	MC	Mihm
94	11	Melanoma Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave., Boston, MA 02215-5450 USA.	Jennifer Y	JY	Lin
94	12	Melanoma Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave., Boston, MA 02215-5450 USA.	Andrew E	AE	Werchniak
94	13	Melanoma Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave., Boston, MA 02215-5450 USA.	Harley A	HA	Haynes
94	14	Melanoma Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave., Boston, MA 02215-5450 USA.	Nancy	N	Bailey
94	15	Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Avenue, EBRC Suite 401, Boston, MA 02115 USA.	Robert	R	Liu
94	16	Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Avenue, EBRC Suite 401, Boston, MA 02115 USA.	George F	GF	Murphy
94	17	Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Avenue, EBRC Suite 401, Boston, MA 02115 USA.	Christine G	CG	Lian
95	0	Department of Radiology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts.	Sree Harsha	SH	Tirumani
95	1	Department of Radiology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts.	Nikhil H	NH	Ramaiya
95	2	Department of Radiology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts.	Abhishek	A	Keraliya
95	3	Department of Radiology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts.	Nancy D	ND	Bailey
95	4	Department of Radiology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts.	Patrick A	PA	Ott
95	5	Department of Radiology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts.	F Stephen	FS	Hodi
95	6	Department of Radiology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts. Mizuki_Nishino@dfci.harvard.edu.	Mizuki	M	Nishino
96	0	Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, Illinois. jluke@medicine.bsd.uchicago.edu.	Jason J	JJ	Luke
96	1	Melanoma Disease Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Hilary	H	Donahue
96	2	Department of Radiology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts.	Mizuki	M	Nishino
96	3	Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Anita	A	Giobbie-Hurder
96	4	Melanoma Disease Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Meredith	M	Davis
96	5	Melanoma Disease Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Nancy	N	Bailey
96	6	Melanoma Disease Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts.	Patrick A	PA	Ott
96	7	Melanoma Disease Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts.	F Stephen	FS	Hodi
97	0	From Memorial Sloan Kettering Cancer Center (M.A.P., J.D.W.), Weill Cornell Medical College (M.A.P., J.D.W.), and New York University, Perlmutter Cancer Center (A.C.P.) - all in New York; J. Graham Brown Cancer Center, University of Louisville, Louisville, KY (J.C.); Institute Gustave Roussy, Villejuif (C.R.), Paris-Sud University, Orsay (C.R.), and Institut Universitaire du Cancer, Toulouse (N.M.) - all in France; Huntsman Cancer Institute, Salt Lake City (K.G.); Beth Israel Deaconess Medical Center (D. McDermott) and Dana-Farber Cancer Institute (P.A.O., F.S.H.) - both in Boston; Washington University in St. Louis, St. Louis (G.P.L.); Greenville Health System, Greenville, SC (J.K.G.); St. Luke's Cancer Center, Bethlehem, PA (S.S.A.); University of New Mexico, Albuquerque (M.S.); Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (M.S.E.); California Pacific Center for Melanoma Research, San Francisco (D. Minor); Duke University, Durham, NC (A.K.S.); Oregon Health and Science University, Portland (M.T.); Bristol-Myers Squibb, Lawrenceville, NJ (C.H.); and Bristol-Myers Squibb, Wallingford, CT (L.M.R., P.G.).	Michael A	MA	Postow
97	1		Jason	J	Chesney
97	2		Anna C	AC	Pavlick
97	3		Caroline	C	Robert
97	4		Kenneth	K	Grossmann
97	5		David	D	McDermott
97	6		Gerald P	GP	Linette
97	7		Nicolas	N	Meyer
97	8		Jeffrey K	JK	Giguere
97	9		Sanjiv S	SS	Agarwala
97	10		Montaser	M	Shaheen
97	11		Marc S	MS	Ernstoff
97	12		David	D	Minor
97	13		April K	AK	Salama
97	14		Matthew	M	Taylor
97	15		Patrick A	PA	Ott
97	16		Linda M	LM	Rollin
97	17		Christine	C	Horak
97	18		Paul	P	Gagnier
97	19		Jedd D	JD	Wolchok
97	20		F Stephen	FS	Hodi
98	0	Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA.	Jason J	JJ	Luke
98	1	Melanoma Disease Center, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.	Patrick A	PA	Ott
99	0	"Cancer Institute, New York University School of Medicine, New York.
Icahn School of Medicine at Mount Sinai Tisch Cancer Institute, Harvard Medical School, New York."	Rachel Lubong	RL	Sabado
99	1	Cancer Institute, New York University School of Medicine, New York.	Anna	A	Pavlick
99	2	"Ludwig Institute for Cancer Research, Harvard Medical School, New York.
Icahn School of Medicine at Mount Sinai Tisch Cancer Institute, Harvard Medical School, New York."	Sacha	S	Gnjatic
99	3	Cancer Institute, New York University School of Medicine, New York.	Crystal M	CM	Cruz
99	4	Cancer Institute, New York University School of Medicine, New York.	Isabelita	I	Vengco
99	5	Cancer Institute, New York University School of Medicine, New York.	Farah	F	Hasan
99	6	Cancer Institute, New York University School of Medicine, New York.	Meredith	M	Spadaccia
99	7	Department of Pathology, New York University School of Medicine, New York.	Farbod	F	Darvishian
99	8	Department of Pathology, New York University School of Medicine, New York.	Luis	L	Chiriboga
99	9	Cancer Institute, New York University School of Medicine, New York.	Rose Marie	RM	Holman
99	10	Cancer Institute, New York University School of Medicine, New York.	Juliet	J	Escalon
99	11	Cancer Institute, New York University School of Medicine, New York.	Caroline	C	Muren
99	12	Cancer Institute, New York University School of Medicine, New York.	Crystal	C	Escano
99	13	Cancer Institute, New York University School of Medicine, New York.	Ethel	E	Yepes
99	14	Cancer Institute, New York University School of Medicine, New York.	Dunbar	D	Sharpe
99	15	3M Drug Delivery Systems Division, Harvard Medical School, New York.	John P	JP	Vasilakos
99	16	Cancer Institute, New York University School of Medicine, New York.	Linda	L	Rolnitzsky
99	17	Cancer Institute, New York University School of Medicine, New York.	Judith	J	Goldberg
99	18	3M Drug Delivery Systems Division, Harvard Medical School, New York.	John	J	Mandeli
99	19	Cancer Institute, New York University School of Medicine, New York.	Sylvia	S	Adams
99	20	Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York.	Achim	A	Jungbluth
99	21	Ludwig Institute for Cancer Research, Harvard Medical School, New York.	Linda	L	Pan
99	22	Ludwig Institute for Cancer Research, Harvard Medical School, New York.	Ralph	R	Venhaus
99	23	"Cancer Institute, New York University School of Medicine, New York.
Dana-Farber Cancer Institute, Harvard Medical School, New York."	Patrick A	PA	Ott
99	24	"Cancer Institute, New York University School of Medicine, New York.
Department of Pathology, New York University School of Medicine, New York.
Icahn School of Medicine at Mount Sinai Tisch Cancer Institute, Harvard Medical School, New York."	Nina	N	Bhardwaj
100	0	Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Boston, Massachusetts. lmin1@partners.org.	Le	L	Min
100	1	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Frank Stephen	FS	Hodi
100	2	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Anita	A	Giobbie-Hurder
100	3	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Patrick A	PA	Ott
100	4	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Melanoma and Developmental Therapeutics Clinics, University of Chicago, Chicago, Illinois.	Jason J	JJ	Luke
100	5	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Hilary	H	Donahue
100	6	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Meredith	M	Davis
100	7	Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Boston, Massachusetts.	Rona S	RS	Carroll
100	8	Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Boston, Massachusetts.	Ursula B	UB	Kaiser
101	0	Melanoma and Developmental Therapeutics Clinics, University of Chicago Cancer Center, University of Chicago, 5841 S. Maryland Ave., MC2115, Chicago, IL, 60637, USA, jluke@medicine.bsd.uchicago.edu.	Jason J	JJ	Luke
101	1		Patrick A	PA	Ott
101	2		Geoffrey I	GI	Shapiro
102	0	Patrick A. Ott and Anna C. Pavlick, New York University Cancer Institute, New York, NY; Omid Hamid and Peter D. Boasberg, The Angeles Clinic and Research Institute, Los Angeles, CA; Harriet Kluger and Mario Sznol, Yale Cancer Center, New Haven, CT; Kevin B. Kim and Patrick Hwu, University of Texas MD Anderson Cancer Center, Houston, TX; Ronit Simantov, Elizabeth Crowley, Jennifer A. Green, Thomas Hawthorne, and Thomas A. Davis, Celldex Therapeutics, Hampton, NJ. patrick_ott@dfci.harvard.edu.	Patrick A	PA	Ott
102	1	Patrick A. Ott and Anna C. Pavlick, New York University Cancer Institute, New York, NY; Omid Hamid and Peter D. Boasberg, The Angeles Clinic and Research Institute, Los Angeles, CA; Harriet Kluger and Mario Sznol, Yale Cancer Center, New Haven, CT; Kevin B. Kim and Patrick Hwu, University of Texas MD Anderson Cancer Center, Houston, TX; Ronit Simantov, Elizabeth Crowley, Jennifer A. Green, Thomas Hawthorne, and Thomas A. Davis, Celldex Therapeutics, Hampton, NJ.	Omid	O	Hamid
102	2	Patrick A. Ott and Anna C. Pavlick, New York University Cancer Institute, New York, NY; Omid Hamid and Peter D. Boasberg, The Angeles Clinic and Research Institute, Los Angeles, CA; Harriet Kluger and Mario Sznol, Yale Cancer Center, New Haven, CT; Kevin B. Kim and Patrick Hwu, University of Texas MD Anderson Cancer Center, Houston, TX; Ronit Simantov, Elizabeth Crowley, Jennifer A. Green, Thomas Hawthorne, and Thomas A. Davis, Celldex Therapeutics, Hampton, NJ.	Anna C	AC	Pavlick
102	3	Patrick A. Ott and Anna C. Pavlick, New York University Cancer Institute, New York, NY; Omid Hamid and Peter D. Boasberg, The Angeles Clinic and Research Institute, Los Angeles, CA; Harriet Kluger and Mario Sznol, Yale Cancer Center, New Haven, CT; Kevin B. Kim and Patrick Hwu, University of Texas MD Anderson Cancer Center, Houston, TX; Ronit Simantov, Elizabeth Crowley, Jennifer A. Green, Thomas Hawthorne, and Thomas A. Davis, Celldex Therapeutics, Hampton, NJ.	Harriet	H	Kluger
102	4	Patrick A. Ott and Anna C. Pavlick, New York University Cancer Institute, New York, NY; Omid Hamid and Peter D. Boasberg, The Angeles Clinic and Research Institute, Los Angeles, CA; Harriet Kluger and Mario Sznol, Yale Cancer Center, New Haven, CT; Kevin B. Kim and Patrick Hwu, University of Texas MD Anderson Cancer Center, Houston, TX; Ronit Simantov, Elizabeth Crowley, Jennifer A. Green, Thomas Hawthorne, and Thomas A. Davis, Celldex Therapeutics, Hampton, NJ.	Kevin B	KB	Kim
102	5	Patrick A. Ott and Anna C. Pavlick, New York University Cancer Institute, New York, NY; Omid Hamid and Peter D. Boasberg, The Angeles Clinic and Research Institute, Los Angeles, CA; Harriet Kluger and Mario Sznol, Yale Cancer Center, New Haven, CT; Kevin B. Kim and Patrick Hwu, University of Texas MD Anderson Cancer Center, Houston, TX; Ronit Simantov, Elizabeth Crowley, Jennifer A. Green, Thomas Hawthorne, and Thomas A. Davis, Celldex Therapeutics, Hampton, NJ.	Peter D	PD	Boasberg
102	6	Patrick A. Ott and Anna C. Pavlick, New York University Cancer Institute, New York, NY; Omid Hamid and Peter D. Boasberg, The Angeles Clinic and Research Institute, Los Angeles, CA; Harriet Kluger and Mario Sznol, Yale Cancer Center, New Haven, CT; Kevin B. Kim and Patrick Hwu, University of Texas MD Anderson Cancer Center, Houston, TX; Ronit Simantov, Elizabeth Crowley, Jennifer A. Green, Thomas Hawthorne, and Thomas A. Davis, Celldex Therapeutics, Hampton, NJ.	Ronit	R	Simantov
102	7	Patrick A. Ott and Anna C. Pavlick, New York University Cancer Institute, New York, NY; Omid Hamid and Peter D. Boasberg, The Angeles Clinic and Research Institute, Los Angeles, CA; Harriet Kluger and Mario Sznol, Yale Cancer Center, New Haven, CT; Kevin B. Kim and Patrick Hwu, University of Texas MD Anderson Cancer Center, Houston, TX; Ronit Simantov, Elizabeth Crowley, Jennifer A. Green, Thomas Hawthorne, and Thomas A. Davis, Celldex Therapeutics, Hampton, NJ.	Elizabeth	E	Crowley
102	8	Patrick A. Ott and Anna C. Pavlick, New York University Cancer Institute, New York, NY; Omid Hamid and Peter D. Boasberg, The Angeles Clinic and Research Institute, Los Angeles, CA; Harriet Kluger and Mario Sznol, Yale Cancer Center, New Haven, CT; Kevin B. Kim and Patrick Hwu, University of Texas MD Anderson Cancer Center, Houston, TX; Ronit Simantov, Elizabeth Crowley, Jennifer A. Green, Thomas Hawthorne, and Thomas A. Davis, Celldex Therapeutics, Hampton, NJ.	Jennifer A	JA	Green
102	9	Patrick A. Ott and Anna C. Pavlick, New York University Cancer Institute, New York, NY; Omid Hamid and Peter D. Boasberg, The Angeles Clinic and Research Institute, Los Angeles, CA; Harriet Kluger and Mario Sznol, Yale Cancer Center, New Haven, CT; Kevin B. Kim and Patrick Hwu, University of Texas MD Anderson Cancer Center, Houston, TX; Ronit Simantov, Elizabeth Crowley, Jennifer A. Green, Thomas Hawthorne, and Thomas A. Davis, Celldex Therapeutics, Hampton, NJ.	Thomas	T	Hawthorne
102	10	Patrick A. Ott and Anna C. Pavlick, New York University Cancer Institute, New York, NY; Omid Hamid and Peter D. Boasberg, The Angeles Clinic and Research Institute, Los Angeles, CA; Harriet Kluger and Mario Sznol, Yale Cancer Center, New Haven, CT; Kevin B. Kim and Patrick Hwu, University of Texas MD Anderson Cancer Center, Houston, TX; Ronit Simantov, Elizabeth Crowley, Jennifer A. Green, Thomas Hawthorne, and Thomas A. Davis, Celldex Therapeutics, Hampton, NJ.	Thomas A	TA	Davis
102	11	Patrick A. Ott and Anna C. Pavlick, New York University Cancer Institute, New York, NY; Omid Hamid and Peter D. Boasberg, The Angeles Clinic and Research Institute, Los Angeles, CA; Harriet Kluger and Mario Sznol, Yale Cancer Center, New Haven, CT; Kevin B. Kim and Patrick Hwu, University of Texas MD Anderson Cancer Center, Houston, TX; Ronit Simantov, Elizabeth Crowley, Jennifer A. Green, Thomas Hawthorne, and Thomas A. Davis, Celldex Therapeutics, Hampton, NJ.	Mario	M	Sznol
102	12	Patrick A. Ott and Anna C. Pavlick, New York University Cancer Institute, New York, NY; Omid Hamid and Peter D. Boasberg, The Angeles Clinic and Research Institute, Los Angeles, CA; Harriet Kluger and Mario Sznol, Yale Cancer Center, New Haven, CT; Kevin B. Kim and Patrick Hwu, University of Texas MD Anderson Cancer Center, Houston, TX; Ronit Simantov, Elizabeth Crowley, Jennifer A. Green, Thomas Hawthorne, and Thomas A. Davis, Celldex Therapeutics, Hampton, NJ.	Patrick	P	Hwu
103	0	Melanoma Disease Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.	Jason J	JJ	Luke
103	1	Melanoma Disease Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.	Patrick A	PA	Ott
104	0	Authors' Affiliations: Cancer Vaccine Center; Department of Medical Oncology, Dana-Farber Cancer Institute; The Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Massachusetts General Hospital; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston; and Broad Institute of MIT and Harvard, Cambridge, MassachusettsAuthors' Affiliations: Cancer Vaccine Center; Department of Medical Oncology, Dana-Farber Cancer Institute; The Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Massachusetts General Hospital; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston; and Broad Institute of MIT and Harvard, Cambridge, MassachusettsAuthors' Affiliations: Cancer Vaccine Center; Department of Medical Oncology, Dana-Farber Cancer Institute; The Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Massachusetts General Hospital; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston; and Broad Institute of MIT and Harvard, Cambridge, Massachusetts.	Edward F	EF	Fritsch
104	1	Authors' Affiliations: Cancer Vaccine Center; Department of Medical Oncology, Dana-Farber Cancer Institute; The Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Massachusetts General Hospital; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston; and Broad Institute of MIT and Harvard, Cambridge, MassachusettsAuthors' Affiliations: Cancer Vaccine Center; Department of Medical Oncology, Dana-Farber Cancer Institute; The Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Massachusetts General Hospital; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston; and Broad Institute of MIT and Harvard, Cambridge, Massachusetts.	Mohini	M	Rajasagi
104	2	Authors' Affiliations: Cancer Vaccine Center; Department of Medical Oncology, Dana-Farber Cancer Institute; The Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Massachusetts General Hospital; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston; and Broad Institute of MIT and Harvard, Cambridge, MassachusettsAuthors' Affiliations: Cancer Vaccine Center; Department of Medical Oncology, Dana-Farber Cancer Institute; The Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Massachusetts General Hospital; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston; and Broad Institute of MIT and Harvard, Cambridge, Massachusetts.	Patrick A	PA	Ott
104	3	Authors' Affiliations: Cancer Vaccine Center; Department of Medical Oncology, Dana-Farber Cancer Institute; The Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Massachusetts General Hospital; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston; and Broad Institute of MIT and Harvard, Cambridge, MassachusettsAuthors' Affiliations: Cancer Vaccine Center; Department of Medical Oncology, Dana-Farber Cancer Institute; The Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Massachusetts General Hospital; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston; and Broad Institute of MIT and Harvard, Cambridge, Massachusetts.	Vladimir	V	Brusic
104	4	Authors' Affiliations: Cancer Vaccine Center; Department of Medical Oncology, Dana-Farber Cancer Institute; The Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Massachusetts General Hospital; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston; and Broad Institute of MIT and Harvard, Cambridge, MassachusettsAuthors' Affiliations: Cancer Vaccine Center; Department of Medical Oncology, Dana-Farber Cancer Institute; The Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Massachusetts General Hospital; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston; and Broad Institute of MIT and Harvard, Cambridge, Massachusetts.	Nir	N	Hacohen
104	5	Authors' Affiliations: Cancer Vaccine Center; Department of Medical Oncology, Dana-Farber Cancer Institute; The Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Massachusetts General Hospital; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston; and Broad Institute of MIT and Harvard, Cambridge, MassachusettsAuthors' Affiliations: Cancer Vaccine Center; Department of Medical Oncology, Dana-Farber Cancer Institute; The Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Massachusetts General Hospital; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston; and Broad Institute of MIT and Harvard, Cambridge, MassachusettsAuthors' Affiliations: Cancer Vaccine Center; Department of Medical Oncology, Dana-Farber Cancer Institute; The Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Massachusetts General Hospital; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston; and Broad Institute of MIT and Harvard, Cambridge, Massachusetts cwu@partners.org.	Catherine J	CJ	Wu
105	0	Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Melanoma Disease Center, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Center for Immuno-Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02215, USA. Electronic address: Patrick_Ott@DFCI.harvard.edu.	Patrick A	PA	Ott
105	1	Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Broad Institute of Harvard and MIT, 7 Cambridge Center, Cambridge, MA 02142, USA.	Edward F	EF	Fritsch
105	2	Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02215, USA; Cancer Vaccine Center, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.	Catherine J	CJ	Wu
105	3	Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02215, USA; Cancer Vaccine Center, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.	Glenn	G	Dranoff
106	0		P A	PA	Ott
106	1		A V	AV	Privalov
106	2		A V	AV	Vazhenin
106	3		E A	EA	Nadvikova
106	4		E Iu	EIu	Lukina
106	5		A V	AV	Komissarov
106	6		E G	EG	Zabolotskaia
107	0	Dana Farber Cancer Institute, Harvard Medical School , Boston, MA , USA.	Patrick A	PA	Ott
107	1		Nina	N	Bhardwaj
108	0	Dana-Farber Cancer Institute, Harvard Medical School, Melanoma Disease Center, Early Drug Development Center, Center for Immuno Oncology , 450 Brookline Ave, Boston, MA 02215 , USA +1 6176324715 ; +1 6176326727 ; Jason_luke@dfci.harvard.edu.	Jason John	JJ	Luke
108	1		Patrick Alexander	PA	Ott
109	0	Authors' Affiliations: Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts; and Institut Gustave Roussy, Villejuif-Paris Sud, Paris, France.	Patrick A	PA	Ott
109	1		F Stephen	FS	Hodi
109	2		Caroline	C	Robert
110	0	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.	Jason J	JJ	Luke
110	1		Margaret K	MK	Callahan
110	2		Michael A	MA	Postow
110	3		Emanuela	E	Romano
110	4		Nikhil	N	Ramaiya
110	5		Mark	M	Bluth
110	6		Anita	A	Giobbie-Hurder
110	7		Donald P	DP	Lawrence
110	8		Nageatte	N	Ibrahim
110	9		Patrick A	PA	Ott
110	10		Keith T	KT	Flaherty
110	11		Ryan J	RJ	Sullivan
110	12		James J	JJ	Harding
110	13		Sandra	S	D'Angelo
110	14		Mark	M	Dickson
110	15		Gary K	GK	Schwartz
110	16		Paul B	PB	Chapman
110	17		Jedd D	JD	Wolchok
110	18		F Stephen	FS	Hodi
110	19		Richard D	RD	Carvajal
111	0		P A	PA	Ott
111	1		A V	AV	Privalov
111	2		A V	AV	Vazhenin
111	3		N A	NA	Chekha
111	4		E G	EG	Zabolotskaia
111	5		A V	AV	Komissarov
112	0		P A	PA	Ott
112	1		A V	AV	Provalov
112	2		A V	AV	Vazhenin
112	3		E A	EA	Nadvikova
112	4		E Iu	EIu	Kandakova
112	5		E G	EG	Zabolotskaia
113	0	Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. carvajar@mskcc.org	Michael A	MA	Postow
113	1		Jason J	JJ	Luke
113	2		Mark J	MJ	Bluth
113	3		Nikhil	N	Ramaiya
113	4		Katherine S	KS	Panageas
113	5		Donald P	DP	Lawrence
113	6		Nageatte	N	Ibrahim
113	7		Keith T	KT	Flaherty
113	8		Ryan J	RJ	Sullivan
113	9		Patrick A	PA	Ott
113	10		Margaret K	MK	Callahan
113	11		James J	JJ	Harding
113	12		Sandra P	SP	D'Angelo
113	13		Mark A	MA	Dickson
113	14		Gary K	GK	Schwartz
113	15		Paul B	PB	Chapman
113	16		Sacha	S	Gnjatic
113	17		Jedd D	JD	Wolchok
113	18		F Stephen	FS	Hodi
113	19		Richard D	RD	Carvajal
114	0	Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.	Patrick A	PA	Ott
114	1		F Stephen	FS	Hodi
115	0	Department of Radiation Oncology, New York University Langone Medical Center, 566 First Avenue HC-107, New York, NY 10016, USA. ashwatha.narayana@greenwichhospital.org	Ashwatha	A	Narayana
115	1		Maya	M	Mathew
115	2		Moses	M	Tam
115	3		Rajni	R	Kannan
115	4		Kathleen M	KM	Madden
115	5		John G	JG	Golfinos
115	6		Erik C	EC	Parker
115	7		Patrick A	PA	Ott
115	8		Anna C	AC	Pavlick
116	0	Vanderbilt-Ingram Cancer Center, 777 Preston Research Building, Nashville, TN 37232-6307, USA. jeff.sosman@vanderbilt.edu	Kerstin	K	Trunzer
116	1		Anna C	AC	Pavlick
116	2		Lynn	L	Schuchter
116	3		Rene	R	Gonzalez
116	4		Grant A	GA	McArthur
116	5		Thomas E	TE	Hutson
116	6		Stergios J	SJ	Moschos
116	7		Keith T	KT	Flaherty
116	8		Kevin B	KB	Kim
116	9		Jeffrey S	JS	Weber
116	10		Peter	P	Hersey
116	11		Georgina V	GV	Long
116	12		Donald	D	Lawrence
116	13		Patrick A	PA	Ott
116	14		Ravi K	RK	Amaravadi
116	15		Karl D	KD	Lewis
116	16		Igor	I	Puzanov
116	17		Roger S	RS	Lo
116	18		Astrid	A	Koehler
116	19		Mark	M	Kockx
116	20		Olivia	O	Spleiss
116	21		Annette	A	Schell-Steven
116	22		Houston N	HN	Gilbert
116	23		Louise	L	Cockey
116	24		Gideon	G	Bollag
116	25		Richard J	RJ	Lee
116	26		Andrew K	AK	Joe
116	27		Jeffrey A	JA	Sosman
116	28		Antoni	A	Ribas
117	0	Department of Radiation Oncology, New York University Langone Medical Center, New York, New York 10016, USA.	Maya	M	Mathew
117	1		Moses	M	Tam
117	2		Patrick A	PA	Ott
117	3		Anna C	AC	Pavlick
117	4		Stephen C	SC	Rush
117	5		Bernadine R	BR	Donahue
117	6		John G	JG	Golfinos
117	7		Erik C	EC	Parker
117	8		Paul P	PP	Huang
117	9		Ashwatha	A	Narayana
118	0	Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.	Patrick A	PA	Ott
118	1	Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Stephen_Hodi@dfci.harvard.edu.	F Stephen	FS	Hodi
119	0	New York University Cancer Institute, New York University School of Medicine, 522 First Avenue, SRB 1303, New York, NY, 10016, USA. patrick_ott@dfci.harvard.edu	Patrick A	PA	Ott
119	1		Trevor	T	Henry
119	2		Sonja Jimenez	SJ	Baranda
119	3		Davor	D	Frleta
119	4		Olivier	O	Manches
119	5		Dusan	D	Bogunovic
119	6		Nina	N	Bhardwaj
120	0	Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. kkim@mdanderson.org	Kevin B	KB	Kim
120	1		Richard	R	Kefford
120	2		Anna C	AC	Pavlick
120	3		Jeffrey R	JR	Infante
120	4		Antoni	A	Ribas
120	5		Jeffrey A	JA	Sosman
120	6		Leslie A	LA	Fecher
120	7		Michael	M	Millward
120	8		Grant A	GA	McArthur
120	9		Patrick	P	Hwu
120	10		Rene	R	Gonzalez
120	11		Patrick A	PA	Ott
120	12		Georgina V	GV	Long
120	13		Olivia S	OS	Gardner
120	14		Daniele	D	Ouellet
120	15		Yanmei	Y	Xu
120	16		Douglas J	DJ	DeMarini
120	17		Ngocdiep T	NT	Le
120	18		Kiran	K	Patel
120	19		Karl D	KD	Lewis
121	0	Division of Medical Oncology, NYU Cancer Institute, New York University School of Medicine, New York, NY 10016, USA. Patrick_Ott@DFCI.harvard.edu	Patrick A	PA	Ott
121	1		Jason	J	Chang
121	2		Kathleen	K	Madden
121	3		Rajni	R	Kannan
121	4		Caroline	C	Muren
121	5		Crystal	C	Escano
121	6		Xin	X	Cheng
121	7		Yongzhao	Y	Shao
121	8		Sandra	S	Mendoza
121	9		Alex	A	Gandhi
121	10		Leonard	L	Liebes
121	11		Anna C	AC	Pavlick
122	0	Department of Medical Oncology, New York University School of Medicine, New York, NY, USA. Patrick_Ott@dfci.harvard.edu	Patrick A	PA	Ott
122	1		Richard D	RD	Carvajal
122	2		Neeta	N	Pandit-Taskar
122	3		Achim A	AA	Jungbluth
122	4		Eric W	EW	Hoffman
122	5		Bor-Wen	BW	Wu
122	6		John S	JS	Bomalaski
122	7		Ralph	R	Venhaus
122	8		Linda	L	Pan
122	9		Lloyd J	LJ	Old
122	10		Anna C	AC	Pavlick
122	11		Jedd D	JD	Wolchok
123	0	Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, NY, USA.	Michelle W	MW	Ma
123	1		Ratna C	RC	Medicherla
123	2		Meng	M	Qian
123	3		Eleazar	E	Vega-Saenz de Miera
123	4		Erica B	EB	Friedman
123	5		Russell S	RS	Berman
123	6		Richard L	RL	Shapiro
123	7		Anna C	AC	Pavlick
123	8		Patrick A	PA	Ott
123	9		Nina	N	Bhardwaj
123	10		Yongzhao	Y	Shao
123	11		Iman	I	Osman
123	12		Farbod	F	Darvishian
124	0	Department of Medicine, New York University School of Medicine, New York, NY, USA.	Nagashree	N	Seetharamu
124	1		Ting J	TJ	Tu
124	2		Paul	P	Christos
124	3		Patrick A	PA	Ott
124	4		Russell S	RS	Berman
124	5		Richard L	RL	Shapiro
124	6		Iman	I	Osman
124	7		Anna C	AC	Pavlick
125	0	New York University Cancer Institute, Division of Medical Oncology, 160 E 34th Street, New York, NY 10016, USA. patrick.ott@nyumc.org	Patrick A	PA	Ott
125	1		Sylvia	S	Adams
126	0	Department of Medical Oncology, New York University School of Medicine, New York, New York, United States of America.	Patrick A	PA	Ott
126	1		Anne	A	Hamilton
126	2		Christina	C	Min
126	3		Sara	S	Safarzadeh-Amiri
126	4		Lauren	L	Goldberg
126	5		Joanne	J	Yoon
126	6		Herman	H	Yee
126	7		Michael	M	Buckley
126	8		Paul J	PJ	Christos
126	9		John J	JJ	Wright
126	10		David	D	Polsky
126	11		Iman	I	Osman
126	12		Leonard	L	Liebes
126	13		Anna C	AC	Pavlick
127	0	Division of Medical Oncology, Department of Medicine, New York University School of Medicine, New York University Cancer Institute, 160 East 34th Street, 9th Floor, New York, NY 10016, USA.	Patrick A	PA	Ott
127	1		Russell S	RS	Berman
128	0	NYU Cancer Institute, 160E 34th Street, New York, New York 10016, USA. anna.pavlick@nyumc.org	Nagashree	N	Seetharamu
128	1		Patrick A	PA	Ott
128	2		Anna C	AC	Pavlick
129	0	Department of Medical Oncology, New York University Cancer Institute, New York, New York, United States of America.	Patrick A	PA	Ott
129	1		Anne	A	Hamilton
129	2		Amanda	A	Jones
129	3		Naomi	N	Haas
129	4		Tsiporah	T	Shore
129	5		Sandra	S	Liddell
129	6		Paul J	PJ	Christos
129	7		L Austin	LA	Doyle
129	8		Michael	M	Millward
129	9		Franco M	FM	Muggia
129	10		Anna C	AC	Pavlick
130	0	NYU Cancer Institute, New York University Medical Center, New York, NY 10016, USA.	Nagashree	N	Seetharamu
130	1		Patrick A	PA	Ott
130	2		Anna C	AC	Pavlick
131	0	Division of Medical Oncology, New York University Cancer Institute, New York University School of Medicine, New York, NY 10016, USA. patrick.ott@nyumc.org	Patrick A	PA	Ott
131	1		Jason L	JL	Chang
131	2		Ruth	R	Oratz
131	3		Amanda	A	Jones
131	4		Kathleen	K	Farrell
131	5		Franco	F	Muggia
131	6		Anna C	AC	Pavlick
132	0	Department of Pathology, Wolstein Research Building, Room # 5128, Case Western Reserve University, School of Medicine, 10900 Euclid Avenue, Cleveland, OH 44116, USA.	Patrick A	PA	Ott
132	1		Magdalena	M	Tary-Lehmann
132	2		Paul V	PV	Lehmann
133	0	Department of Pathology, Case Western Reserve University, Cleveland OH 44106-4943, USA.	Harald H	HH	Hofstetter
133	1		Alexey Y	AY	Karulin
133	2		Thomas G	TG	Forsthuber
133	3		Patrick A	PA	Ott
133	4		Magdalena	M	Tary-Lehmann
133	5		Paul V	PV	Lehmann
134	0	Department of Pathology, Case Western Reserve University, Cleveland, OH 44106, USA, and University Hospital of Ulm, Section of Endocrinology, Germany.	Stefan	S	Quast
134	1		Wenji	W	Zhang
134	2		Carey	C	Shive
134	3		Damian	D	Kovalovski
134	4		Patrick A	PA	Ott
134	5		Bernhard A	BA	Herzog
134	6		Bernhard O	BO	Boehm
134	7		Magdalena	M	Tary-Lehmann
134	8		Alexey Y	AY	Karulin
134	9		Paul V	PV	Lehmann
135	0	Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.	Patrick A	PA	Ott
135	1		Michael R	MR	Anderson
135	2		Magdalena	M	Tary-Lehmann
135	3		Paul V	PV	Lehmann
136	0	Department of Pathology, Case Western Reserve University, School of Medicine, Cleveland, OH 44106, USA.	Patrick A	PA	Ott
136	1		Bernhard A	BA	Herzog
136	2		Stefan	S	Quast
136	3		Harald H	HH	Hofstetter
136	4		Bernhard O	BO	Boehm
136	5		Magdalena	M	Tary-Lehmann
136	6		Ivana	I	Durinovic-Bello
136	7		Beate R	BR	Berner
136	8		Paul V	PV	Lehmann
137	0	Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, USA.	Bernhard A	BA	Herzog
137	1		Patrick A	PA	Ott
137	2		Marcus T	MT	Dittrich
137	3		Stefan	S	Quast
137	4		Alexey Y	AY	Karulin
137	5		Hubert	H	Kalbacher
137	6		Wolfram	W	Karges
137	7		Magdalena	M	Tary-Lehmann
137	8		Paul V	PV	Lehmann
137	9		Bernhard O	BO	Boehm
137	10		Ivana	I	Durinovic-Belló
138	0	Department of Pathology, Case Western Reserve University, BRB 929, 10900 Euclid Avenue, Cleveland, Ohio 44116, USA.	Patrick A	PA	Ott
138	1		Marcus T	MT	Dittrich
138	2		Bernhard A	BA	Herzog
138	3		Robert	R	Guerkov
138	4		Peter A	PA	Gottlieb
138	5		Amy L	AL	Putnam
138	6		Ivana	I	Durinovic-Bello
138	7		Bernhard O	BO	Boehm
138	8		Magdalena	M	Tary-Lehmann
138	9		Paul V	PV	Lehmann
139	0	Department of Pathology, School of Medicine, Case Western Reserve University, BRB 930, 10900 Euclid Avenue, Cleveland, OH 44106, USA.	Patrick A	PA	Ott
139	1		Beate R	BR	Berner
139	2		Bernhard A	BA	Herzog
139	3		Robert	R	Guerkov
139	4		Nicole L	NL	Yonkers
139	5		Ivana	I	Durinovic-Bello
139	6		Magdalena	M	Tary-Lehmann
139	7		Paul V	PV	Lehmann
139	8		Donald D	DD	Anthony
140	0	German Diabetes Research Institute, Auf'm Hennekamp 65, 40225 Düsseldorf, Germany.	Guido	G	Meierhoff
140	1		Patrick A	PA	Ott
140	2		Paul V	PV	Lehmann
140	3		Nanette C	NC	Schloot
141	0	Department of Gastroenterology, Cleveland Clinic, USA.	E	E	Achkar
141	1		V J	VJ	Block
141	2		P A	PA	Ott
142	0	Department of Cardiology, The Cleveland Clinic Foundation, OH 44195, USA. elliss@cesmtp.ccf.org	S G	SG	Ellis
142	1		K J	KJ	Brown
142	2		R	R	Ellert
142	3		G L	GL	Howell
142	4		D P	DP	Miller
142	5		N M	NM	Flowers
142	6		P A	PA	Ott
142	7		T	T	Keys
142	8		F D	FD	Loop
142	9		E J	EJ	Topol
143	0		P A	PA	Ott
